4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
| Title | Journal |
|---|---|
| Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. | Toxicology letters 20181001 |
| Supramolecular strategy for reducing the cardiotoxicity of bedaquiline without compromising its antimycobacterial efficacy. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20180901 |
| Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. | Toxicology in vitro : an international journal published in association with BIBRA 20180901 |
| Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. | Toxicology letters 20180701 |
| Flavan enantiomers from Daphne giraldii selectively induce apoptotic cell death in p53-null hepatocarcinoma cells in vitro. | Chemico-biological interactions 20180601 |
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. | Lancet (London, England) 20180324 |
| Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. | Toxicology 20180215 |
| Why are most phospholipidosis inducers also hERG blockers? | Archives of toxicology 20171201 |
| Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. | The Journal of biological chemistry 20170908 |
| Novel 1,2,4-triazole derivatives as antitumor agents against hepatocellular carcinoma. | Chemico-biological interactions 20170825 |
| Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma. | Molecular carcinogenesis 20160801 |
| Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation. | Toxicology in vitro : an international journal published in association with BIBRA 20160301 |
| Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. | BMC nephrology 20160101 |
| New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. | Nutrition and cancer 20160101 |
| Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. | Chemico-biological interactions 20151205 |
| A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. | Nature chemical biology 20151201 |
| Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. | Oncotarget 20150929 |
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Small molecule discoidin domain receptor kinase inhibitors and potential medical applications. | Journal of medicinal chemistry 20150423 |
| Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20150401 |
| Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. | Toxicological sciences : an official journal of the Society of Toxicology 20150201 |
| Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity. | Chemical research in toxicology 20150120 |
| Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. | Journal of medicinal chemistry 20141009 |
| Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition. | Toxicology in vitro : an international journal published in association with BIBRA 20140601 |
| Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. | Molecular cancer therapeutics 20140401 |
| Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. | Toxicology and applied pharmacology 20140115 |
| Trinorditerpenes from the roots of Flueggea virosa. | Bioorganic & medicinal chemistry letters 20140115 |
| A high-throughput screen for teratogens using human pluripotent stem cells. | Toxicological sciences : an official journal of the Society of Toxicology 20140101 |
| Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1. | Toxicology and applied pharmacology 20131101 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. | Cancer chemotherapy and pharmacology 20130501 |
| Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130501 |
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | The Biochemical journal 20130415 |
| Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. | Journal of cellular physiology 20130201 |
| Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. | Cancer letters 20130201 |
| Activity-based kinase profiling of approved tyrosine kinase inhibitors. | Genes to cells : devoted to molecular & cellular mechanisms 20130201 |
| Targeted agents and systemic therapy in hepatocellular carcinoma. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20130101 |
| The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. | PloS one 20130101 |
| EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. | International journal of cancer 20121215 |
| Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. | Investigational new drugs 20121201 |
| Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. | Investigational new drugs 20121201 |
| Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. | Cancer treatment reviews 20121201 |
| Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. | Investigational new drugs 20121201 |
| Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. | Medical oncology (Northwood, London, England) 20121201 |
| Extrahepatic spread of hepatocellular carcinoma. | Panminerva medica 20121201 |
| Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia. | Molecular pharmaceutics 20121105 |
| The effects of sorafenib on liver regeneration in a model of partial hepatectomy. | The Journal of surgical research 20121101 |
| Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. | Pediatric blood & cancer 20121101 |
| The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. | Cancer 20121101 |
| A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. | Annals of surgical oncology 20121101 |
| Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. | Cancer treatment reviews 20121101 |
| The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. | Haematologica 20121101 |
| BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20121101 |
| MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20121101 |
| Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib. | International journal of urology : official journal of the Japanese Urological Association 20121101 |
| Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9. | Journal of hepatology 20121101 |
| Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. | Toxicological sciences : an official journal of the Society of Toxicology 20121101 |
| Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20121101 |
| High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. | Transplant international : official journal of the European Society for Organ Transplantation 20121101 |
| Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. | European journal of endocrinology 20121101 |
| Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. | International journal of oncology 20121101 |
| Design, synthesis and biological activities of sorafenib derivatives as antitumor agents. | Bioorganic & medicinal chemistry letters 20121101 |
| Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents. | Bioorganic & medicinal chemistry letters 20121101 |
| Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20121101 |
| Letter: sorafenib in portal hypertension. | Alimentary pharmacology & therapeutics 20121101 |
| A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3. | Haematologica 20121101 |
| Ontogeny and sorafenib metabolism. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121015 |
| Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121015 |
| Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. | Blood 20121011 |
| Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. | American journal of clinical oncology 20121001 |
| Saturable absorption of sorafenib in patients with solid tumors: a population model. | Investigational new drugs 20121001 |
| Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. | Investigational new drugs 20121001 |
| Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. | Investigational new drugs 20121001 |
| Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. | Pediatric blood & cancer 20121001 |
| Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. | Pediatric blood & cancer 20121001 |
| Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer. | Anti-cancer agents in medicinal chemistry 20121001 |
| AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. | Journal of cellular and molecular medicine 20121001 |
| Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. | Investigational new drugs 20121001 |
| Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. | Cancer treatment reviews 20121001 |
| Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors. | Clinical and experimental dermatology 20121001 |
| Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. | Critical reviews in oncology/hematology 20121001 |
| Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. | Journal of gastroenterology 20121001 |
| Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? | International journal of urology : official journal of the Japanese Urological Association 20121001 |
| Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20121001 |
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. | Journal of hepatology 20121001 |
| Sorafenib for lung cancer: is the 'Battle' still open? | Expert opinion on investigational drugs 20121001 |
| Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20121001 |
| Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. | Molecular cancer therapeutics 20121001 |
| The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. | Acta pharmacologica Sinica 20121001 |
| Vemurafenib: in unresectable or metastatic melanoma. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20121001 |
| Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. | The Annals of pharmacotherapy 20121001 |
| Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. | Hepatobiliary & pancreatic diseases international : HBPD INT 20121001 |
| [Renal cell carcinoma-response criteria of molecular targeted therapy and the timing of sequential drugs in patients with advanced renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20121001 |
| Stem cell factor receptor/c-Kit: from basic science to clinical implications. | Physiological reviews 20121001 |
| Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations. | Cancer letters 20120928 |
| An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. | Biochemical and biophysical research communications 20120928 |
| A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma. | International journal of cardiology 20120920 |
| Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. | The Journal of biological chemistry 20120914 |
| Conformation-specific effects of Raf kinase inhibitors. | Journal of medicinal chemistry 20120913 |
| FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. | Cell stem cell 20120907 |
| Hepatocellular carcinoma presenting as an incidental isolated malignant portal vein thrombosis. | Journal of gastrointestinal cancer 20120901 |
| Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. | European journal of radiology 20120901 |
| Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. | Medical oncology (Northwood, London, England) 20120901 |
| Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2. | Medical oncology (Northwood, London, England) 20120901 |
| Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? | Medical oncology (Northwood, London, England) 20120901 |
| Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. | Urologic oncology 20120901 |
| Beyond bevacizumab: antiangiogenic agents. | Clinical lung cancer 20120901 |
| Sorafenib rechallenge in patients with metastatic renal cell carcinoma. | BJU international 20120901 |
| Sorafenib rechalenge in metastatic renal cell carcinoma. | BJU international 20120901 |
| K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. | Cancer letters 20120901 |
| Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. | BJU international 20120901 |
| Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. | Journal of gastroenterology 20120901 |
| Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. | Retina (Philadelphia, Pa.) 20120901 |
| Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. | Hepatology (Baltimore, Md.) 20120901 |
| A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. | Clinical genitourinary cancer 20120901 |
| Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20120901 |
| Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. | Journal of hepatology 20120901 |
| Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. | Cancer metastasis reviews 20120901 |
| Quality of life and supportive care for patients with metastatic renal cell carcinoma. | Cancer metastasis reviews 20120901 |
| Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. | Carcinogenesis 20120901 |
| Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. | Nuclear medicine communications 20120901 |
| Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. | The Journal of clinical endocrinology and metabolism 20120901 |
| Sorafenib in non-small cell lung cancer. | Expert opinion on investigational drugs 20120901 |
| Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. | The oncologist 20120901 |
| Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. | Japanese journal of clinical oncology 20120901 |
| Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. | Clinical genitourinary cancer 20120901 |
| Novel agents and approaches for advanced renal cell carcinoma. | The Journal of urology 20120901 |
| Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. | Cancer metastasis reviews 20120901 |
| Autophagic action of new targeting agents in head and neck oncology. | Cancer biology & therapy 20120901 |
| Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120901 |
| Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. | European journal of medicinal chemistry 20120901 |
| Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management. | Zeitschrift fur Gastroenterologie 20120901 |
| Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? | Transplantation proceedings 20120901 |
| Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. | Annals of oncology : official journal of the European Society for Medical Oncology 20120901 |
| Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. | Anticancer research 20120901 |
| Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. | Cancer journal (Sudbury, Mass.) 20120901 |
| [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]. | Magyar onkologia 20120901 |
| Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. | Clinics (Sao Paulo, Brazil) 20120901 |
| Commentary on 'comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial.' B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T.E. Hutson, M.D. Michaelson, V.A. Gorbunova, M.E. Gore, I.G. Rusakov, S. Negrier, Y.C. Ou, D. Castellano, H.Y. Lim, H. Uemura, J. Tarazi, D. Cella, C. Chen, B. Rosbrook, S. Kim, R.J. Motzer: Lancet 2011;378:1931-9 [Epub;2011, November 4]. | Urologic oncology 20120901 |
| [Multidisciplinary management of hepatocellular carcinoma in cirrhotic patients]. | Revue medicale de Bruxelles 20120901 |
| Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice. | Clinical drug investigation 20120808 |
| Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. | Clinical drug investigation 20120808 |
| Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. | Clinical drug investigation 20120808 |
| Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®). | Clinical drug investigation 20120808 |
| Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. | Clinical drug investigation 20120808 |
| Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. | British journal of cancer 20120807 |
| The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. | Investigational new drugs 20120801 |
| Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. | Investigational new drugs 20120801 |
| Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. | Investigational new drugs 20120801 |
| Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma. | Investigational new drugs 20120801 |
| SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. | Investigational new drugs 20120801 |
| A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. | Investigational new drugs 20120801 |
| Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells. | Investigational new drugs 20120801 |
| Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. | International journal of cancer 20120801 |
| Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. | Critical reviews in oncology/hematology 20120801 |
| Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20120801 |
| PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. | The Journal of surgical research 20120801 |
| Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. | Hepatology (Baltimore, Md.) 20120801 |
| Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma. | Hepatology (Baltimore, Md.) 20120801 |
| Inhibition of corneal neovascularization in rats by systemic administration of sorafenib. | Cornea 20120801 |
| The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. | Current oncology reports 20120801 |
| New use for an old drug: inhibiting ABCG2 with sorafenib. | Molecular cancer therapeutics 20120801 |
| Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. | The Journal of pathology 20120801 |
| Sorafenib in locally advanced or metastatic breast cancer. | Expert opinion on investigational drugs 20120801 |
| Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. | Japanese journal of clinical oncology 20120801 |
| Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. | Recent patents on anti-infective drug discovery 20120801 |
| Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. | International journal of oncology 20120801 |
| Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. | Molecular cancer therapeutics 20120801 |
| Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. | Endocrine-related cancer 20120801 |
| Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. | British journal of haematology 20120801 |
| Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. | Cancer chemotherapy and pharmacology 20120801 |
| Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. | HPB : the official journal of the International Hepato Pancreato Biliary Association 20120801 |
| Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | The Journal of urology 20120801 |
| Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. | Thyroid : official journal of the American Thyroid Association 20120801 |
| Molecular mechanisms of sorafenib action in liver cancer cells. | Cell cycle (Georgetown, Tex.) 20120801 |
| Targeting angiogenesis in metastatic breast cancer. | The oncologist 20120801 |
| HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells. | Anticancer research 20120801 |
| Molecular targeted therapies in hepatocellular carcinoma. | Seminars in oncology 20120801 |
| Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. | Seminars in oncology 20120801 |
| Chemoembolization for hepatocellular carcinoma. | Seminars in oncology 20120801 |
| Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20120801 |
| Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension. | American journal of respiratory and critical care medicine 20120801 |
| [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20120801 |
| Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. | Journal of the National Comprehensive Cancer Network : JNCCN 20120801 |
| The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. | Future oncology (London, England) 20120801 |
| Impact of restricting access to high-cost medications for hepatocellular carcinoma. | Expert review of pharmacoeconomics & outcomes research 20120801 |
| [Small intestinal metastasis from renal cell carcinoma: a case report]. | Hinyokika kiyo. Acta urologica Japonica 20120801 |
| [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma]. | Hinyokika kiyo. Acta urologica Japonica 20120801 |
| Cytotoxic prenylated acetophenone dimers from Acronychia pedunculata. | Journal of natural products 20120727 |
| Sorafenib in advanced melanoma: a critical role for pharmacokinetics? | British journal of cancer 20120724 |
| PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines. | International journal of cancer 20120715 |
| Preliminary experience with personalized and targeted therapy for pediatric brain tumors. | Pediatric blood & cancer 20120715 |
| Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. | Biochemical pharmacology 20120715 |
| Combining antiangiogenics to overcome resistance: rationale and clinical experience. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120715 |
| Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors. | Bioorganic & medicinal chemistry 20120715 |
| 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). | Bioorganic & medicinal chemistry letters 20120715 |
| GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). | Biochemical and biophysical research communications 20120706 |
| Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option? | Archives of medical science : AMS 20120704 |
| Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. | European journal of radiology 20120701 |
| Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. | Journal of cellular and molecular medicine 20120701 |
| Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. | The Journal of surgical research 20120701 |
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. | European journal of cancer (Oxford, England : 1990) 20120701 |
| Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy. | Cancer letters 20120701 |
| Targeted therapy for biliary tract cancers. | Journal of hepato-biliary-pancreatic sciences 20120701 |
| Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. | Hepatology (Baltimore, Md.) 20120701 |
| Sorafenib prolongs survival, but what happens to the symptoms? | Journal of hepatology 20120701 |
| Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. | Leukemia 20120701 |
| A maxillary mass in a HBV-cirrhotic patient. | Liver international : official journal of the International Association for the Study of the Liver 20120701 |
| Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. | Journal of hepatology 20120701 |
| Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. | Journal of hepatology 20120701 |
| Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. | Scandinavian journal of gastroenterology 20120701 |
| RAIN-Droplet: a novel 3D in vitro angiogenesis model. | Laboratory investigation; a journal of technical methods and pathology 20120701 |
| Phase II study of sorafenib in patients with relapsed or refractory lymphoma. | British journal of haematology 20120701 |
| Antiangiogenic approaches for the treatment of advanced synovial sarcomas. | Current opinion in oncology 20120701 |
| Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120701 |
| Words of wisdom. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | European urology 20120701 |
| Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2. | Bioorganic & medicinal chemistry letters 20120701 |
| Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. | Cancer biology & therapy 20120701 |
| Re: Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. | The Journal of urology 20120701 |
| First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. | International journal of clinical practice 20120701 |
| Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. | Journal of vascular and interventional radiology : JVIR 20120701 |
| Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. | Anticancer research 20120701 |
| The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. | Anticancer research 20120701 |
| New therapeutic agents in uveal melanoma. | Anticancer research 20120701 |
| Novel agents in renal carcinoma: a reality check. | Therapeutic advances in medical oncology 20120701 |
| [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20120701 |
| Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. | Cell death & disease 20120701 |
| Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? | Expert review of anticancer therapy 20120701 |
| Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients. | Acta medica Indonesiana 20120701 |
| Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. | Journal of medicinal chemistry 20120628 |
| Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. | Blood 20120621 |
| BH3 mimetics and multi-kinase inhibition in AML. | Blood 20120621 |
| Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120615 |
| Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors. | Bioorganic & medicinal chemistry 20120615 |
| Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo. | Biochemical and biophysical research communications 20120615 |
| Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. | Nature 20120606 |
| Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. | British journal of cancer 20120605 |
| Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. | British journal of cancer 20120605 |
| Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. | Journal of gastrointestinal cancer 20120601 |
| Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. | Investigational new drugs 20120601 |
| Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. | Investigational new drugs 20120601 |
| Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. | Medical oncology (Northwood, London, England) 20120601 |
| Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. | Investigational new drugs 20120601 |
| Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. | Investigational new drugs 20120601 |
| Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. | Surgical oncology 20120601 |
| A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. | Investigational new drugs 20120601 |
| Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. | Medical oncology (Northwood, London, England) 20120601 |
| Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. | Hematological oncology 20120601 |
| Brain metastases from renal cell carcinoma. Should we change the current standard? | Cancer treatment reviews 20120601 |
| Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia. | Bone marrow transplantation 20120601 |
| Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. | Critical reviews in oncology/hematology 20120601 |
| Sorafenib in hepatocellular carcinoma - a post marketing evaluation. | Immunopharmacology and immunotoxicology 20120601 |
| Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. | Leukemia & lymphoma 20120601 |
| Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20120601 |
| Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. | Cancer metastasis reviews 20120601 |
| Gastrointestinal stromal tumors. | International journal of colorectal disease 20120601 |
| Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. | Leukemia 20120601 |
| Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease. | Arthritis and rheumatism 20120601 |
| Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. | European radiology 20120601 |
| Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report. | Clinical genitourinary cancer 20120601 |
| Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. | Cancer letters 20120601 |
| [Long stabilization of sarcomatoid renal cell carcinoma treated with sorafenib]. | Actas urologicas espanolas 20120601 |
| Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. | Clinical and experimental nephrology 20120601 |
| Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. | Journal of hepatology 20120601 |
| Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. | Journal of hepatology 20120601 |
| Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. | Journal of hepatology 20120601 |
| Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. | Journal of cancer research and clinical oncology 20120601 |
| Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. | Anti-cancer drugs 20120601 |
| An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. | Cancer chemotherapy and pharmacology 20120601 |
| Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. | Endocrine-related cancer 20120601 |
| TACE with or without systemic therapy? | Journal of hepatology 20120601 |
| A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. | Angiogenesis 20120601 |
| Functional imaging techniques in hepatocellular carcinoma. | European journal of nuclear medicine and molecular imaging 20120601 |
| Management of hepatocellular carcinoma: beyond sorafenib. | Current oncology reports 20120601 |
| Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma. | European journal of endocrinology 20120601 |
| Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. | Cell biochemistry and biophysics 20120601 |
| Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis. | Asia-Pacific journal of clinical oncology 20120601 |
| The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. | Asia-Pacific journal of clinical oncology 20120601 |
| An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. | Analytical and bioanalytical chemistry 20120601 |
| Multiple cutaneous metastatic chordomas from the sacrum. | Journal of the American Academy of Dermatology 20120601 |
| Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. | Targeted oncology 20120601 |
| Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. | Clinical genitourinary cancer 20120601 |
| [News in management of colorectal cancer at JFHOD 2012 meeting]. | Bulletin du cancer 20120601 |
| International variability in the reimbursement of cancer drugs by publically funded drug programs. | Current oncology (Toronto, Ont.) 20120601 |
| New developments in castrate-resistant prostate cancer. | BJU international 20120601 |
| Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. | Medical ultrasonography 20120601 |
| [A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20120601 |
| Status quo of chronic liver diseases, including hepatocellular carcinoma, in Mongolia. | The Korean journal of internal medicine 20120601 |
| Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib. | Archives of dermatology 20120601 |
| The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. | Neoplasia (New York, N.Y.) 20120601 |
| [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients]. | Zhonghua wai ke za zhi [Chinese journal of surgery] 20120601 |
| Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. | Blood 20120531 |
| Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. | The EMBO journal 20120530 |
| Concomitant lung metastasis in patients with advanced hepatocellular carcinoma. | World journal of gastroenterology 20120528 |
| Synthesis and biological evaluation of novel N-methyl-picolinamide-4-thiol derivatives as potential antitumor agents. | Molecules (Basel, Switzerland) 20120525 |
| Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. | American journal of physiology. Gastrointestinal and liver physiology 20120515 |
| A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma. | World journal of gastrointestinal oncology 20120515 |
| [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation]. | Zhonghua yi xue za zhi 20120515 |
| Novel molecular targeted therapies for refractory thyroid cancer. | Head & neck 20120501 |
| Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. | Critical reviews in oncology/hematology 20120501 |
| Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. | BJU international 20120501 |
| Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. | Annals of surgical oncology 20120501 |
| Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. | Cancer chemotherapy and pharmacology 20120501 |
| Design and synthesis of 2-iminothiazolidin-4-one moiety-containing compounds as potent antiproliferative agents. | Archiv der Pharmazie 20120501 |
| Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. | Journal of clinical pharmacology 20120501 |
| Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. | Journal of hepatology 20120501 |
| Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20120501 |
| Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. | Cancer chemotherapy and pharmacology 20120501 |
| An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma - a flawed analysis? | Expert opinion on pharmacotherapy 20120501 |
| MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. | British journal of haematology 20120501 |
| Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. | European journal of gastroenterology & hepatology 20120501 |
| Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). | Oncology reports 20120501 |
| Narrowing the knowledge gaps for melanoma. | Upsala journal of medical sciences 20120501 |
| Targeted therapeutic strategies for the management of renal cell carcinoma. | Current opinion in oncology 20120501 |
| Blood vessels as targets in tumor therapy. | Upsala journal of medical sciences 20120501 |
| Targeted therapy of hepatocellular carcinoma: present and future. | Journal of gastroenterology and hepatology 20120501 |
| Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. | European journal of cancer (Oxford, England : 1990) 20120501 |
| Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. | Cancer biology & therapy 20120501 |
| Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. | Cancer biology & therapy 20120501 |
| Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. | British journal of haematology 20120501 |
| Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120501 |
| Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. | Histology and histopathology 20120501 |
| Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20120501 |
| Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. | Thyroid : official journal of the American Thyroid Association 20120501 |
| Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. | Radiology 20120501 |
| Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma. | Japanese journal of clinical oncology 20120501 |
| Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. | Clinical and experimental pharmacology & physiology 20120501 |
| Sorafenib for treatment of hepatocellular carcinoma: a systematic review. | Digestive diseases and sciences 20120501 |
| New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line. | Bioorganic & medicinal chemistry letters 20120501 |
| Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents. | Bioorganic & medicinal chemistry 20120501 |
| Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancer. | Thyroid : official journal of the American Thyroid Association 20120501 |
| Sorafenib in liver cancer. | Expert opinion on pharmacotherapy 20120501 |
| Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions. | Journal of the National Comprehensive Cancer Network : JNCCN 20120501 |
| [First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)]. | Der Urologe. Ausg. A 20120501 |
| Painful leg mass. | The Journal of family practice 20120501 |
| Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. | Future oncology (London, England) 20120501 |
| Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. | Clinical advances in hematology & oncology : H&O 20120501 |
| Synthesis and cytotoxic activity of some novel N-pyridinyl-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide derivatives. | Molecules (Basel, Switzerland) 20120423 |
| Resampling phase III data to assess phase II trial designs and endpoints. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120415 |
| Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120415 |
| Synthesis and evaluation of 1-(substituted)-3-prop-2-ynylureas as antiangiogenic agents. | Bioorganic & medicinal chemistry letters 20120415 |
| Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. | Cell 20120413 |
| Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib. | Rare tumors 20120412 |
| Treatment selection in metastatic renal cell carcinoma: expert consensus. | Nature reviews. Clinical oncology 20120410 |
| [Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma]. | Zhonghua yi xue za zhi 20120403 |
| The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. | Investigational new drugs 20120401 |
| Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. | Journal of cellular physiology 20120401 |
| Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. | European journal of oncology nursing : the official journal of European Oncology Nursing Society 20120401 |
| Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. | Pediatric blood & cancer 20120401 |
| Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. | Cellular and molecular life sciences : CMLS 20120401 |
| Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. | Hepatology research : the official journal of the Japan Society of Hepatology 20120401 |
| A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. | Cancer chemotherapy and pharmacology 20120401 |
| Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice. | Liver international : official journal of the International Association for the Study of the Liver 20120401 |
| Sorafenib in clinical practice: evidence-based use or abuse? | Hepatology (Baltimore, Md.) 20120401 |
| Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. | Journal of neuro-oncology 20120401 |
| Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. | Journal of cancer research and clinical oncology 20120401 |
| Sorafenib in metastatic thyroid cancer. | Endocrine-related cancer 20120401 |
| The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds? | Arzneimittel-Forschung 20120401 |
| Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. | European urology 20120401 |
| Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120401 |
| Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor. | Cancer biology & therapy 20120401 |
| Novel targets for VEGF-independent anti-angiogenic drugs. | Expert opinion on investigational drugs 20120401 |
| A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. | Molecular cancer therapeutics 20120401 |
| Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120401 |
| Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors. | European journal of medicinal chemistry 20120401 |
| Intracranial metastasis from pediatric GI stromal tumor. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120401 |
| Sorafenib in melanoma. | Expert opinion on investigational drugs 20120401 |
| Improved chemotherapy for hepatocellular carcinoma. | Anticancer research 20120401 |
| Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. | Cell death & disease 20120401 |
| Molecular targeted therapy in acute myeloid leukemia. | Hematology (Amsterdam, Netherlands) 20120401 |
| Current status of targeted therapy for advanced renal cell carcinoma. | Korean journal of urology 20120401 |
| The optimal selection of radiotherapy treatment for hepatocellular carcinoma. | Gut and liver 20120401 |
| The Hirschsprung's-multiple endocrine neoplasia connection. | Clinics (Sao Paulo, Brazil) 20120401 |
| Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2. | Clinics (Sao Paulo, Brazil) 20120401 |
| Kinase inhibitors for advanced medullary thyroid carcinoma. | Clinics (Sao Paulo, Brazil) 20120401 |
| Side effects of anti-angiogenic drugs. | Thrombosis research 20120401 |
| Hepatocellular carcinoma. | Lancet (London, England) 20120331 |
| Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. | World journal of hepatology 20120327 |
| Indian health groups welcome country's first compulsory licence. | BMJ (Clinical research ed.) 20120316 |
| Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. | Rapid communications in mass spectrometry : RCM 20120315 |
| Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120315 |
| Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma. | British journal of cancer 20120313 |
| Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120310 |
| Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance. | Molecular pharmaceutics 20120305 |
| Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells. | Journal of proteome research 20120302 |
| A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib. | Journal of gastrointestinal cancer 20120301 |
| Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120301 |
| Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. | Gut 20120301 |
| Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? | Journal of hepatology 20120301 |
| Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. | Journal of hepatology 20120301 |
| Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. | Cancer chemotherapy and pharmacology 20120301 |
| Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. | Acta neuropathologica 20120301 |
| Sorafenib use while waiting for liver transplant: we still need to wait. | Journal of hepatology 20120301 |
| [Renal tolerance of targeted therapies]. | Bulletin du cancer 20120301 |
| Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. | Clinical genitourinary cancer 20120301 |
| Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. | Journal of gastroenterology 20120301 |
| Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. | Angiogenesis 20120301 |
| Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. | European journal of endocrinology 20120301 |
| Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. | American journal of hematology 20120301 |
| Sorafenib for advanced-stage hepatocellular carcinoma. | European journal of gastroenterology & hepatology 20120301 |
| Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120301 |
| Objective response to sorafenib in advanced clear-cell sarcoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20120301 |
| Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. | European journal of cancer (Oxford, England : 1990) 20120301 |
| Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. | Annals of oncology : official journal of the European Society for Medical Oncology 20120301 |
| Antiproliferative effect of novel platinum(II) and palladium(II) complexes on hepatic tumor stem cells in vitro. | European journal of medicinal chemistry 20120301 |
| Revealing multi-binding sites for taspine to VEGFR-2 by cell membrane chromatography zonal elution. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120301 |
| Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. | The oncologist 20120301 |
| How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided. | Expert review of anticancer therapy 20120301 |
| Using NF-κB as a molecular target for theranostics in radiation oncology research. | Expert review of molecular diagnostics 20120301 |
| [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. | Magyar onkologia 20120301 |
| Advanced HCC: emerging molecular therapies. | Minerva gastroenterologica e dietologica 20120301 |
| Pathways and gene expression profiles in hepatocellular carcinoma. | Minerva gastroenterologica e dietologica 20120301 |
| Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. | Oncotarget 20120301 |
| LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. | PLoS genetics 20120301 |
| Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? | Cancer biology & therapy 20120301 |
| Present status and problems on molecular targeted therapy of cancer. | Cancer research and treatment : official journal of Korean Cancer Association 20120301 |
| Developments in metastatic pancreatic cancer: is gemcitabine still the standard? | World journal of gastroenterology 20120227 |
| Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis. | Biochemical and biophysical research communications 20120217 |
| Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120215 |
| Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). | Clinical cancer research : an official journal of the American Association for Cancer Research 20120215 |
| Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. | World journal of gastroenterology 20120214 |
| Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210 |
| Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210 |
| Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas. | Oncogene 20120209 |
| A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. | Investigational new drugs 20120201 |
| Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. | Investigational new drugs 20120201 |
| Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. | Investigational new drugs 20120201 |
| Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. | Investigational new drugs 20120201 |
| Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. | Investigational new drugs 20120201 |
| Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. | Pediatric blood & cancer 20120201 |
| The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? | Critical reviews in oncology/hematology 20120201 |
| A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. | Annals of oncology : official journal of the European Society for Medical Oncology 20120201 |
| Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. | Annals of oncology : official journal of the European Society for Medical Oncology 20120201 |
| Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. | Molecular biology reports 20120201 |
| [KIT and KIT: from biology to clinical use]. | Bulletin du cancer 20120201 |
| Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. | Cancer chemotherapy and pharmacology 20120201 |
| Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. | Cancer 20120201 |
| Radioembolization for hepatocellular carcinoma. | Journal of hepatology 20120201 |
| [Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma]. | Actas urologicas espanolas 20120201 |
| Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? | European urology 20120201 |
| Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. | Gut 20120201 |
| Anti-angiogenic therapy: concept to clinic. | Microcirculation (New York, N.Y. : 1994) 20120201 |
| Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. | Endocrine-related cancer 20120201 |
| Targeted therapies in metastatic renal cell carcinoma: overview of the past year. | Current urology reports 20120201 |
| Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. | Molecular cancer therapeutics 20120201 |
| Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. | Molecular cancer therapeutics 20120201 |
| Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. | Clinical and experimental immunology 20120201 |
| [Hepatocellular carcinoma: what's new?]. | Deutsche medizinische Wochenschrift (1946) 20120201 |
| Liver-specific microRNA-122: Biogenesis and function. | RNA biology 20120201 |
| Sorafenib for the treatment of renal cancer. | Expert opinion on pharmacotherapy 20120201 |
| Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120201 |
| Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. | The oncologist 20120201 |
| Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. | AJR. American journal of roentgenology 20120201 |
| Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). | The oncologist 20120201 |
| Phase II studies in soft tissue sarcoma: time for reappraisal. | The oncologist 20120201 |
| Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. | Anticancer research 20120201 |
| Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report. | Anticancer research 20120201 |
| Targeting Mnks for cancer therapy. | Oncotarget 20120201 |
| [Sorafenib and octreotide combination therapy can inhibit proliferation of and induce apoptosis in human hepatoma cells]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20120201 |
| Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. | Cancer letters 20120128 |
| New sorafenib derivatives: synthesis, antiproliferative activity against tumour cell lines and antimetabolic evaluation. | Molecules (Basel, Switzerland) 20120123 |
| RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120 |
| Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. | Clinica chimica acta; international journal of clinical chemistry 20120118 |
| Targeted therapies for renal cell carcinoma: review of adverse event management strategies. | Journal of the National Cancer Institute 20120118 |
| Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. | Cancer cell 20120117 |
| The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. | Cancer 20120115 |
| [Endocrinology]. | Revue medicale suisse 20120111 |
| mTOR pathway inhibition in renal cell carcinoma. | Urologic oncology 20120101 |
| An update on targeted therapy in metastatic renal cell carcinoma. | Urologic oncology 20120101 |
| Functional analysis of microRNAs in human hepatocellular cancer stem cells. | Journal of cellular and molecular medicine 20120101 |
| Molecular remission of FLT3-ITD(+) positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib. | Bone marrow transplantation 20120101 |
| A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20120101 |
| A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. | Cancer chemotherapy and pharmacology 20120101 |
| Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. | Cancer 20120101 |
| Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma. | Pediatric blood & cancer 20120101 |
| Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy? | Journal of surgical oncology 20120101 |
| Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. | Journal of oncology 20120101 |
| Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. | Leukemia 20120101 |
| The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas. | Advances in hematology 20120101 |
| [Long-standing differentiated thyroid carcinoma]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101 |
| Targeting the tumor microenvironment: focus on angiogenesis. | Journal of oncology 20120101 |
| Targeting angiogenesis for controlling neuroblastoma. | Journal of oncology 20120101 |
| Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. | Journal of biochemistry 20120101 |
| Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy--retrospective analysis of changes over 3 yr in a German hospital. | European journal of haematology 20120101 |
| An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening. | Disease models & mechanisms 20120101 |
| Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. | Journal of oncology 20120101 |
| The Role of PTEN in Tumor Angiogenesis. | Journal of oncology 20120101 |
| Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20120101 |
| Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. | Investigative radiology 20120101 |
| Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. | Journal of oncology 20120101 |
| Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). | Molecular medicine (Cambridge, Mass.) 20120101 |
| Molecular pathogenesis of cholangiocarcinoma. | International journal of hepatology 20120101 |
| The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics. | Leukemia research 20120101 |
| VEGF spliced variants: possible role of anti-angiogenesis therapy. | Journal of nucleic acids 20120101 |
| Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. | World journal of surgery 20120101 |
| Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. | The Journal of clinical endocrinology and metabolism 20120101 |
| The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. | Alimentary pharmacology & therapeutics 20120101 |
| New targeted therapies for anaplastic thyroid cancer. | Anti-cancer agents in medicinal chemistry 20120101 |
| Basal breast cancer: a complex and deadly molecular subtype. | Current molecular medicine 20120101 |
| Investigational VEGF antagonists for psoriasis. | Expert opinion on investigational drugs 20120101 |
| Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120101 |
| Biomarkers as key contributors in treating malignant melanoma metastases. | Dermatology research and practice 20120101 |
| Angiogenesis in head and neck cancer: a review of the literature. | Journal of oncology 20120101 |
| Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. | Pharmacological research 20120101 |
| Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase. | Bioorganic & medicinal chemistry letters 20120101 |
| Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib. | Urologia internationalis 20120101 |
| Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors. | International journal of clinical pharmacology and therapeutics 20120101 |
| Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. | The oncologist 20120101 |
| Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. | BJU international 20120101 |
| Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. | Current medicinal chemistry 20120101 |
| Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. | Dermatology research and practice 20120101 |
| Ovarian cancer: opportunity for targeted therapy. | Journal of oncology 20120101 |
| Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. | PloS one 20120101 |
| Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. | BMC cancer 20120101 |
| Aflibercept in the treatment of metastatic colorectal cancer. | Clinical Medicine Insights. Oncology 20120101 |
| Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. | Clinical Medicine Insights. Oncology 20120101 |
| Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. | Clinical Medicine Insights. Oncology 20120101 |
| TGFβ signaling and cardiovascular diseases. | International journal of biological sciences 20120101 |
| BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. | Cell death & disease 20120101 |
| Rottlerin and cancer: novel evidence and mechanisms. | TheScientificWorldJournal 20120101 |
| Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. | Cell death & disease 20120101 |
| Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. | Journal of medical case reports 20120101 |
| Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer. | Nanoscale research letters 20120101 |
| Monoclonal antibodies and Fc fragments for treating solid tumors. | Biologics : targets & therapy 20120101 |
| Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients. | Clinical & developmental immunology 20120101 |
| Loss of the orphan nuclear receptor SHP is more pronounced in fibrolamellar carcinoma than in typical hepatocellular carcinoma. | PloS one 20120101 |
| Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors. | BMC cancer 20120101 |
| Drug transporter regulation in tumors by DNA methylation. | Genome medicine 20120101 |
| Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. | PloS one 20120101 |
| ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. | PloS one 20120101 |
| Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. | Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20120101 |
| Management of HCC. | Journal of hepatology 20120101 |
| Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma. | International journal of molecular sciences 20120101 |
| Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. | PloS one 20120101 |
| Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. | Journal of translational medicine 20120101 |
| Surgical approach to multifocal hepatocellular carcinoma with portal vein thrombosis and arterioportal shunt leading to portal hypertension and bleeding: a case report. | World journal of surgical oncology 20120101 |
| Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. | International journal of nanomedicine 20120101 |
| Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. | Journal of neuroinflammation 20120101 |
| Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. | World journal of surgical oncology 20120101 |
| Pulmonary arterial hypertension: advances in pathophysiology and management. | Indian journal of pharmacology 20120101 |
| Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia. | Clinical Medicine Insights. Oncology 20120101 |
| Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. | TheScientificWorldJournal 20120101 |
| Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). | PloS one 20120101 |
| Quercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells. | PloS one 20120101 |
| Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models. | Cancer cell international 20120101 |
| Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. | Oncology 20120101 |
| Gastrointestinal stromal tumors as an incidental finding in patients with a presumptive diagnosis of ovarian cancer. | Journal of gynecologic oncology 20120101 |
| Post-radiation increase in VEGF enhances glioma cell motility in vitro. | Radiation oncology (London, England) 20120101 |
| Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. | Journal of experimental & clinical cancer research : CR 20120101 |
| A genome-wide study of cytogenetic changes in colorectal cancer using SNP microarrays: opportunities for future personalized treatment. | PloS one 20120101 |
| Therapy for metastatic melanoma: the past, present, and future. | BMC medicine 20120101 |
| Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. | PloS one 20120101 |
| Novel VEGF-independent strategies targeting tumor vasculature: clinical aspects. | Current pharmaceutical design 20120101 |
| Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia. | PloS one 20120101 |
| Systemic delivery of oncolytic viruses: hopes and hurdles. | Advances in virology 20120101 |
| JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms. | Advances in hematology 20120101 |
| A pathological fracture and a solitary mass in the right clavicle: an unusual first presentation of HCC and the role of immunohistochemistry. | World journal of surgical oncology 20120101 |
| Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma. | BMC cancer 20120101 |
| The mTOR signalling pathway in human cancer. | International journal of molecular sciences 20120101 |
| Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. | PloS one 20120101 |
| Targeted agents for the treatment of metastatic melanoma. | OncoTargets and therapy 20120101 |
| Molecular prognostic prediction for locally advanced nasopharyngeal carcinoma by support vector machine integrated approach. | PloS one 20120101 |
| Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. | PloS one 20120101 |
| Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. | BMC cancer 20120101 |
| NF-κB as potential target in the treatment of melanoma. | Journal of translational medicine 20120101 |
| The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. | BMC cancer 20120101 |
| Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. | BMC cancer 20120101 |
| Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. | Molecular cancer 20120101 |
| Molecular alterations associated with osteosarcoma development. | Sarcoma 20120101 |
| Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation. | International journal of nanomedicine 20120101 |
| Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. | PloS one 20120101 |
| Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. | PloS one 20120101 |
| Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. | PloS one 20120101 |
| Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model. | Journal of oncology 20120101 |
| Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase. | Journal of oncology 20120101 |
| Immunotherapy of genitourinary malignancies. | Journal of oncology 20120101 |
| Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. | Journal of oncology 20120101 |
| Targeting the mTOR pathway in Chromophobe Kidney Cancer. | Journal of Cancer 20120101 |
| Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. | TheScientificWorldJournal 20120101 |
| Toward integrative cancer immunotherapy: targeting the tumor microenvironment. | Journal of translational medicine 20120101 |
| Icariside II induces apoptosis in U937 acute myeloid leukemia cells: role of inactivation of STAT3-related signaling. | PloS one 20120101 |
| Novel Insights into the Interplay between Apoptosis and Autophagy. | International journal of cell biology 20120101 |
| Phloroglucinol inhibits the bioactivities of endothelial progenitor cells and suppresses tumor angiogenesis in LLC-tumor-bearing mice. | PloS one 20120101 |
| Genetic polymorphism in a VEGF-independent angiogenesis gene ANGPT1 and overall survival of colorectal cancer patients after surgical resection. | PloS one 20120101 |
| RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer. | PloS one 20120101 |
| Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. | Journal of Cancer 20120101 |
| Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. | PloS one 20120101 |
| (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside. | International journal of molecular imaging 20120101 |
| Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin. | International journal of hepatology 20120101 |
| Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. | World journal of surgical oncology 20120101 |
| Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma. | ISRN surgery 20120101 |
| Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report. | Journal of medical case reports 20120101 |
| Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer. | Journal of biomedicine & biotechnology 20120101 |
| GRP78 knockdown enhances apoptosis via the down-regulation of oxidative stress and Akt pathway after epirubicin treatment in colon cancer DLD-1 cells. | PloS one 20120101 |
| Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. | PloS one 20120101 |
| Castration-resistant prostate cancer: mechanisms, targets, and treatment. | Prostate cancer 20120101 |
| Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. | Journal of thyroid research 20120101 |
| Novel therapies for aggressive B-cell lymphoma. | Advances in hematology 20120101 |
| Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. | PloS one 20120101 |
| Sulforaphane potentiates RNA damage induced by different xenobiotics. | PloS one 20120101 |
| Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. | Journal of biomedicine & biotechnology 20120101 |
| Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma. | Molecular biology international 20120101 |
| Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? | Clinical Medicine Insights. Oncology 20120101 |
| Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. | BMC cancer 20120101 |
| A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. | PloS one 20120101 |
| Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer. | EJNMMI research 20120101 |
| Osteosarcoma models: from cell lines to zebrafish. | Sarcoma 20120101 |
| Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies. | Sarcoma 20120101 |
| Solitary fibrous tumors and so-called hemangiopericytoma. | Sarcoma 20120101 |
| Hypoxia promotes tumor growth in linking angiogenesis to immune escape. | Frontiers in immunology 20120101 |
| Conformationally constrained peptides as protein tyrosine kinase inhibitors. | Current pharmaceutical design 20120101 |
| Alterations in cell cycle and induction of apoptotic cell death in breast cancer cells treated with α-mangostin extracted from mangosteen pericarp. | Journal of biomedicine & biotechnology 20120101 |
| MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions. | Sarcoma 20120101 |
| Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. | ISRN gastroenterology 20120101 |
| Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma. | ISRN oncology 20120101 |
| Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. | Clinical sarcoma research 20120101 |
| The role of bevacizumab in advanced epithelial ovarian cancer. | Current pharmaceutical design 20120101 |
| Development and validation of an automated high-throughput system for zebrafish in vivo screenings. | PloS one 20120101 |
| Combination drug delivery approaches in metastatic breast cancer. | Journal of drug delivery 20120101 |
| Childhood adrenocortical carcinoma: Case report and review. | Indian journal of endocrinology and metabolism 20120101 |
| Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? | Frontiers in endocrinology 20120101 |
| Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. | Frontiers in oncology 20120101 |
| Acute myeloid leukemia: focus on novel therapeutic strategies. | Clinical Medicine Insights. Oncology 20120101 |
| Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a-induced breast cancer cell migration. | PloS one 20120101 |
| Hepatocellular carcinoma: focus on different aspects of management. | ISRN oncology 20120101 |
| Current knowledge on pancreatic cancer. | Frontiers in oncology 20120101 |
| Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations. | Frontiers in oncology 20120101 |
| Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. | Frontiers in oncology 20120101 |
| Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? | Frontiers in oncology 20120101 |
| Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma. | Frontiers in oncology 20120101 |
| Locally advanced cancer of the esophagus, current treatment strategies, and future directions. | Frontiers in oncology 20120101 |
| Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. | Frontiers in endocrinology 20120101 |
| p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. | PloS one 20120101 |
| The molecular biology of soft-tissue sarcomas and current trends in therapy. | Sarcoma 20120101 |
| Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. | Case reports in oncology 20120101 |
| Emerging targeted therapies for castration-resistant prostate cancer. | Frontiers in endocrinology 20120101 |
| Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. | Clinical & developmental immunology 20120101 |
| Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. | PloS one 20120101 |
| Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. | Pathology research international 20120101 |
| Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma. | PloS one 20120101 |
| A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. | Oncology 20120101 |
| Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases. | Tumori 20120101 |
| The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines. | Chemotherapy 20120101 |
| Hepatocellular carcinoma: important biomarkers and their significance in molecular diagnostics and therapy. | Current medicinal chemistry 20120101 |
| An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review. | Case reports in medicine 20120101 |
| Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. | BMC cancer 20120101 |
| Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20120101 |
| Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma. | Cancer management and research 20120101 |
| Targeted therapies in sarcomas: challenging the challenge. | Sarcoma 20120101 |
| Extra-abdominal desmoid tumors associated with familial adenomatous polyposis. | Sarcoma 20120101 |
| Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. | PloS one 20120101 |
| Acute progression of BCR-FGFR1 induced murine B-lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage. | PloS one 20120101 |
| The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. | BMC cancer 20120101 |
| Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells. | In vivo (Athens, Greece) 20120101 |
| The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines. | Clinical laboratory 20120101 |
| Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. | International journal of nanomedicine 20120101 |
| Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. | OncoTargets and therapy 20120101 |
| Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. | Oncology 20120101 |
| Long-term survivors with metastatic uveal melanoma. | The open ophthalmology journal 20120101 |
| Metastatic gastric cancer - focus on targeted therapies. | Biologics : targets & therapy 20120101 |
| Active home-based cancer treatment. | Journal of multidisciplinary healthcare 20120101 |
| Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed? | Transplantation proceedings 20120101 |
| Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. | Onkologie 20120101 |
| Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases. | Onkologie 20120101 |
| Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. | Oncology 20120101 |
| Hepatocellular carcinoma: natural history, current management, and emerging tools. | Biologics : targets & therapy 20120101 |
| Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. | PloS one 20120101 |
| A rare adverse reaction of sorafenib. | The Libyan journal of medicine 20120101 |
| [Hepatocellular carcinoma - long-term treatable disease]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20120101 |
| Hypothyroidism during treatment with tyrosine kinase inhibitors. | Endokrynologia Polska 20120101 |
| State of the art of the therapeutic perspective of sorafenib against hematological malignancies. | Current medicinal chemistry 20120101 |
| Clinicopathological characteristics of hepatocellular carcinoma in Turkey. | Asian Pacific journal of cancer prevention : APJCP 20120101 |
| Affinity purification of protein kinases that adopt a specific inactive conformation. | Methods in molecular biology (Clifton, N.J.) 20120101 |
| Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. | BMC cancer 20120101 |
| Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. | Current topics in medicinal chemistry 20120101 |
| Sorafenib-induced tuberculosis reactivation. | Onkologie 20120101 |
| [Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL]. | Biofizika 20120101 |
| Molecularly targeted therapies in head and neck cancers. | Otolaryngologia polska = The Polish otolaryngology 20120101 |
| Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner. | BMC cancer 20120101 |
| Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. | International journal of molecular sciences 20120101 |
| Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase. | Journal of chemical information and modeling 20111227 |
| Role of BRAF in thyroid oncogenesis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111215 |
| A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. | Circulation research 20111209 |
| Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. | British journal of cancer 20111206 |
| Tilting the AXIS towards therapeutic limits in renal cancer. | Lancet (London, England) 20111203 |
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Lancet (London, England) 20111203 |
| Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. | Investigational new drugs 20111201 |
| Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. | Medical oncology (Northwood, London, England) 20111201 |
| Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. | Medical oncology (Northwood, London, England) 20111201 |
| Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. | Medical oncology (Northwood, London, England) 20111201 |
| Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. | Medical oncology (Northwood, London, England) 20111201 |
| Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. | Investigational new drugs 20111201 |
| Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report. | Medical oncology (Northwood, London, England) 20111201 |
| Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer. | Medical oncology (Northwood, London, England) 20111201 |
| Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. | World journal of urology 20111201 |
| Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. | Journal of clinical pharmacology 20111201 |
| Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. | BJU international 20111201 |
| Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression. | Cancer chemotherapy and pharmacology 20111201 |
| Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. | Cancer treatment reviews 20111201 |
| Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. | Pharmaceutical research 20111201 |
| Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20111201 |
| Revisiting the role of molecular targeted therapies in patients with brain metastases. | Journal of neuro-oncology 20111201 |
| Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. | European urology 20111201 |
| Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. | Journal of clinical immunology 20111201 |
| Ca2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy. | Molecular pharmacology 20111201 |
| Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. | Hepatology (Baltimore, Md.) 20111201 |
| BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. | Endocrine-related cancer 20111201 |
| Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. | Neuro-oncology 20111201 |
| Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. | Gynecologic oncology 20111201 |
| Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors. | Bioorganic & medicinal chemistry letters 20111201 |
| New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies. | European journal of medicinal chemistry 20111201 |
| Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. | Expert review of anticancer therapy 20111201 |
| Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. | Cancer chemotherapy and pharmacology 20111201 |
| A MEK-independent role for CRAF in mitosis and tumor progression. | Nature medicine 20111201 |
| Hepatocellular carcinoma treated with sorafenib. | Alimentary pharmacology & therapeutics 20111201 |
| Combination therapy for renal cell cancer: what are possible options? | Oncology 20111201 |
| Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? | Experimental dermatology 20111201 |
| Progress and contrasts of the development of tivozanib for therapy of kidney cancer. | Expert opinion on pharmacotherapy 20111201 |
| A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis. | Therapeutic drug monitoring 20111201 |
| Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20111201 |
| Erythema multiforme-like drug reaction to sorafenib. | Journal of drugs in dermatology : JDD 20111201 |
| The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). | The oncologist 20111201 |
| Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. | Journal of Korean medical science 20111201 |
| Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma. | The Canadian journal of urology 20111201 |
| VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20111201 |
| Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. | Medical molecular morphology 20111201 |
| Patterns of presentation, referral, and treatment of hepatocellular carcinoma in a pre-sorafenib era: experience of a Canadian provincial cancer agency. | Current oncology (Toronto, Ont.) 20111201 |
| Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. | Archives of dermatology 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Sorafenib: muscle wasting. | Prescrire international 20111201 |
| Metastatic hepatocellular carcinoma presenting as facial nerve palsy and facial pain. | The Korean journal of hepatology 20111201 |
| Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma. | Annals of dermatology 20111201 |
| Diagnostic and prognostic markers in differentiated thyroid cancer. | Current genomics 20111201 |
| Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. | Current genomics 20111201 |
| New targeted therapies for thyroid cancer. | Current genomics 20111201 |
| Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. | British journal of cancer 20111122 |
| Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. | European journal of pharmacology 20111116 |
| Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action. | Biochemical pharmacology 20111115 |
| Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets. | Biochemical pharmacology 20111115 |
| Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111115 |
| Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111115 |
| Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells. | Bioorganic & medicinal chemistry 20111115 |
| Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. | British journal of cancer 20111108 |
| Angiosarcoma: state of the art and perspectives. | Critical reviews in oncology/hematology 20111101 |
| HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. | Breast cancer research and treatment 20111101 |
| Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. | Critical reviews in oncology/hematology 20111101 |
| Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. | Cancer chemotherapy and pharmacology 20111101 |
| Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. | Journal of hepatology 20111101 |
| Sorafenib in renal cell carcinoma. | Critical reviews in oncology/hematology 20111101 |
| Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. | Cancer chemotherapy and pharmacology 20111101 |
| Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. | Cancer 20111101 |
| BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. | British journal of haematology 20111101 |
| Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. | Journal of gastroenterology and hepatology 20111101 |
| Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. | Lung cancer (Amsterdam, Netherlands) 20111101 |
| Targeting STAT3 in hepatocellular carcinoma: sorafenib again…. | Journal of hepatology 20111101 |
| A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish. | Disease models & mechanisms 20111101 |
| Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20111101 |
| ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. | Toxicological sciences : an official journal of the Society of Toxicology 20111101 |
| Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20111101 |
| Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. | Cancer biology & therapy 20111101 |
| Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up. | Transplant international : official journal of the European Society for Organ Transplantation 20111101 |
| Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. | Current cancer drug targets 20111101 |
| A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. | European journal of gastroenterology & hepatology 20111101 |
| Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. | BJU international 20111101 |
| Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1-carboxamide derivatives against melanoma cell line. | Archiv der Pharmazie 20111101 |
| Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. | Alimentary pharmacology & therapeutics 20111101 |
| Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. | Japanese journal of clinical oncology 20111101 |
| Clinical experience with antiangiogenic therapy in leukemia. | Current cancer drug targets 20111101 |
| The two faces of FBW7 in cancer drug resistance. | BioEssays : news and reviews in molecular, cellular and developmental biology 20111101 |
| Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma? | Journal of gastroenterology and hepatology 20111101 |
| Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. | Journal of gastroenterology and hepatology 20111101 |
| Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. | The oncologist 20111101 |
| Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? | The oncologist 20111101 |
| [Tyrosine kinase inhibitors]. | Bulletin du cancer 20111101 |
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | Nature biotechnology 20111101 |
| Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. | Expert review of anticancer therapy 20111101 |
| Role of sorafenib in renal cell carcinoma: focus on elderly patients. | Expert review of anticancer therapy 20111101 |
| Chloracne-like drug eruption associated with sorafenib. | Journal of drugs in dermatology : JDD 20111101 |
| Tyrosine kinase inhibitors for metastatic renal cell carcinoma. | Drug and therapeutics bulletin 20111101 |
| Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. | Anticancer research 20111101 |
| [Hyperthemia enhances activated lymphocytes and molecular target therapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. | International journal of pharmaceutics 20111031 |
| Comprehensive analysis of kinase inhibitor selectivity. | Nature biotechnology 20111030 |
| Reversible cardiomyopathy associated with sunitinib and sorafenib. | The New England journal of medicine 20111027 |
| Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. | Rare tumors 20111021 |
| Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111020 |
| TACE and sorafenib: a good marriage? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111020 |
| Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. | Human molecular genetics 20111015 |
| A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. | Investigational new drugs 20111001 |
| Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. | Investigational new drugs 20111001 |
| Ultraviolet recall dermatitis reaction with sorafenib. | Investigational new drugs 20111001 |
| How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20111001 |
| A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. | American journal of clinical oncology 20111001 |
| Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. | Journal of hepatology 20111001 |
| Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. | Journal of hepatology 20111001 |
| Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. | American journal of respiratory cell and molecular biology 20111001 |
| Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. | BJU international 20111001 |
| Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. | Autophagy 20111001 |
| ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. | European urology 20111001 |
| [Targeting the RAS signalling pathway in cancer]. | Bulletin du cancer 20111001 |
| Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. | Gynecologic oncology 20111001 |
| Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. | The Journal of investigative dermatology 20111001 |
| Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. | PharmacoEconomics 20111001 |
| Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. | Transplant international : official journal of the European Society for Organ Transplantation 20111001 |
| Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. | Autophagy 20111001 |
| The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target. | The Journal of clinical endocrinology and metabolism 20111001 |
| Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. | Current cancer drug targets 20111001 |
| Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents. | European journal of medicinal chemistry 20111001 |
| Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way. | Journal of biomolecular screening 20111001 |
| Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. | Alimentary pharmacology & therapeutics 20111001 |
| The clinical development of FLT3 inhibitors in acute myeloid leukemia. | Expert opinion on investigational drugs 20111001 |
| [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?]. | Bulletin du cancer 20111001 |
| [Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients]. | Gastroenterologia y hepatologia 20111001 |
| Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma. | Clinical journal of oncology nursing 20111001 |
| Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways. | Anticancer research 20111001 |
| Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus. | Anticancer research 20111001 |
| [Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology)]. | Der Urologe. Ausg. A 20111001 |
| [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111001 |
| [Dermatologic side effects induced by new angiogenesis inhibitors]. | Bulletin du cancer 20111001 |
| [Myocardial metastasis from renal cell carcinoma treated with sorafenib]. | Hinyokika kiyo. Acta urologica Japonica 20111001 |
| Induction of cancer cell death by isoflavone: the role of multiple signaling pathways. | Nutrients 20111001 |
| Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. | British journal of cancer 20110927 |
| The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. | Journal of molecular biology 20110916 |
| A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. | Cancer 20110915 |
| c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. | Cancer biology & therapy 20110915 |
| 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors. | Bioorganic & medicinal chemistry letters 20110915 |
| Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. | World journal of gastroenterology 20110914 |
| Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. | ChemMedChem 20110905 |
| Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901 |
| Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib. | Journal of clinical gastroenterology 20110901 |
| Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. | BJU international 20110901 |
| Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. | BJU international 20110901 |
| Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. | Journal of neuro-oncology 20110901 |
| Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. | Journal of cancer survivorship : research and practice 20110901 |
| Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. | Hepatology international 20110901 |
| [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies]. | Der Urologe. Ausg. A 20110901 |
| Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. | American journal of physiology. Cell physiology 20110901 |
| Late recurrence of hepatocellular carcinoma after liver transplantation. | World journal of surgery 20110901 |
| t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. | Leukemia research 20110901 |
| Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20110901 |
| Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. | European journal of cancer (Oxford, England : 1990) 20110901 |
| Targeted-therapy and imaging response: a new paradigm for clinical evaluation? | Reviews on recent clinical trials 20110901 |
| Current systemic management of metastatic renal cell carcinoma - first line and second line therapy. | Current opinion in supportive and palliative care 20110901 |
| Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. | Liver international : official journal of the International Association for the Study of the Liver 20110901 |
| Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. | The FEBS journal 20110901 |
| Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. | Gastroenterology 20110901 |
| Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. | Clinical pharmacokinetics 20110901 |
| An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. | Clinical colorectal cancer 20110901 |
| Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab. | The neurologist 20110901 |
| The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. | The oncologist 20110901 |
| A computational approach to finding novel targets for existing drugs. | PLoS computational biology 20110901 |
| Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports. | Transplantation proceedings 20110901 |
| Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis. | Archives of ophthalmology (Chicago, Ill. : 1960) 20110901 |
| Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. | Medical molecular morphology 20110901 |
| Interstitial granulomatous drug reaction to sorafenib. | Archives of dermatology 20110901 |
| [Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20110901 |
| Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production. | Histopathology 20110901 |
| [Small renal cell carcinoma presented with pleural metastasis and multiple bone metastasis ; a case report]. | Hinyokika kiyo. Acta urologica Japonica 20110901 |
| Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines. | The Korean journal of hepatology 20110901 |
| [Synthesis and biological evaluation of sorafenib thiourea derivatives]. | Yao xue xue bao = Acta pharmaceutica Sinica 20110901 |
| Intra-atrial tumor thrombi secondary to hepatocellular carcinoma responding to chemotherapy. | North American journal of medical sciences 20110901 |
| Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. | Blood 20110825 |
| Objective assessment of tumour response to therapy based on tumour growth kinetics. | British journal of cancer 20110823 |
| Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. | British journal of cancer 20110823 |
| Multikinase inhibitors: a new option for the treatment of thyroid cancer. | Nature reviews. Endocrinology 20110823 |
| Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820 |
| Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110815 |
| Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110815 |
| The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. | Cancer chemotherapy and pharmacology 20110801 |
| Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. | Annals of oncology : official journal of the European Society for Medical Oncology 20110801 |
| Population pharmacokinetic analysis of sorafenib in patients with solid tumours. | British journal of clinical pharmacology 20110801 |
| Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. | Cancer prevention research (Philadelphia, Pa.) 20110801 |
| Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. | The British journal of dermatology 20110801 |
| Classic biphasic pulmonary blastoma: a case report and review of the literature. | Lung cancer (Amsterdam, Netherlands) 20110801 |
| In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. | Endocrine-related cancer 20110801 |
| Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. | European journal of endocrinology 20110801 |
| Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. | International journal of oncology 20110801 |
| Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. | Hepatology (Baltimore, Md.) 20110801 |
| Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. | European journal of medicinal chemistry 20110801 |
| PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. | Cancer chemotherapy and pharmacology 20110801 |
| Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. | European journal of cancer (Oxford, England : 1990) 20110801 |
| Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. | Biochemical pharmacology 20110801 |
| An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. | Expert opinion on investigational drugs 20110801 |
| cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. | Toxicological sciences : an official journal of the Society of Toxicology 20110801 |
| Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. | Cancer biology & therapy 20110801 |
| Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. | Cancer biology & therapy 20110801 |
| A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801 |
| Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. | Cancer investigation 20110801 |
| Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. | Cancer investigation 20110801 |
| Sorafenib-induced eruption resembling pityriasis rubra pilaris. | Journal of the American Academy of Dermatology 20110801 |
| Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. | Hematology/oncology clinics of North America 20110801 |
| Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. | Hematology/oncology clinics of North America 20110801 |
| Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. | The oncologist 20110801 |
| Receptor kinase inhibitors target NSCLC: two antibodies and a small-molecule MET inhibitor. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110801 |
| Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. | Clinical lymphoma, myeloma & leukemia 20110801 |
| Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20110801 |
| Toxicities of targeted agents in advanced renal cell carcinoma. | Current clinical pharmacology 20110801 |
| Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. | Journal of Korean medical science 20110801 |
| [Systemic treatment of renal cell carcinoma - recent update]. | Wiener medizinische Wochenschrift (1946) 20110801 |
| An approach to meta-analysis of dose-finding studies. | Statistics in medicine 20110730 |
| [Adverse effects of new oncologic therapies]. | Praxis 20110727 |
| Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. | British journal of cancer 20110726 |
| Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. | British journal of cancer 20110726 |
| Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. | International journal of cancer 20110715 |
| The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. | Biochemical pharmacology 20110715 |
| Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. | Cancer research 20110715 |
| Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). | Bioorganic & medicinal chemistry 20110715 |
| Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. | World journal of gastroenterology 20110714 |
| Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. | British journal of cancer 20110712 |
| Locally advanced pancreatic adenocarcinoma: are we making progress?. Highlights from the '2011 ASCO Annual Meeting'. Chicago, IL, USA; June 3-7, 2011. | JOP : Journal of the pancreas 20110708 |
| Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the '2011 ASCO Annual Meeting'. Chicago, IL, USA; June 3-7, 2011. | JOP : Journal of the pancreas 20110708 |
| Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110701 |
| Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. | Cancer chemotherapy and pharmacology 20110701 |
| High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. | Cancer chemotherapy and pharmacology 20110701 |
| Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. | Annals of oncology : official journal of the European Society for Medical Oncology 20110701 |
| Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. | Annals of oncology : official journal of the European Society for Medical Oncology 20110701 |
| Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. | Journal of gastroenterology and hepatology 20110701 |
| Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. | Leukemia 20110701 |
| EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. | European journal of nuclear medicine and molecular imaging 20110701 |
| Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. | European journal of medicinal chemistry 20110701 |
| FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. | International journal of oncology 20110701 |
| Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. | Cancer research 20110701 |
| One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. | European journal of cancer (Oxford, England : 1990) 20110701 |
| Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. | Molecular cancer therapeutics 20110701 |
| Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma. | Journal of pediatric hematology/oncology 20110701 |
| Targeting cell death and survival receptors in hepatocellular carcinoma. | Anti-cancer agents in medicinal chemistry 20110701 |
| Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. | Anti-cancer agents in medicinal chemistry 20110701 |
| An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. | Expert opinion on pharmacotherapy 20110701 |
| Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies. | Current cancer drug targets 20110701 |
| The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. | Alimentary pharmacology & therapeutics 20110701 |
| Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110701 |
| Personalized medicine: new genomics, old lessons. | Human genetics 20110701 |
| Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110701 |
| [Comments on the article 'Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib']. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20110701 |
| [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. | Aktuelle Urologie 20110701 |
| Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. | Clinical lung cancer 20110701 |
| Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. | Neuro-oncology 20110701 |
| Pancreatic endocrine tumors: a report on a patient treated with sorafenib. | Journal of Korean medical science 20110701 |
| Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia. | Blood cancer journal 20110701 |
| microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. | FEBS letters 20110623 |
| Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620 |
| Synthesis and cytotoxic evaluation of novel N-methyl-4-phenoxypicolinamide derivatives. | Molecules (Basel, Switzerland) 20110620 |
| Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. | Drugs 20110618 |
| Activity of Sorafenib against desmoid tumor/deep fibromatosis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110615 |
| Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. | Journal of the National Cancer Institute 20110608 |
| Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). | British journal of cancer 20110607 |
| Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. | Investigational new drugs 20110601 |
| Painless acute pancreatitis associated with sorafenib treatment: a case report. | Medical oncology (Northwood, London, England) 20110601 |
| Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor. | International journal of clinical oncology 20110601 |
| Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. | British journal of clinical pharmacology 20110601 |
| Hepatocellular nodules in liver cirrhosis: state of the art CT evaluation (perfusion CT/volume helical shuttle scan/dual-energy CT, etc.). | Abdominal imaging 20110601 |
| Assessment of the treatment response of HCC. | Abdominal imaging 20110601 |
| Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. | Journal of gastroenterology 20110601 |
| Immunomodulatory effects of anti-angiogenic drugs. | Leukemia 20110601 |
| Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. | Cancer immunology, immunotherapy : CII 20110601 |
| Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. | Molecular therapy : the journal of the American Society of Gene Therapy 20110601 |
| Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. | European journal of medicinal chemistry 20110601 |
| Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents. | Archiv der Pharmazie 20110601 |
| Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. | Clinical & experimental metastasis 20110601 |
| Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. | World journal of urology 20110601 |
| Treatment of metastatic renal cell carcinoma and renal pelvic cancer. | Clinical and experimental nephrology 20110601 |
| Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. | International journal of urology : official journal of the Japanese Urological Association 20110601 |
| Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. | European journal of cancer (Oxford, England : 1990) 20110601 |
| Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. | Molecular cancer therapeutics 20110601 |
| VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. | Current cancer drug targets 20110601 |
| Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. | Molecular cancer therapeutics 20110601 |
| Meta-analysis of dermatological toxicities associated with sorafenib. | Clinical and experimental dermatology 20110601 |
| Oral complications of targeted cancer therapies: a narrative literature review. | Oral oncology 20110601 |
| Targeted nanogels: a versatile platform for drug delivery to tumors. | Molecular cancer therapeutics 20110601 |
| Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib. | Journal of the American Academy of Dermatology 20110601 |
| Sorafenib-associated multivessel coronary artery vasospasm. | Herz 20110601 |
| Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. | Asia-Pacific journal of clinical oncology 20110601 |
| Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series. | Asia-Pacific journal of clinical oncology 20110601 |
| Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. | International journal of urology : official journal of the Japanese Urological Association 20110601 |
| [New therapeutic options for advanced thyroid cancer]. | Deutsche medizinische Wochenschrift (1946) 20110601 |
| Targeting angiogenesis in esophagogastric adenocarcinoma. | The oncologist 20110601 |
| Pathway inhibition: emerging molecular targets for treating glioblastoma. | Neuro-oncology 20110601 |
| [In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma]. | Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20110601 |
| Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. | NMR in biomedicine 20110601 |
| [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110601 |
| Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. | Clinical therapeutics 20110601 |
| Sorafenib for the management of advanced renal cell carcinoma. | Expert review of anticancer therapy 20110601 |
| Allogeneic stem cell transplantation for renal cell carcinoma. | Expert review of anticancer therapy 20110601 |
| Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. | Expert review of anticancer therapy 20110601 |
| Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. | The Korean journal of hepatology 20110601 |
| Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis. | Korean journal of pediatrics 20110601 |
| The BATTLE trial: personalizing therapy for lung cancer. | Cancer discovery 20110601 |
| Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. | British journal of cancer 20110524 |
| Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. | British journal of cancer 20110524 |
| A painful cranial bulge. | Lancet (London, England) 20110521 |
| Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. | World journal of gastroenterology 20110521 |
| Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110515 |
| Severe sorafenib-induced hand-foot skin reaction. | Dermatology online journal 20110515 |
| Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. | Clinica chimica acta; international journal of clinical chemistry 20110512 |
| Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity. | Journal of medicinal chemistry 20110512 |
| Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. | Proceedings of the Japan Academy. Series B, Physical and biological sciences 20110511 |
| Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. | British journal of cancer 20110510 |
| Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. | World journal of gastroenterology 20110507 |
| Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. | Journal of the National Cancer Institute 20110504 |
| Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. | Cancer treatment reviews 20110501 |
| Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. | Journal of cancer research and clinical oncology 20110501 |
| Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. | Journal of hepatology 20110501 |
| New perspectives for the treatment of pulmonary hypertension. | British journal of pharmacology 20110501 |
| Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. | Angiogenesis 20110501 |
| The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20110501 |
| [Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium]. | Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 20110501 |
| Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. | Leukemia 20110501 |
| Molecular pathogenesis of hepatocellular carcinoma. | Alcoholism, clinical and experimental research 20110501 |
| Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. | European urology 20110501 |
| Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. | Hepatology (Baltimore, Md.) 20110501 |
| A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. | Molecular cancer therapeutics 20110501 |
| Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. | Japanese journal of clinical oncology 20110501 |
| HCC and angiogenesis: possible targets and future directions. | Nature reviews. Clinical oncology 20110501 |
| Targeted therapies for hepatocellular carcinoma. | Gastroenterology 20110501 |
| Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? | Expert opinion on drug metabolism & toxicology 20110501 |
| Tyrosine kinase inhibitors, pancreatic hyperenzymemia and acute pancreatitis: a review. | Recent patents on inflammation & allergy drug discovery 20110501 |
| Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. | Current opinion in clinical nutrition and metabolic care 20110501 |
| The search for an effective partner for sorafenib: the failure of doxorubicin. | Gastroenterology 20110501 |
| Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. | Liver international : official journal of the International Association for the Study of the Liver 20110501 |
| Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. | Cancer investigation 20110501 |
| Pazopanib for the treatment of renal cancer. | Expert opinion on pharmacotherapy 20110501 |
| Genetics of hepatobiliary carcinogenesis. | Seminars in liver disease 20110501 |
| [Indications and current development of new targeted therapies in pediatric oncology]. | Bulletin du cancer 20110501 |
| [Sorafenib in the treatment of hepatocellular carcinoma]. | Vnitrni lekarstvi 20110501 |
| [News on melanoma from the 2010 Dermatology Days in Paris]. | Annales de dermatologie et de venereologie 20110501 |
| [Progression of sorafenib in the treatment of acute myeloid leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110501 |
| Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma. | Acta histochemica et cytochemica 20110428 |
| [Novelties in the treatment for advanced renal-cell cancer]. | Orvosi hetilap 20110424 |
| Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110420 |
| B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger. | The Journal of biological chemistry 20110415 |
| CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? | Clinical cancer research : an official journal of the American Association for Cancer Research 20110415 |
| [11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. | Bioorganic & medicinal chemistry letters 20110415 |
| Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors. | Bioorganic & medicinal chemistry letters 20110415 |
| Assessing mitochondrial dysfunction in cells. | The Biochemical journal 20110415 |
| Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. | British journal of cancer 20110412 |
| Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. | Molecular pharmaceutics 20110404 |
| Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. | American journal of clinical oncology 20110401 |
| Skin care management in cancer patients: an evaluation of quality of life and tolerability. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110401 |
| Experience with sorafenib and adverse event management. | Critical reviews in oncology/hematology 20110401 |
| A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. | Cancer chemotherapy and pharmacology 20110401 |
| Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasis. | Cardiovascular and interventional radiology 20110401 |
| MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition. | Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20110401 |
| Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. | Annals of hematology 20110401 |
| A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. | BJU international 20110401 |
| Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. | Breast (Edinburgh, Scotland) 20110401 |
| Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. | Pharmacological research 20110401 |
| Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. | The Journal of pharmacology and experimental therapeutics 20110401 |
| Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20110401 |
| Overview of anti-angiogenic agents in development for ovarian cancer. | Gynecologic oncology 20110401 |
| Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. | Urology 20110401 |
| Biomarkers in renal cell carcinoma: what next? | Current oncology reports 20110401 |
| Toxicities of targeted therapy and their management in kidney cancer. | European urology 20110401 |
| Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. | Experimental hematology 20110401 |
| Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. | The Journal of clinical endocrinology and metabolism 20110401 |
| Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer. | Urology 20110401 |
| Development of second-generation VEGFR tyrosine kinase inhibitors: current status. | Current oncology reports 20110401 |
| Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. | Annals of oncology : official journal of the European Society for Medical Oncology 20110401 |
| Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. | Laboratory investigation; a journal of technical methods and pathology 20110401 |
| Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. | Thyroid : official journal of the American Thyroid Association 20110401 |
| An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. | The Journal of clinical investigation 20110401 |
| Sorafenib-induced premalignant and malignant skin lesions. | International journal of dermatology 20110401 |
| Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. | Seminars in oncology 20110401 |
| Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. | The oncologist 20110401 |
| Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110401 |
| [Hepatocellular carcinoma]. | Therapeutische Umschau. Revue therapeutique 20110401 |
| Targeted therapies for thyroid tumors. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20110401 |
| [Treatment of metastatic renal cell carcinoma]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20110401 |
| [Sorafenib induces apoptosis of U937 cells via inhibiting WNT signal pathway]. | Zhongguo shi yan xue ye xue za zhi 20110401 |
| Enhancing proteotoxic stress as an anticancer strategy. | Oncotarget 20110401 |
| Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. | Cell death & disease 20110401 |
| Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. | Molecular aspects of medicine 20110401 |
| Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. | PLoS computational biology 20110401 |
| A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. | Clinical advances in hematology & oncology : H&O 20110401 |
| Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. | Clinical advances in hematology & oncology : H&O 20110401 |
| Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy. | Clinical advances in hematology & oncology : H&O 20110401 |
| Metastatic medullary thyroid carcinoma: A case report. | Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20110401 |
| Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. | North American journal of medical sciences 20110401 |
| Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. | British journal of cancer 20110329 |
| FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. | Blood 20110324 |
| Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. | Journal of medicinal chemistry 20110324 |
| [Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer 20110320 |
| Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. | Bioorganic & medicinal chemistry 20110315 |
| Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. | British journal of cancer 20110315 |
| Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. | World journal of clinical oncology 20110310 |
| First-line treatment for advanced pancreatic cancer. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011. | JOP : Journal of the pancreas 20110309 |
| Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. | Drugs 20110305 |
| SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. | Nature 20110303 |
| NSCLC drug targets acquire new visibility. | Journal of the National Cancer Institute 20110302 |
| Osteonecrosis of the jaw related to sunitinib. | Oral and maxillofacial surgery 20110301 |
| Marginal increase of sunitinib exposure by grapefruit juice. | Cancer chemotherapy and pharmacology 20110301 |
| Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. | Journal of gastrointestinal cancer 20110301 |
| The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. | Cellular and molecular life sciences : CMLS 20110301 |
| Rapid response to sorafenib in metastatic medullary thyroid carcinoma. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20110301 |
| Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. | Annals of oncology : official journal of the European Society for Medical Oncology 20110301 |
| Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. | Leukemia research 20110301 |
| Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia. | Leukemia research 20110301 |
| Cardiotoxicity associated with targeting kinase pathways in cancer. | Toxicological sciences : an official journal of the Society of Toxicology 20110301 |
| RAF inhibition and induction of cutaneous squamous cell carcinoma. | Current opinion in oncology 20110301 |
| Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. | European journal of cancer (Oxford, England : 1990) 20110301 |
| Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110301 |
| Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110301 |
| Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. | Molecular cancer therapeutics 20110301 |
| Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. | Cancer biology & therapy 20110301 |
| Sunitinib and other targeted therapies for renal cell carcinoma. | British journal of cancer 20110301 |
| Targeted therapies for metastatic esophagogastric cancer. | Current treatment options in oncology 20110301 |
| Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. | Cancer metastasis reviews 20110301 |
| Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. | Radiology 20110301 |
| Sorafenib-associated hand-foot syndrome in Japanese patients. | The Journal of dermatology 20110301 |
| Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. | Clinics and research in hepatology and gastroenterology 20110301 |
| Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. | Journal of gastroenterology 20110301 |
| Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions. | Annals of clinical biochemistry 20110301 |
| Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. | Journal of drugs in dermatology : JDD 20110301 |
| Management of hepatocellular carcinoma: an update. | Hepatology (Baltimore, Md.) 20110301 |
| Synthesis of 1H-pyrazole-1-carboxamide derivatives and their antiproliferative activity against melanoma cell line. | Archiv der Pharmazie 20110301 |
| [Update on the different histological types of renal cell carcinoma and their specific treatment]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20110301 |
| Recent advances in anti-angiogenic therapy of cancer. | Oncotarget 20110301 |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. | Oncotarget 20110301 |
| Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. | Oncotarget 20110301 |
| Management of medullary thyroid cancer. | Minerva endocrinologica 20110301 |
| Current treatment strategies for castration-resistant prostate cancer. | Korean journal of urology 20110301 |
| Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment. | The Korean journal of hematology 20110301 |
| Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. | Targeted oncology 20110301 |
| Depressogenic effects of medications: a review. | Dialogues in clinical neuroscience 20110301 |
| [Hepatocellular carcinoma]. | Nihon Geka Gakkai zasshi 20110301 |
| What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. | Oncology (Williston Park, N.Y.) 20110301 |
| Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge? | Oncology (Williston Park, N.Y.) 20110301 |
| Sorafenib for HCC: a pragmatic perspective. | Oncology (Williston Park, N.Y.) 20110301 |
| Control of advanced cancer: the road to chronicity. | International journal of environmental research and public health 20110301 |
| Mcl-1 ubiquitination and destruction. | Oncotarget 20110301 |
| Saudi Oncology Society clinical management guidelines for renal cell carcinoma. | Urology annals 20110301 |
| Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. | Therapeutic advances in medical oncology 20110301 |
| Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: a pilot study. | World journal of gastroenterology 20110227 |
| The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. | Oncogene 20110224 |
| Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma. | JAMA 20110223 |
| The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors. | Bioorganic & medicinal chemistry letters 20110215 |
| PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. | British journal of cancer 20110215 |
| Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. | Investigational new drugs 20110201 |
| Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. | Journal of cellular and molecular medicine 20110201 |
| A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. | Lung cancer (Amsterdam, Netherlands) 20110201 |
| The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. | European radiology 20110201 |
| Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. | Cytokine 20110201 |
| Hypothyroidism in patients with renal cell carcinoma: blessing or curse? | Cancer 20110201 |
| Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. | Laboratory investigation; a journal of technical methods and pathology 20110201 |
| The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. | The Journal of investigative dermatology 20110201 |
| Mitogen-activated protein kinases in hepatocellular carcinoma development. | Seminars in cancer biology 20110201 |
| Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. | Cancer biology & therapy 20110201 |
| mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. | Journal of hepatology 20110201 |
| A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. | Leukemia 20110201 |
| Targeting BRAF for patients with melanoma. | British journal of cancer 20110201 |
| Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. | Thyroid : official journal of the American Thyroid Association 20110201 |
| Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. | Expert opinion on pharmacotherapy 20110201 |
| Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. | International journal of clinical practice 20110201 |
| [Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20110201 |
| [Medical therapies for hepatocellular carcinoma]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20110201 |
| [Sorafenib and radiotherapy association for hepatocellular carcinoma]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20110201 |
| Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. | Hepatology (Baltimore, Md.) 20110201 |
| Effect of sorafenib on murine liver regeneration. | Hepatology (Baltimore, Md.) 20110201 |
| Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. | Thyroid : official journal of the American Thyroid Association 20110201 |
| Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. | British journal of cancer 20110201 |
| Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? | Journal of Korean medical science 20110201 |
| [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20110201 |
| [Squamous cell carcinoma in a patient receiving sorafenib]. | Annales de dermatologie et de venereologie 20110201 |
| Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. | The oncologist 20110201 |
| Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. | The oncologist 20110201 |
| Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. | The oncologist 20110201 |
| Targeted therapies: Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma. | Nature reviews. Clinical oncology 20110201 |
| Sorafenib for advanced hepatocellular carcinoma: a systematic review. | Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20110201 |
| The need for third-line treatment in non-small cell lung cancer: an overview of new options. | Anticancer research 20110201 |
| Targeting translation dependence in cancer. | Oncotarget 20110201 |
| The Relationship between B7-H4 Expression and Clinicopathological Characteristics in Clinical Stage T1 Conventional Renal Cell Carcinoma. | Korean journal of urology 20110201 |
| [Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats]. | Bulletin du cancer 20110201 |
| Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. | British journal of haematology 20110201 |
| Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema. | Annals of dermatology 20110201 |
| Talactoferrin immunotherapy in metastatic renal cell carcinoma: a case series of four long-term survivors. | Journal of clinical medicine research 20110201 |
| c-Met: A potential therapeutic target for hepatocellular carcinoma. | Drug discoveries & therapeutics 20110201 |
| Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. | Blood 20110120 |
| Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. | British journal of cancer 20110118 |
| EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. | Cancer cell 20110118 |
| Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. | World journal of gastroenterology 20110114 |
| Trends in kinase selectivity: insights for target class-focused library screening. | Journal of medicinal chemistry 20110113 |
| Brazilian Propolis Suppresses Angiogenesis by Inducing Apoptosis in Tube-Forming Endothelial Cells through Inactivation of Survival Signal ERK1/2. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. | Urologic oncology 20110101 |
| An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. | Urologic oncology 20110101 |
| Types of pancreatic cancer in EUS-FNA and chemotherapy. | American journal of therapeutics 20110101 |
| Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. | BJU international 20110101 |
| Genomic and proteomic approaches to renal cell carcinoma. | Journal of nephrology 20110101 |
| Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. | Journal of neuro-oncology 20110101 |
| Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. | Urologic oncology 20110101 |
| Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7. | Biochimica et biophysica acta 20110101 |
| Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. | European journal of cancer (Oxford, England : 1990) 20110101 |
| Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. | Anti-cancer drugs 20110101 |
| Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. | Academic radiology 20110101 |
| Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. | The Journal of clinical endocrinology and metabolism 20110101 |
| The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. | The Journal of pharmacology and experimental therapeutics 20110101 |
| Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. | Haematologica 20110101 |
| Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. | Japanese journal of clinical oncology 20110101 |
| Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. | Lung cancer (Amsterdam, Netherlands) 20110101 |
| Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. | Breast cancer research and treatment 20110101 |
| Analysis of phosphoproteomics data. | Methods in molecular biology (Clifton, N.J.) 20110101 |
| The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. | The Journal of urology 20110101 |
| Regulation of posttranscriptional modification as a possible therapeutic approach for retinal neuroprotection. | Journal of ophthalmology 20110101 |
| Anti-VEGF therapy in breast and lung mouse models of cancers. | Journal of biomedicine & biotechnology 20110101 |
| Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110101 |
| Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. | International journal of oncology 20110101 |
| Kidney cancer: Does hypothyroidism predict clinical outcome? | Nature reviews. Urology 20110101 |
| Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20110101 |
| Blood vessel density in Basal cell carcinomas and benign trichogenic tumors as a marker for differential diagnosis in dermatopathology. | Journal of skin cancer 20110101 |
| Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? | Journal of gastroenterology and hepatology 20110101 |
| Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib. | Nephrology (Carlton, Vic.) 20110101 |
| In pursuit of new anti-angiogenic therapies for cancer treatment. | Frontiers in bioscience (Landmark edition) 20110101 |
| Targeting EGFR in bilio-pancreatic and liver carcinoma. | Frontiers in bioscience (Scholar edition) 20110101 |
| Therapeutic advances in women's cancers. | Frontiers in bioscience (Scholar edition) 20110101 |
| Targeting angiogenesis in childhood sarcomas. | Sarcoma 20110101 |
| How I manage my patients with hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20110101 |
| Novel molecular therapies in hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20110101 |
| Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer. | Acta crystallographica. Section C, Crystal structure communications 20110101 |
| Systematic review of medical treatment in melanoma: current status and future prospects. | The oncologist 20110101 |
| Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. | The oncologist 20110101 |
| Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. | Molecular cancer therapeutics 20110101 |
| Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. | BMC medical research methodology 20110101 |
| Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. | Journal of hematology & oncology 20110101 |
| Saddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma. | Cardiology research and practice 20110101 |
| Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. | Wiener klinische Wochenschrift 20110101 |
| Complete response for advanced liver cancer during sorafenib therapy: case report. | BMC gastroenterology 20110101 |
| Invasive squamous cell carcinoma and sorafenib in a black patient. | Archives of dermatology 20110101 |
| Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. | Indian journal of cancer 20110101 |
| Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography. | BMC cancer 20110101 |
| Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. | Sarcoma 20110101 |
| Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. | Journal of skin cancer 20110101 |
| TNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. | PloS one 20110101 |
| MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. | BMC cancer 20110101 |
| Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. | Anticancer research 20110101 |
| Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. | Digestion 20110101 |
| Pathogenesis, diagnosis and management of primary melanoma of the colon. | World journal of surgical oncology 20110101 |
| Cold agglutinin disease in fibrolamellar hepatocellular carcinoma: a rare association with a rare cancer variant. | Annals of Saudi medicine 20110101 |
| Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. | Molecular cancer 20110101 |
| Advanced hepatocellular carcinoma. Review of targeted molecular drugs. | Annals of hepatology 20110101 |
| DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer. | PloS one 20110101 |
| Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. | BMC cancer 20110101 |
| Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. | PloS one 20110101 |
| Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. | Korean journal of urology 20110101 |
| Role of cancer stem cells in hepatocarcinogenesis. | Genome medicine 20110101 |
| Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. | BMC cancer 20110101 |
| The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. | Head & neck oncology 20110101 |
| Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. | PloS one 20110101 |
| Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. | Biological & pharmaceutical bulletin 20110101 |
| Zebrafish bioassay-guided natural product discovery: isolation of angiogenesis inhibitors from East African medicinal plants. | PloS one 20110101 |
| Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. | Endocrine journal 20110101 |
| Vaccines targeting the neovasculature of tumors. | Vascular cell 20110101 |
| Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model. | PloS one 20110101 |
| Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. | PloS one 20110101 |
| Characteristics of human Ewing/PNET sarcoma models. | Annals of Saudi medicine 20110101 |
| Common secondary causes of resistant hypertension and rational for treatment. | International journal of hypertension 20110101 |
| Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. | PloS one 20110101 |
| Molecular predictors of response to antiangiogenesis therapies. | Cancer journal (Sudbury, Mass.) 20110101 |
| Targeted-therapy in advanced renal cell carcinoma. | Current medicinal chemistry 20110101 |
| [Sorafenib in combination with chemotherapy in the induction therapy for FLT3-ITD positive acute monocytic leukemia: a case report and literature review]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110101 |
| Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. | BMC cancer 20110101 |
| Future perspectives in melanoma research. Meeting report from the 'Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010'. | Journal of translational medicine 20110101 |
| [Detection by SPECT-CT scan with (99m)Tc-(V) DMSA of bone metastases in patient with medullary thyroid cancer]. | Revista espanola de medicina nuclear 20110101 |
| Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis. | BMC cancer 20110101 |
| Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. | BMC cancer 20110101 |
| Therapeutic Implications of Targeting AKT Signaling in Melanoma. | Enzyme research 20110101 |
| Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis. | Molecular cancer 20110101 |
| Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. | The journal of supportive oncology 20110101 |
| All that glitters: sorafenib. | Internal medicine (Tokyo, Japan) 20110101 |
| Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development. | Journal of Cancer 20110101 |
| Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. | Radiation oncology (London, England) 20110101 |
| A melanoma molecular disease model. | PloS one 20110101 |
| A theoretical entropy score as a single value to express inhibitor selectivity. | BMC bioinformatics 20110101 |
| Early finding of chest wall metastasis of hepatocellular carcinoma in a woman by fluorodeoxyglucose-positron emission tomography scan: a case report. | Journal of medical case reports 20110101 |
| Tumor suppressor gene-based nanotherapy: from test tube to the clinic. | Journal of drug delivery 20110101 |
| Apoptotic sphingolipid ceramide in cancer therapy. | Journal of lipids 20110101 |
| Renal involvement in preeclampsia: similarities to VEGF ablation therapy. | Journal of pregnancy 20110101 |
| Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. | Radiation oncology (London, England) 20110101 |
| Thyroid cancer: burden of illness and management of disease. | Journal of Cancer 20110101 |
| Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. | Hepato-gastroenterology 20110101 |
| Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways. | Current topics in medicinal chemistry 20110101 |
| High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde. | Molecular cancer 20110101 |
| Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. | Case reports in oncology 20110101 |
| Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. | PloS one 20110101 |
| Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. | Respiratory research 20110101 |
| Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. | Case reports in oncology 20110101 |
| MicroRNA gene dosage alterations and drug response in lung cancer. | Journal of biomedicine & biotechnology 20110101 |
| Target therapies in lung cancer. | Journal of biomedicine & biotechnology 20110101 |
| Metastatic malignant melanoma presenting as an appendiceal mucocele. | Journal of oncology 20110101 |
| Novel therapeutic strategies for targeting liver cancer stem cells. | International journal of biological sciences 20110101 |
| Survey of activated FLT3 signaling in leukemia. | PloS one 20110101 |
| Critical appraisal of trastuzumab in treatment of advanced stomach cancer. | Cancer management and research 20110101 |
| Apoptosis inducing effect of plumbagin on colonic cancer cells depends on expression of COX-2. | PloS one 20110101 |
| Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. | Journal of oncology 20110101 |
| Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. | PloS one 20110101 |
| A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. | BMC complementary and alternative medicine 20110101 |
| Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. | Journal of experimental & clinical cancer research : CR 20110101 |
| Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. | Journal of translational medicine 20110101 |
| Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. | BMC gastroenterology 20110101 |
| Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes. | Clinical & developmental immunology 20110101 |
| Recent advances in molecular diagnosis of thyroid cancer. | Journal of thyroid research 20110101 |
| Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer. | Oncology 20110101 |
| Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. | BMC medicine 20110101 |
| Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. | BMC cancer 20110101 |
| Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells. | Radiation oncology (London, England) 20110101 |
| Interpreting clinical assays for histone deacetylase inhibitors. | Cancer management and research 20110101 |
| Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. | Cancer management and research 20110101 |
| Induction of differentiation by panaxydol in human hepatocarcinoma SMMC-7721 cells via cAMP and MAP kinase dependent mechanism. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101 |
| Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. | Cardiology research and practice 20110101 |
| Review of cardiotoxicity in pediatric cancer patients: during and after therapy. | Cardiology research and practice 20110101 |
| Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. | PloS one 20110101 |
| Vascular wall-resident CD44+ multipotent stem cells give rise to pericytes and smooth muscle cells and contribute to new vessel maturation. | PloS one 20110101 |
| Next generation therapies change the landscape in melanoma. | F1000 medicine reports 20110101 |
| Recent trends in pulmonary arterial hypertension. | Lung India : official organ of Indian Chest Society 20110101 |
| Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. | BMC gastroenterology 20110101 |
| Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. | Journal of hematology & oncology 20110101 |
| Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. | Gastrointestinal cancer research : GCR 20110101 |
| Separation and purification of sulforaphane from broccoli by solid phase extraction. | International journal of molecular sciences 20110101 |
| Pricing and reimbursement of orphan drugs: the need for more transparency. | Orphanet journal of rare diseases 20110101 |
| Diagnostic challenge for ovarian malignant melanoma in premenopausal women: primary or metastatic? | World journal of surgical oncology 20110101 |
| Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. | Journal of thyroid research 20110101 |
| Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma. | Gastroenterology research and practice 20110101 |
| Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature. | Case reports in oncology 20110101 |
| Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. | OncoTargets and therapy 20110101 |
| Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy. | Radiation oncology (London, England) 20110101 |
| Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. | Oncology 20110101 |
| Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo. | Journal of microencapsulation 20110101 |
| Promising molecular targeted therapies in breast cancer. | Indian journal of pharmacology 20110101 |
| Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? | Journal of Cancer 20110101 |
| Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC). | Journal of Cancer 20110101 |
| Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord. | Molecular pain 20110101 |
| Targeting insulin-like growth factor axis in hepatocellular carcinoma. | Journal of hematology & oncology 20110101 |
| Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. | Cancer management and research 20110101 |
| How to manage hypersensitivity reactions to biological agents? | European journal of dermatology : EJD 20110101 |
| Plitidepsin has a safe cardiac profile: a comprehensive analysis. | Marine drugs 20110101 |
| Metastatic collecting duct carcinoma of the kidney treated with sunitinib. | World journal of surgical oncology 20110101 |
| Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. | BMC cancer 20110101 |
| How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. | Journal of thyroid research 20110101 |
| Hypoxia-inducible factor in thyroid carcinoma. | Journal of thyroid research 20110101 |
| Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. | Journal of oncology 20110101 |
| Combination therapy: the next opportunity and challenge of medicine. | Journal of translational medicine 20110101 |
| Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells. | Journal of oncology 20110101 |
| Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. | Journal of translational medicine 20110101 |
| Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations. | Pathology research international 20110101 |
| Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. | BMC cancer 20110101 |
| Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. | Molecular cancer 20110101 |
| Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). | Patient preference and adherence 20110101 |
| Latest developments and emerging treatment options in the management of stomach cancer. | Cancer management and research 20110101 |
| Progressive resistance training and cancer testis (PROTRACT) - efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial. | BMC cancer 20110101 |
| Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action. | Annals of Saudi medicine 20110101 |
| Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice. | BMC immunology 20110101 |
| Targeted drug therapies and cancer. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101 |
| Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. | PloS one 20110101 |
| Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. | Digestive diseases (Basel, Switzerland) 20110101 |
| Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. | Digestive diseases (Basel, Switzerland) 20110101 |
| Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. | Digestive diseases (Basel, Switzerland) 20110101 |
| Future treatment option for hepatocellular carcinoma: a focus on brivanib. | Digestive diseases (Basel, Switzerland) 20110101 |
| Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. | Digestive diseases (Basel, Switzerland) 20110101 |
| Management of patients with hepatocellular carcinoma and extrahepatic metastasis. | Digestive diseases (Basel, Switzerland) 20110101 |
| Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. | BMC cancer 20110101 |
| Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. | Journal of translational medicine 20110101 |
| Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer. | Clinical Medicine Insights. Oncology 20110101 |
| HIF-1α effects on angiogenic potential in human small cell lung carcinoma. | Journal of experimental & clinical cancer research : CR 20110101 |
| Biology of metastatic renal cell carcinoma. | Journal of Cancer 20110101 |
| Psoriasiform skin eruption associated with sorafenib therapy. | Indian journal of dermatology, venereology and leprology 20110101 |
| Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma. | Current medicinal chemistry 20110101 |
| Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. | BMC cancer 20110101 |
| Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. | Molecular cancer 20110101 |
| Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study. | Journal of clinical bioinformatics 20110101 |
| Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics. | Drug metabolism and pharmacokinetics 20110101 |
| An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities. | PloS one 20110101 |
| [Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101 |
| Chemotherapy in advanced bladder cancer: current status and future. | Journal of hematology & oncology 20110101 |
| Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. | Dermatologic therapy 20110101 |
| Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. | Radiation oncology (London, England) 20110101 |
| Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. | PloS one 20110101 |
| Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101 |
| Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. | PloS one 20110101 |
| Sorafenib-induced erythema multiforme: three cases. | European journal of dermatology : EJD 20110101 |
| Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. | Molecular cancer 20110101 |
| Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. | Cancer management and research 20110101 |
| Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. | PloS one 20110101 |
| New inhibitors of VEGFR-2 targeting the extracellular domain dimerization process. | Bioinformation 20110101 |
| Leukocytoclastic vasculitis after long-term treatment with sunitinib: a case report. | Case reports in oncology 20110101 |
| Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling. | International journal of inflammation 20110101 |
| Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report. | Journal of medical case reports 20110101 |
| Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. | OncoTargets and therapy 20110101 |
| Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. | OncoTargets and therapy 20110101 |
| Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. | Journal of medical case reports 20110101 |
| Renal cell carcinoma with unusual metastasis to the small intestine manifesting as extensive polyposis: successful management with intraoperative therapeutic endoscopy. | Case reports in gastroenterology 20110101 |
| A solitary crateriform ulcer of the lower lip: a case report with review of literature. | Indian journal of dermatology 20110101 |
| Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. | Clinical & developmental immunology 20110101 |
| Angiogenesis imaging in neoplasia. | Journal of clinical imaging science 20110101 |
| The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. | PloS one 20110101 |
| Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. | PloS one 20110101 |
| Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. | BMC health services research 20110101 |
| Improved curve fits to summary survival data: application to economic evaluation of health technologies. | BMC medical research methodology 20110101 |
| Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. | Journal of translational medicine 20110101 |
| Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. | BMC cancer 20110101 |
| AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. | Onkologie 20110101 |
| High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. | Oncology 20110101 |
| Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies. | Journal of translational medicine 20110101 |
| Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. | Tumori 20110101 |
| Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib. | ISRN gastroenterology 20110101 |
| Radiofrequency ablation of hepatocellular carcinoma: a literature review. | International journal of hepatology 20110101 |
| Targeted therapy in hepatocellular carcinoma. | International journal of hepatology 20110101 |
| The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. | International journal of hepatology 20110101 |
| Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. | International journal of hepatology 20110101 |
| Non-invasive radiofrequency-induced targeted hyperthermia for the treatment of hepatocellular carcinoma. | International journal of hepatology 20110101 |
| Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. | International journal of hepatology 20110101 |
| The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. | PloS one 20110101 |
| Tumour macrophages as potential targets of bisphosphonates. | Journal of translational medicine 20110101 |
| Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. | Obstetrics and gynecology international 20110101 |
| TFE3 Translocation-Associated Renal Cell Carcinoma Presenting as Avascular Necrosis of the Femur in a 19-Year-Old Patient: Case Report and Review of the Literature. | Case reports in medicine 20110101 |
| Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma. | Case reports in medicine 20110101 |
| Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? | Journal of skin cancer 20110101 |
| Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. | Journal of thyroid research 20110101 |
| Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. | International journal of molecular sciences 20110101 |
| Sunitinib induced pyoderma gangrenosum-like ulcerations. | European journal of medical research 20110101 |
| Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. | BMC cancer 20110101 |
| A clinical overview of centrosome amplification in human cancers. | International journal of biological sciences 20110101 |
| Results of combined treatment of anaplastic thyroid carcinoma (ATC). | BMC cancer 20110101 |
| Diagnostic and prognostic molecular markers in hepatocellular carcinoma. | Disease markers 20110101 |
| Role of centralized review processes for making reimbursement decisions on new health technologies in Europe. | ClinicoEconomics and outcomes research : CEOR 20110101 |
| PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. | Clinical & developmental immunology 20110101 |
| Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. | PloS one 20110101 |
| The role of antiangiogenetic agents in the treatment of breast cancer. | Current medicinal chemistry 20110101 |
| Choroid plexus transport: gene deletion studies. | Fluids and barriers of the CNS 20110101 |
| Biomarkers in tumor angiogenesis and anti-angiogenic therapy. | International journal of molecular sciences 20110101 |
| A rare bladder cancer--small cell carcinoma: review and update. | Orphanet journal of rare diseases 20110101 |
| Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. | Clinical Medicine Insights. Oncology 20110101 |
| Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. | PloS one 20110101 |
| The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation. | PloS one 20110101 |
| Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. | Cancer cell international 20110101 |
| Spermatic cord metastasis of primary hepatocellular carcinoma presenting as an inguinal mass: a case report. | ISRN oncology 20110101 |
| Innovative Therapies against Human Glioblastoma Multiforme. | ISRN oncology 20110101 |
| The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. | PloS one 20110101 |
| p21-Activated kinase 1 (Pak1) phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112. | PloS one 20110101 |
| Subtle hepatocellular carcinoma: a persisting role for alpha-fetoprotein monitoring in high-risk patients with cirrhosis. | Case reports in gastroenterology 20110101 |
| Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. | Oncology 20110101 |
| Regulation of neutrophil survival/apoptosis by Mcl-1. | TheScientificWorldJournal 20110101 |
| Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. | PloS one 20110101 |
| Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. | BMC cancer 20110101 |
| Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. | Biological & pharmaceutical bulletin 20110101 |
| Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy. | Journal of ophthalmology 20110101 |
| Retinal degenerations: genetics, mechanisms, and therapies. | Journal of ophthalmology 20110101 |
| Liver resection after downstaging hepatocellular carcinoma with sorafenib. | International journal of hepatology 20110101 |
| Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials. | BMC medical research methodology 20110101 |
| Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. | Clinical & developmental immunology 20110101 |
| Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. | OncoTargets and therapy 20110101 |
| Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib? | Clinical Medicine Insights. Oncology 20110101 |
| Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. | PloS one 20110101 |
| BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. | Journal of skin cancer 20110101 |
| The molecular pathogenesis and clinical implications of hepatocellular carcinoma. | International journal of hepatology 20110101 |
| High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. | Journal of translational medicine 20110101 |
| Radiotherapy and 'new' drugs-new side effects? | Radiation oncology (London, England) 20110101 |
| Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. | Journal of carcinogenesis 20110101 |
| Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemia. | Stem cells international 20110101 |
| Laser ablation for small hepatocellular carcinoma. | Radiology research and practice 20110101 |
| Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. | Journal of hematology & oncology 20110101 |
| DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. | Genome medicine 20110101 |
| Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes. | PloS one 20110101 |
| Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. | Cancer cell international 20110101 |
| Signaling pathways in hepatocellular carcinoma. | Oncology 20110101 |
| Adjuvant therapy after curative treatment for hepatocellular carcinoma. | Oncology 20110101 |
| Radiotherapeutic strategies in the management of hepatocellular carcinoma. | Oncology 20110101 |
| Multidisciplinary management of nonresectable hepatocellular carcinoma. | Oncology 20110101 |
| Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. | Oncology 20110101 |
| Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. | Oncology 20110101 |
| Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. | Oncology 20110101 |
| Management of melanoma brain metastases in the era of targeted therapy. | Journal of skin cancer 20110101 |
| Monoclonal antibodies in gynecological cancer: a critical point of view. | Clinical & developmental immunology 20110101 |
| New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. | Therapeutics and clinical risk management 20110101 |
| Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer. | OncoTargets and therapy 20110101 |
| Novel immunotherapeutic strategies of gastric cancer treatment. | Journal of biomedicine & biotechnology 20110101 |
| An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. | Journal of cancer research and therapeutics 20110101 |
| Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. | Oncology 20110101 |
| New drug therapies, dedicated specialists and desperately-ill patients-but who will fly the flag for service developments in lung cancer as NHS budgets come under pressure? | Ecancermedicalscience 20110101 |
| Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. | Acta medica (Hradec Kralove) 20110101 |
| New agents targeting angiogenesis in glioblastoma. | Chemotherapy research and practice 20110101 |
| Autophagy: friend or foe in breast cancer development, progression, and treatment. | International journal of breast cancer 20110101 |
| RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally. | Frontiers in genetics 20110101 |
| Familial renal cancer: molecular genetics and surgical management. | International journal of surgical oncology 20110101 |
| Triple-negative breast cancer: adjuvant therapeutic options. | Chemotherapy research and practice 20110101 |
| Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report. | Tumori 20110101 |
| Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101 |
| A case with postchemotherapy eruptive compound nevus. | Indian journal of dermatology 20110101 |
| Study of the role of 'gatekeeper' mutations V654A and T670I of c-kit kinase in the interaction with inhibitors by means mixed molecular dynamics/docking approach. | Bioinformation 20110101 |
| Treatment of FLT3-ITD acute myeloid leukemia. | American journal of blood research 20110101 |
| Hepatocellular Carcinoma Metastasis to the Orbit in a Coinfected HIV+ HBV+ Patient Previously Treated with Orthotopic Liver Transplantation: A Case Report. | Case reports in ophthalmological medicine 20110101 |
| Genitourinary oncology: current status and future challenges. | Frontiers in oncology 20110101 |
| Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells. | Frontiers in endocrinology 20110101 |
| Cell death signaling and anticancer therapy. | Frontiers in oncology 20110101 |
| Targeting apoptosis signaling pathways for anticancer therapy. | Frontiers in oncology 20110101 |
| Renal cell cancer: what can we learn from pre-operative studies? | Frontiers in oncology 20110101 |
| Investigational approaches for mesothelioma. | Frontiers in oncology 20110101 |
| Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. | Cancer biomarkers : section A of Disease markers 20110101 |
| Targeting RET receptor tyrosine kinase activation in cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101215 |
| Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. | Cancer biology & therapy 20101215 |
| Pazopanib in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101215 |
| A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. | Cancer 20101215 |
| Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. | International journal of cancer 20101215 |
| Cancer and renal insufficiency results of the BIRMA study. | British journal of cancer 20101207 |
| A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. | British journal of cancer 20101207 |
| Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. | Investigational new drugs 20101201 |
| Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. | Investigational new drugs 20101201 |
| Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. | Medical oncology (Northwood, London, England) 20101201 |
| Experience with sorafenib and the elderly patient. | Medical oncology (Northwood, London, England) 20101201 |
| Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy? | Journal of gastrointestinal cancer 20101201 |
| Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. | BJU international 20101201 |
| Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? | European radiology 20101201 |
| 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. | The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 20101201 |
| Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. | Pediatric blood & cancer 20101201 |
| Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. | Japanese journal of clinical oncology 20101201 |
| Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. | Cancer 20101201 |
| Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. | Journal of surgical oncology 20101201 |
| Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | Toxicological sciences : an official journal of the Society of Toxicology 20101201 |
| The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. | Toxicology and applied pharmacology 20101201 |
| [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. | Gastroenterologia y hepatologia 20101201 |
| Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. | European urology 20101201 |
| Sorafenib: rays of hope in thyroid cancer. | Thyroid : official journal of the American Thyroid Association 20101201 |
| Oncogenic RAF: a brief history of time. | Pigment cell & melanoma research 20101201 |
| Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma. | The Journal of urology 20101201 |
| The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. | The Journal of urology 20101201 |
| Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. | Cancer science 20101201 |
| Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication. | American journal of clinical pathology 20101201 |
| AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. | Nature cell biology 20101201 |
| Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. | Acta pharmacologica Sinica 20101201 |
| [Systemic therapy of renal cell carcinoma]. | Der Urologe. Ausg. A 20101201 |
| Deactylase inhibition in myeloproliferative neoplasms. | Investigational new drugs 20101201 |
| Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. | Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20101201 |
| The utility of BRAF testing in the management of papillary thyroid cancer. | The oncologist 20101201 |
| [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines]. | Magyar onkologia 20101201 |
| Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. | Transplantation proceedings 20101201 |
| Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. | Archives of dermatology 20101201 |
| High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. | PLoS biology 20101201 |
| PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. | Anticancer research 20101201 |
| More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. | Anticancer research 20101201 |
| Established and emerging therapies for hepatocellular carcinoma. | Minerva medica 20101201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20101201 |
| Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. | Gut and liver 20101201 |
| Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era. | Cancer research and treatment : official journal of Korean Cancer Association 20101201 |
| A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy. | Cancer research and treatment : official journal of Korean Cancer Association 20101201 |
| Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. | Clinics (Sao Paulo, Brazil) 20101201 |
| Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. | Cell death & disease 20101201 |
| Hemodynamic alterations in cirrhosis and portal hypertension. | The Korean journal of hepatology 20101201 |
| Which treatment modality should we choose for advanced hepatocellular carcinoma? | The Korean journal of hepatology 20101201 |
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | Chemistry & biology 20101124 |
| Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. | World journal of gastroenterology 20101121 |
| Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. | JAMA 20101117 |
| Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. | Cancer 20101115 |
| Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. | Cancer research 20101115 |
| Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. | British journal of cancer 20101109 |
| MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. | British journal of cancer 20101109 |
| Synergistic activity of letrozole and sorafenib on breast cancer cells. | Breast cancer research and treatment 20101101 |
| Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. | BJU international 20101101 |
| Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. | Liver international : official journal of the International Association for the Study of the Liver 20101101 |
| Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. | European journal of cancer (Oxford, England : 1990) 20101101 |
| Angiogenesis as a therapeutic target in urothelial carcinoma. | Anti-cancer drugs 20101101 |
| Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. | American journal of physiology. Renal physiology 20101101 |
| Targeting B-Raf as a treatment strategy for polycystic kidney disease. | American journal of physiology. Renal physiology 20101101 |
| Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media. | Radiology 20101101 |
| Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101 |
| Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. | Journal of cancer research and clinical oncology 20101101 |
| Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. | European journal of medicinal chemistry 20101101 |
| Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101101 |
| Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101101 |
| Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101101 |
| [Multimodality treatment for hepatocellular carcinoma]. | Der Internist 20101101 |
| Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. | Acta pharmacologica Sinica 20101101 |
| Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. | Expert opinion on biological therapy 20101101 |
| 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20101101 |
| Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. | The British journal of ophthalmology 20101101 |
| Blastomycosis-like pyoderma: response to systemic retinoid therapy. | International journal of dermatology 20101101 |
| Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. | The oncologist 20101101 |
| Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. | Journal of gastroenterology and hepatology 20101101 |
| A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. | British journal of cancer 20101101 |
| Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. | The oncologist 20101101 |
| Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. | Neoplasia (New York, N.Y.) 20101101 |
| Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? | British journal of cancer 20101101 |
| Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma. | Anticancer research 20101101 |
| Targeted therapy for renal cell cancer: current perspectives. | Discovery medicine 20101101 |
| The therapy of kidney cancer with biomolecular drugs. | Cancer treatment reviews 20101101 |
| An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20101101 |
| [Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101101 |
| [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. | Oncotarget 20101101 |
| Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. | Oncotarget 20101101 |
| The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. | Oncotarget 20101101 |
| Toxin-based therapeutic approaches. | Toxins 20101101 |
| Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. | British journal of cancer 20101026 |
| [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology]. | Orvosi hetilap 20101024 |
| Risk of arterial thrombosis not increased by sorafenib or sunitinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020 |
| Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101015 |
| A combined A431 cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening compounds from total alkaloid of Radix Caulophylli acting on the human EGFR. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101015 |
| Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. | Blood 20101014 |
| A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. | British journal of cancer 20101012 |
| A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. | British journal of cancer 20101012 |
| Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'. | British journal of cancer 20101012 |
| Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. | Investigational new drugs 20101001 |
| Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. | Cancer chemotherapy and pharmacology 20101001 |
| Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. | International journal of clinical oncology 20101001 |
| A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount. | Leukemia research 20101001 |
| Effect of sorafenib on experimental choroidal neovascularization in the rat. | Clinical & experimental ophthalmology 20101001 |
| Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. | Cancer 20101001 |
| Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. | Expert opinion on pharmacotherapy 20101001 |
| Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. | Leukemia research 20101001 |
| The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages. | International immunopharmacology 20101001 |
| Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101001 |
| Health-related quality of life and sorafenib. | Hepatology (Baltimore, Md.) 20101001 |
| Metabolism considerations for kinase inhibitors in cancer treatment. | Expert opinion on drug metabolism & toxicology 20101001 |
| Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. | European journal of cancer (Oxford, England : 1990) 20101001 |
| Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. | Molecular cancer therapeutics 20101001 |
| Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101001 |
| A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001 |
| [Nonsurgical management of hepatocellular carcinoma]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20101001 |
| Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line. | Bioorganic & medicinal chemistry letters 20101001 |
| The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. | Hepatology (Baltimore, Md.) 20101001 |
| Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. | Oncology reports 20101001 |
| Thymoma and thymic carcinoma: molecular pathology and targeted therapy. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001 |
| Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib. | International journal of dermatology 20101001 |
| Atypical linear toxicodermia by sorafenib. | International journal of dermatology 20101001 |
| Developing better treatments in hepatocellular carcinoma. | Expert review of gastroenterology & hepatology 20101001 |
| Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? | Expert review of anticancer therapy 20101001 |
| Latest developments in targeted therapy for hepatocellular carcinoma. | Expert review of anticancer therapy 20101001 |
| [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101001 |
| Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. | PLoS pathogens 20101001 |
| [Hepatocellular carcinoma]. | Nihon rinsho. Japanese journal of clinical medicine 20101001 |
| [Molecular targeted therapy for renal cell carcinoma and other urological cancers]. | Nihon rinsho. Japanese journal of clinical medicine 20101001 |
| Inherited hepatocellular carcinoma. | Best practice & research. Clinical gastroenterology 20101001 |
| Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization. | Current oncology (Toronto, Ont.) 20101001 |
| Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis. | Health technology assessment (Winchester, England) 20101001 |
| Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma. | Gan to kagaku ryoho. Cancer & chemotherapy 20101001 |
| Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. | The Israel Medical Association journal : IMAJ 20101001 |
| An activating transcription factor 5-mediated survival pathway as a target for cancer therapy? | Oncotarget 20101001 |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. | Nature 20100930 |
| Rare tumors research in emerging countries. | Rare tumors 20100930 |
| A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. | British journal of cancer 20100928 |
| Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. | British journal of cancer 20100928 |
| Improved endpoints for cancer immunotherapy trials. | Journal of the National Cancer Institute 20100922 |
| Current approach in the treatment of hepatocellular carcinoma. | World journal of gastrointestinal oncology 20100915 |
| [Surgical oncology of hepatocellular carcinoma (HCC)]. | Orvosi hetilap 20100912 |
| Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. | British journal of cancer 20100907 |
| Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. | British journal of cancer 20100907 |
| [Treatment of primary hepatocellular carcinoma]. | Orvosi hetilap 20100905 |
| Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. | Medical oncology (Northwood, London, England) 20100901 |
| Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases. | Medical oncology (Northwood, London, England) 20100901 |
| Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. | Cancer chemotherapy and pharmacology 20100901 |
| Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. | Annals of oncology : official journal of the European Society for Medical Oncology 20100901 |
| Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. | BJU international 20100901 |
| Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. | European journal of gastroenterology & hepatology 20100901 |
| BRAF as therapeutic target in melanoma. | Biochemical pharmacology 20100901 |
| Molecularly targeted therapy in hepatocellular carcinoma. | Biochemical pharmacology 20100901 |
| Targeted therapy of thyroid cancer. | Biochemical pharmacology 20100901 |
| The hand-foot-syndrome associated with medical tumor therapy - classification and management. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20100901 |
| In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. | Current cancer drug targets 20100901 |
| Novel targeted therapy for advanced renal carcinoma: trials in progress. | Current opinion in urology 20100901 |
| Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology. | Gastroenterologie clinique et biologique 20100901 |
| Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. | International journal of urology : official journal of the Japanese Urological Association 20100901 |
| Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. | European journal of cancer (Oxford, England : 1990) 20100901 |
| Population-based risk factors and resource utilization for HCC: US perspective. | Current medical research and opinion 20100901 |
| Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. | Expert opinion on pharmacotherapy 20100901 |
| Sorafenib and radiation: a promising combination in colorectal cancer. | International journal of radiation oncology, biology, physics 20100901 |
| Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients. | International journal of urology : official journal of the Japanese Urological Association 20100901 |
| [Sorafenib]. | Deutsche medizinische Wochenschrift (1946) 20100901 |
| [Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option]. | Deutsche medizinische Wochenschrift (1946) 20100901 |
| Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. | IDrugs : the investigational drugs journal 20100901 |
| Thyroid function: Sorafenib alters metabolism of T3. | Nature reviews. Endocrinology 20100901 |
| Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation. | Hepatology (Baltimore, Md.) 20100901 |
| Sorafenib-induced destructive thyroiditis. | Thyroid : official journal of the American Thyroid Association 20100901 |
| Liver Cancer Working Group report. | Japanese journal of clinical oncology 20100901 |
| Kidney Cancer Working Group report. | Japanese journal of clinical oncology 20100901 |
| Transient perforating folliculitis induced by sorafenib. | The Journal of dermatology 20100901 |
| Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas. | Anticancer research 20100901 |
| Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. | Gut and liver 20100901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100901 |
| [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100901 |
| Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma? | Oncotarget 20100901 |
| Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. | Clinical advances in hematology & oncology : H&O 20100901 |
| Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. | Gastroenterology & hepatology 20100901 |
| In vitro selection of a DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitors. | Journal of the American Chemical Society 20100825 |
| Myelosuppression by sunitinib is flt-3 genotype dependent. | British journal of cancer 20100824 |
| [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma]. | Zhonghua yi xue za zhi 20100817 |
| Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors. | Journal of medicinal chemistry 20100812 |
| From a cancer drug fund to value based pricing of drugs. | BMJ (Clinical research ed.) 20100812 |
| Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. | British journal of cancer 20100810 |
| Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. | British journal of cancer 20100810 |
| Primitive neuroectodermal tumor of the kidney with inferior vena cava tumor thrombus during pregnancy response to sorafenib. | Chinese medical journal 20100805 |
| Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy? | European journal of gastroenterology & hepatology 20100801 |
| Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20100801 |
| Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. | Annals of oncology : official journal of the European Society for Medical Oncology 20100801 |
| Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. | Cancer treatment reviews 20100801 |
| Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. | Urology 20100801 |
| Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. | European journal of haematology 20100801 |
| In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. | Drug metabolism and disposition: the biological fate of chemicals 20100801 |
| Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. | Journal of cellular physiology 20100801 |
| Sorafenib plus valproic acid for infant spinal glioblastoma. | Journal of pediatric hematology/oncology 20100801 |
| A case of variant angina in a patient under chronic treatment with sorafenib. | Nature reviews. Clinical oncology 20100801 |
| Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. | The Journal of clinical endocrinology and metabolism 20100801 |
| Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. | Japanese journal of clinical oncology 20100801 |
| Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. | Radiology 20100801 |
| Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib. | Leukemia 20100801 |
| A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. | Leukemia 20100801 |
| Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. | Radiology 20100801 |
| ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells. | Cancer biology & therapy 20100801 |
| Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. | Cancer 20100801 |
| Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. | Journal of gastroenterology 20100801 |
| Sorafenib: a clinical and pharmacologic review. | Expert opinion on pharmacotherapy 20100801 |
| Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation. | International journal of oncology 20100801 |
| Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. | Toxicologic pathology 20100801 |
| The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. | Bioorganic & medicinal chemistry 20100801 |
| Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. | Advances in therapy 20100801 |
| Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. | Cancer research 20100801 |
| [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20100801 |
| Tumor-stromal cell interactions and opportunities for therapeutic intervention. | Current opinion in pharmacology 20100801 |
| BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. | Molecular cancer research : MCR 20100801 |
| Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. | British journal of pharmacology 20100801 |
| A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. | Journal of pharmacokinetics and pharmacodynamics 20100801 |
| Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. | Molecular cancer therapeutics 20100801 |
| Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801 |
| Novel therapies for hypereosinophilic syndromes. | The Netherlands journal of medicine 20100801 |
| [Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100801 |
| Everolimus in renal cell carcinoma. | Drugs of today (Barcelona, Spain : 1998) 20100801 |
| Sorafenib in hepatocellular carcinoma. | British journal of hospital medicine (London, England : 2005) 20100801 |
| [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100801 |
| Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. | World journal of gastroenterology 20100728 |
| [Interventional radiological treatment of hepatocellular carcinoma]. | Orvosi hetilap 20100725 |
| Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100715 |
| Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. | Transplantation 20100715 |
| Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. | British journal of cancer 20100713 |
| Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. | British journal of cancer 20100713 |
| Sorafenib exerts anti-glioma activity in vitro and in vivo. | Neuroscience letters 20100712 |
| Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100710 |
| Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the '2010 ASCO Annual Meeting'. Chicago, IL, USA. June 4-8, 2010. | JOP : Journal of the pancreas 20100705 |
| Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. | Journal of hepato-biliary-pancreatic sciences 20100701 |
| Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. | Journal of cellular physiology 20100701 |
| Bench to bedside targeting of FLT3 in acute leukemia. | Current drug targets 20100701 |
| Antiangiogenesis agents in colorectal cancer. | Current opinion in oncology 20100701 |
| Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. | Current drug targets 20100701 |
| Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. | Current drug targets 20100701 |
| Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. | Journal of hepatology 20100701 |
| New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. | Journal of hepatology 20100701 |
| The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. | Asian journal of andrology 20100701 |
| Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. | Current opinion in oncology 20100701 |
| Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. | International journal of oncology 20100701 |
| Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20100701 |
| Molecular approaches to treatment of hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20100701 |
| The present and the future landscape of treatment of advanced hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20100701 |
| Future perspectives in hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20100701 |
| Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. | The oncologist 20100701 |
| Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors. | Bioorganic & medicinal chemistry 20100701 |
| Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100701 |
| Targeted therapies for non-small cell lung cancer: an evolving landscape. | Molecular cancer therapeutics 20100701 |
| Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. | Molecular cancer therapeutics 20100701 |
| Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20100701 |
| Sorafenib: where do we go from here? | Hepatology (Baltimore, Md.) 20100701 |
| A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100701 |
| Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. | Oncology 20100701 |
| Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. | Oncology 20100701 |
| Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective. | Oncology 20100701 |
| Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. | International journal of clinical practice 20100701 |
| [Molecular targeted therapy for advanced renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100701 |
| [Hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100701 |
| Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience. | Korean journal of urology 20100701 |
| Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20100701 |
| Hepatocellular carcinoma: the place of new medical therapies. | Therapeutic advances in gastroenterology 20100701 |
| Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib. | World journal of hepatology 20100627 |
| Probing the probes: fitness factors for small molecule tools. | Chemistry & biology 20100625 |
| Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620 |
| 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors. | Bioorganic & medicinal chemistry letters 20100615 |
| Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. | Cancer research 20100615 |
| Gatekeeper mutations mediate resistance to BRAF-targeted therapies. | Science translational medicine 20100609 |
| BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. | British journal of cancer 20100608 |
| [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. | Orvosi hetilap 20100606 |
| Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. | American journal of clinical oncology 20100601 |
| Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. | Cancer investigation 20100601 |
| RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. | European radiology 20100601 |
| Hepatocellular carcinoma: sorafenib before liver transplantation? | Hepatology (Baltimore, Md.) 20100601 |
| Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics. | Annals of surgical oncology 20100601 |
| Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models. | Japanese journal of clinical oncology 20100601 |
| Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. | Anti-cancer drugs 20100601 |
| Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. | Neuro-oncology 20100601 |
| Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. | Growth factors (Chur, Switzerland) 20100601 |
| Update on systemic therapies of metastatic renal cell carcinoma. | World journal of urology 20100601 |
| Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives. | European journal of medicinal chemistry 20100601 |
| Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells. | European journal of medicinal chemistry 20100601 |
| Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting. | Annals of oncology : official journal of the European Society for Medical Oncology 20100601 |
| Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation. | Journal of clinical pathology 20100601 |
| Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. | Current cancer drug targets 20100601 |
| Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. | The Journal of clinical endocrinology and metabolism 20100601 |
| A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100601 |
| Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma. | Journal of gastrointestinal cancer 20100601 |
| Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. | International journal of oncology 20100601 |
| Treatment of metastatic renal cell carcinoma. | Nature reviews. Urology 20100601 |
| [Antiangionic drugs in soft tissue sarcoma]. | Bulletin du cancer 20100601 |
| [Focus on GIST management]. | Bulletin du cancer 20100601 |
| Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. | AJR. American journal of roentgenology 20100601 |
| A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. | Nature medicine 20100601 |
| Targeted therapy for thyroid cancer: An updated review of investigational agents. | Current opinion in investigational drugs (London, England : 2000) 20100601 |
| Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. | International journal of clinical oncology 20100601 |
| Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. | International journal of clinical oncology 20100601 |
| [New therapies targeting the genetic mutations responsible for different types of melanoma]. | Actas dermo-sifiliograficas 20100601 |
| Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. | The Journal of clinical endocrinology and metabolism 20100601 |
| [Anti-angiogenic drugs]. | Nihon rinsho. Japanese journal of clinical medicine 20100601 |
| [mTOR inhibitors]. | Nihon rinsho. Japanese journal of clinical medicine 20100601 |
| [Current therapy for hepatocellular carcinoma]. | Nihon rinsho. Japanese journal of clinical medicine 20100601 |
| Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. | Expert review of anticancer therapy 20100601 |
| [Effect of sorafenib combined with daunorubicin on K562 cell line]. | Zhongguo shi yan xue ye xue za zhi 20100601 |
| Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. | Asia-Pacific journal of clinical oncology 20100601 |
| Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. | Journal of chemotherapy (Florence, Italy) 20100601 |
| Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea. | Korean journal of urology 20100601 |
| Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. | HPB : the official journal of the International Hepato Pancreato Biliary Association 20100601 |
| Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. | HPB : the official journal of the International Hepato Pancreato Biliary Association 20100601 |
| Targeted therapies in renal cell cancer: recent developments in imaging. | Targeted oncology 20100601 |
| Sorafenib and thyrotoxicosis. | Journal of endocrinological investigation 20100601 |
| Annular leukocytoclastic vasculitis associated with sorafenib administration. | Journal of drugs in dermatology : JDD 20100601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100601 |
| Sorafenib-associated psoriasiform skin changes. | Cutis 20100601 |
| Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. | Analytical and quantitative cytology and histology 20100601 |
| FLT3 inhibitors for the treatment of acute myeloid leukemia. | Clinical advances in hematology & oncology : H&O 20100601 |
| Microarray-based gene expression analysis of hepatocellular carcinoma. | Current genomics 20100601 |
| STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. | British journal of cancer 20100525 |
| Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. | Oncogene 20100520 |
| Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. | Cancer 20100515 |
| Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. | Bioorganic & medicinal chemistry 20100515 |
| Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. | British journal of cancer 20100511 |
| Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100510 |
| [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. | Medicina clinica 20100508 |
| Optimal de novo design of MRM experiments for rapid assay development in targeted proteomics. | Journal of proteome research 20100507 |
| Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. | Journal of the National Cancer Institute 20100505 |
| Sorafenib-induced acute pancreatitis. | JOP : Journal of the pancreas 20100505 |
| The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. | Toxicology letters 20100504 |
| Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. | Biochemistry 20100504 |
| Unique molecular characteristics of pediatric myxopapillary ependymoma. | Brain pathology (Zurich, Switzerland) 20100501 |
| Incidence of brain metastases in renal cell carcinoma treated with sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20100501 |
| Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. | BJU international 20100501 |
| The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. | Urology 20100501 |
| Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. | Expert opinion on drug safety 20100501 |
| Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. | Cancer chemotherapy and pharmacology 20100501 |
| Recent advances in the treatment of hepatocellular carcinoma. | Current opinion in gastroenterology 20100501 |
| Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. | Breast cancer research and treatment 20100501 |
| The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. | Journal of hepatology 20100501 |
| Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. | Journal of hepatology 20100501 |
| Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100501 |
| Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. | Expert opinion on investigational drugs 20100501 |
| Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100501 |
| Alterations in VHL as potential biomarkers in renal-cell carcinoma. | Nature reviews. Clinical oncology 20100501 |
| Novel inhibitors in development for hepatocellular carcinoma. | Expert opinion on investigational drugs 20100501 |
| Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100501 |
| Systemic treatment of hepatocellular carcinoma: dawn of a new era? | Annals of surgical oncology 20100501 |
| Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100501 |
| Soluble epoxide hydrolase in atherosclerosis. | Current atherosclerosis reports 20100501 |
| Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. | The oncologist 20100501 |
| Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. | IDrugs : the investigational drugs journal 20100501 |
| Drug therapy: sorafenib. | Hepatology (Baltimore, Md.) 20100501 |
| Editorial comment. | Urology 20100501 |
| Editorial comment. | Urology 20100501 |
| Clinical overview of sorafenib in breast cancer. | Future oncology (London, England) 20100501 |
| Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. | Expert review of anticancer therapy 20100501 |
| [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. | Aktuelle Urologie 20100501 |
| Sorafenib for the treatment of advanced hepatocellular carcinoma. | Health technology assessment (Winchester, England) 20100501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100501 |
| Non-pigmenting fixed drug eruption induced by sorafenib. | Acta dermato-venereologica 20100501 |
| Present state of target therapy for disseminated renal cell carcinoma. | Immunotherapy 20100501 |
| Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. | International journal of palliative nursing 20100501 |
| Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation. | Journal of the Chinese Medical Association : JCMA 20100501 |
| Updates on novel therapies for metastatic renal cell carcinoma. | Therapeutic advances in medical oncology 20100501 |
| The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. | Toxicology and applied pharmacology 20100415 |
| Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors. | British journal of cancer 20100413 |
| Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. | British journal of cancer 20100413 |
| Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100410 |
| Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100410 |
| Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group. | Journal of medicinal chemistry 20100408 |
| Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. | Investigational new drugs 20100401 |
| The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. | International journal of cancer 20100401 |
| Cutaneous side effects of inhibition of VEGF signal transduction. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20100401 |
| Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. | European journal of gastroenterology & hepatology 20100401 |
| Docetaxel inhibits progression of human hepatoma cell line in vitro and is effective in advanced hepatocellular carcinoma. | Hepatology research : the official journal of the Japan Society of Hepatology 20100401 |
| Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. | Hepatology (Baltimore, Md.) 20100401 |
| Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. | Scandinavian journal of gastroenterology 20100401 |
| A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. | Gynecologic oncology 20100401 |
| Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). | The Lancet. Oncology 20100401 |
| Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. | The Lancet. Oncology 20100401 |
| Metronomic chemotherapy for renal cancer in the landscape of targeted therapy. | The Lancet. Oncology 20100401 |
| Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. | Molecular cancer therapeutics 20100401 |
| Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed. | Molecular cancer therapeutics 20100401 |
| Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. | Cancer control : journal of the Moffitt Cancer Center 20100401 |
| Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. | Thrombosis research 20100401 |
| Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. | Journal of chemotherapy (Florence, Italy) 20100401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100401 |
| Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? | European review for medical and pharmacological sciences 20100401 |
| [Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100401 |
| Imatinib plasma levels: correlation with clinical benefit in GIST patients. | British journal of cancer 20100330 |
| Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. | World journal of hepatology 20100327 |
| Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100320 |
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. | Nature 20100318 |
| Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. | British journal of cancer 20100316 |
| Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. | International journal of cancer 20100315 |
| BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring. | Journal of medicinal chemistry 20100311 |
| Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. | Journal of medicinal chemistry 20100311 |
| Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. | British journal of cancer 20100302 |
| Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. | British journal of cancer 20100302 |
| NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. | British journal of cancer 20100302 |
| Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. | Journal of cancer research and clinical oncology 20100301 |
| Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. | Cardiovascular toxicology 20100301 |
| [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)]. | Aktuelle Urologie 20100301 |
| Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. | Gastroenterology 20100301 |
| A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. | Clinical pharmacology and therapeutics 20100301 |
| Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? | Angiogenesis 20100301 |
| Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. | Anti-cancer drugs 20100301 |
| Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. | The British journal of dermatology 20100301 |
| Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan. | Japanese journal of clinical oncology 20100301 |
| Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? | Current opinion in hematology 20100301 |
| The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. | European journal of cancer (Oxford, England : 1990) 20100301 |
| Toxicity of sorafenib: clinical and molecular aspects. | Expert opinion on drug safety 20100301 |
| Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. | Cancer 20100301 |
| Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. | Leukemia research 20100301 |
| Tyrosine kinase inhibitors to treat liver cancer. | Expert opinion on emerging drugs 20100301 |
| Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. | Bioorganic & medicinal chemistry letters 20100301 |
| Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100301 |
| [Use of sorafenib in patients with hepatocellular or renal carcinoma]. | Gastroenterologie clinique et biologique 20100301 |
| Recent advances and future directions in the management of metastatic renal cell carcinoma. | Anti-cancer agents in medicinal chemistry 20100301 |
| Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. | Molecular cancer therapeutics 20100301 |
| Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. | Molecular cancer therapeutics 20100301 |
| Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. | The oncologist 20100301 |
| Raf inhibitors as therapeutic agents against neurodegenerative diseases. | CNS & neurological disorders drug targets 20100301 |
| Approach to the thyroid cancer patient with extracervical metastases. | The Journal of clinical endocrinology and metabolism 20100301 |
| Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. | The oncologist 20100301 |
| Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. | Neoplasia (New York, N.Y.) 20100301 |
| Management of hepatocellular carcinoma recurrence after liver transplantation. | Transplantation proceedings 20100301 |
| Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. | Targeted oncology 20100301 |
| [Chemotherapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100301 |
| The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. | Journal of gastroenterology and hepatology 20100301 |
| Molecular therapy of pancreatic cancer. | Minerva endocrinologica 20100301 |
| New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. | Asia-Pacific journal of clinical oncology 20100301 |
| Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. | International journal of urology : official journal of the Japanese Urological Association 20100301 |
| A multidisciplinary approach to the management of hepatocellular carcinoma. | Gastroenterology & hepatology 20100301 |
| Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. | Oncogene 20100225 |
| Identification of bona fide esophageal adenocarcinoma cell lines. | Journal of the National Cancer Institute 20100224 |
| Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. | Journal of the National Cancer Institute 20100224 |
| Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220 |
| Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. | Lancet (London, England) 20100220 |
| FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. | Blood 20100218 |
| Treatment options for small cell lung cancer - do we have more choice? | British journal of cancer 20100216 |
| Review article: the management of hepatocellular carcinoma. | Alimentary pharmacology & therapeutics 20100215 |
| Sorafenib-associated remission of psoriasis in hypernephroma: case report. | Dermatology online journal 20100215 |
| Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. | British journal of cancer 20100202 |
| Metastasis of genitourinary tumors to the head and neck region. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 20100201 |
| Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. | Cancer letters 20100201 |
| The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. | Research in veterinary science 20100201 |
| Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. | Annals of surgical oncology 20100201 |
| Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event. | Lung cancer (Amsterdam, Netherlands) 20100201 |
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. | Cardiovascular and interventional radiology 20100201 |
| VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20100201 |
| Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma. | Anti-cancer drugs 20100201 |
| Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. | Anti-cancer drugs 20100201 |
| Angiogenesis inhibitors in the management of breast cancer. | Current opinion in obstetrics & gynecology 20100201 |
| Sorafenib - a small molecule with big promise? | Leukemia & lymphoma 20100201 |
| Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34. | The Journal of urology 20100201 |
| Advances in target therapy for lung cancer. | Japanese journal of clinical oncology 20100201 |
| Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era. | Hepatology research : the official journal of the Japan Society of Hepatology 20100201 |
| Targeted therapy of hepatocellular cancer. | Expert opinion on investigational drugs 20100201 |
| Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. | Molecular cancer therapeutics 20100201 |
| Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100201 |
| Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100201 |
| A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. | Leukemia & lymphoma 20100201 |
| [Diagnosis and multimodal therapy for hepatocellular carcinoma]. | Zeitschrift fur Gastroenterologie 20100201 |
| Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? | The oncologist 20100201 |
| Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. | The oncologist 20100201 |
| Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. | Nature reviews. Urology 20100201 |
| Risk of bleeding not increased by sorafenib or sunitinib. | The Lancet. Oncology 20100201 |
| Current strategy for staging and treatment: the BCLC update and future prospects. | Seminars in liver disease 20100201 |
| Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. | Journal of drugs in dermatology : JDD 20100201 |
| Prognostic factors in patients treated with VEGF-targeted therapies. | Clinical advances in hematology & oncology : H&O 20100201 |
| [Treatment of locally advanced renal tumors]. | Actas urologicas espanolas 20100201 |
| Hepatocellular carcinoma--what's new? | Journal of visceral surgery 20100201 |
| Advances in renal cell carcinoma treatment. | Therapeutic advances in urology 20100201 |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. | Cell 20100122 |
| CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. | British journal of cancer 20100119 |
| Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. | Bioorganic & medicinal chemistry 20100115 |
| Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? | Clinical cancer research : an official journal of the American Association for Cancer Research 20100115 |
| Displacement assay for the detection of stabilizers of inactive kinase conformations. | Journal of medicinal chemistry 20100114 |
| Sorafenib-induced bilateral osteonecrosis of femoral heads. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100110 |
| Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. | Journal of the National Cancer Institute 20100106 |
| Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. | British journal of cancer 20100105 |
| Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. | British journal of cancer 20100105 |
| Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study. | Urologic oncology 20100101 |
| A survey of therapy for advanced renal cell carcinoma. | Urologic oncology 20100101 |
| Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. | Urologic oncology 20100101 |
| Sorafenib induces partial response in metastatic medullary thyroid carcinoma. | Acta oncologica (Stockholm, Sweden) 20100101 |
| Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. | Pediatric blood & cancer 20100101 |
| Molecular targets for liver cancer therapy: From screening of target genes to clinical trials. | Hepatology research : the official journal of the Japan Society of Hepatology 20100101 |
| Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma. | Haemophilia : the official journal of the World Federation of Hemophilia 20100101 |
| Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101 |
| Acute aortic dissection during sorafenib-containing therapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20100101 |
| It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. | Cancer science 20100101 |
| Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. | Cancer 20100101 |
| Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. | Hepatology (Baltimore, Md.) 20100101 |
| Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20100101 |
| Where does the combination of sorafenib and interferon in renal cell carcinoma stand? | Cancer 20100101 |
| Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma. | Bioorganic & medicinal chemistry letters 20100101 |
| About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? | Annals of oncology : official journal of the European Society for Medical Oncology 20100101 |
| AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). | Journal of hepatology 20100101 |
| Evidence-based urology in practice: when to believe a subgroup analysis? | BJU international 20100101 |
| Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. | Journal of hepatology 20100101 |
| Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. | Urologic oncology 20100101 |
| Synthesis and antiproliferative activity of novel diaryl ureas possessing a 4H-pyrido[1,2-a]pyrimidin-4-one group. | Archiv der Pharmazie 20100101 |
| Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. | Gerontology 20100101 |
| Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20100101 |
| Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. | Dermatology (Basel, Switzerland) 20100101 |
| Platelet count less than SHARP: what does a case series reveal? | Expert opinion on drug safety 20100101 |
| VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. | European journal of cancer (Oxford, England : 1990) 20100101 |
| Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20100101 |
| Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. | AJR. American journal of roentgenology 20100101 |
| Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. | AJR. American journal of roentgenology 20100101 |
| Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. | Pharmacotherapy 20100101 |
| Compounds in clinical Phase III and beyond. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101 |
| Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models. | Hepatology (Baltimore, Md.) 20100101 |
| Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. | The oncologist 20100101 |
| Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. | Molecular cancer therapeutics 20100101 |
| Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. | Annual review of medicine 20100101 |
| Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101 |
| [Differentiated therapy of liver tumors]. | Der Internist 20100101 |
| A current review of targeted therapeutics for ovarian cancer. | Journal of oncology 20100101 |
| Antivascular therapy for epithelial ovarian cancer. | Journal of oncology 20100101 |
| Sorafenib. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101 |
| Molecular basis for the treatment of renal cell carcinoma. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100101 |
| Managing adverse events associated with sorafenib in renal cell carcinoma. | British journal of nursing (Mark Allen Publishing) 20100101 |
| Progress in the management of advanced renal cell carcinoma (RCC). | Aktuelle Urologie 20100101 |
| A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma. | The Netherlands journal of medicine 20100101 |
| The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. | Molecular cancer 20100101 |
| A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. | Journal of translational medicine 20100101 |
| Targeted therapies in epithelial ovarian cancer. | Journal of oncology 20100101 |
| Targeted therapy in ovarian cancer. | Journal of oncology 20100101 |
| [Renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100101 |
| Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. | International journal of cell biology 20100101 |
| Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. | Journal of translational medicine 20100101 |
| Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? | Obstetrics and gynecology international 20100101 |
| From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. | Journal of hematology & oncology 20100101 |
| Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. | Radiation oncology (London, England) 20100101 |
| Choroidal metastasis of renal cell carcinoma: a case report. | Japanese journal of ophthalmology 20100101 |
| Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. | Biologics : targets & therapy 20100101 |
| Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. | BMC cancer 20100101 |
| [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma]. | Onkologie 20100101 |
| [Outlook: Future therapy of renal cell carcinoma]. | Onkologie 20100101 |
| Angiogenesis inhibition in prostate cancer: current uses and future promises. | Journal of oncology 20100101 |
| Liver development, regeneration, and carcinogenesis. | Journal of biomedicine & biotechnology 20100101 |
| Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. | Journal of molecular signaling 20100101 |
| A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report. | Journal of medical case reports 20100101 |
| Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. | mAbs 20100101 |
| Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension. | Advances in experimental medicine and biology 20100101 |
| Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach. | Gastroenterologie clinique et biologique 20100101 |
| Molecular mechanisms of resistance to tumour anti-angiogenic strategies. | Journal of oncology 20100101 |
| Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. | Journal of oncology 20100101 |
| Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. | Journal of oncology 20100101 |
| [Treatment of advanced hepatocellular carcinoma]. | Gastroenterologia y hepatologia 20100101 |
| Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis. | BMC genomics 20100101 |
| Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. | Journal of hematology & oncology 20100101 |
| A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. | Molecular cancer 20100101 |
| Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. | Molecular cancer 20100101 |
| New therapeutic strategies for renal cell carcinoma. | Urologic nursing 20100101 |
| Multiple distant metastases of hepatocellular carcinoma to the oral cavity. | In vivo (Athens, Greece) 20100101 |
| Molecular profiling of endometrial malignancies. | Obstetrics and gynecology international 20100101 |
| Cancer-drug associations: a complex system. | PloS one 20100101 |
| Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. | PloS one 20100101 |
| Thyroid cancer: current molecular perspectives. | Journal of oncology 20100101 |
| [Targeted therapies in hepatocellular carcinoma]. | Presse medicale (Paris, France : 1983) 20100101 |
| Progress on antiangiogenic therapy for patients with malignant glioma. | Journal of oncology 20100101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. | Molecular cancer 20100101 |
| Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. | Case reports in medicine 20100101 |
| Molecular targeted therapies in head and neck cancer--an update of recent developments-. | Head & neck oncology 20100101 |
| Melanoma: a model for testing new agents in combination therapies. | Journal of translational medicine 20100101 |
| Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. | Journal of oncology 20100101 |
| Prospects for non-immunological molecular therapeutics in melanoma. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101 |
| Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. | Journal of hematology & oncology 20100101 |
| Evaluation of multiple targeted agents as potential therapies for hepatocellular carcinoma (HCC). Foreword. | Current problems in cancer 20100101 |
| Current problems with systemic treatment of advanced hepatocellular cancer. | Current problems in cancer 20100101 |
| [Renal cell carcinoma management and therapies in 2010]. | Bulletin du cancer 20100101 |
| [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. | Bulletin du cancer 20100101 |
| [Targeted therapies: sequential and combined treatments]. | Bulletin du cancer 20100101 |
| [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]. | Bulletin du cancer 20100101 |
| [Advanced renal carcinomas with special situations. How to treat them?]. | Bulletin du cancer 20100101 |
| Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. | PloS one 20100101 |
| A comprehensive molecular interaction map for rheumatoid arthritis. | PloS one 20100101 |
| Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? | Swiss medical weekly 20100101 |
| A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. | Oncology 20100101 |
| Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma. | Molecular cancer 20100101 |
| Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. | Journal of carcinogenesis 20100101 |
| Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. | Journal of oncology 20100101 |
| Adhesion of renal carcinoma cells to endothelial cells depends on PKCmu. | BMC cancer 20100101 |
| Should the NHS be privatized? Annual varsity medical debate - London, 22 January 2010. | Philosophy, ethics, and humanities in medicine : PEHM 20100101 |
| A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. | BMC cancer 20100101 |
| [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers]. | Therapie 20100101 |
| Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. | International journal of clinical and experimental pathology 20100101 |
| Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma. | Radiation oncology (London, England) 20100101 |
| Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity. | Onkologie 20100101 |
| Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. | PloS one 20100101 |
| Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. | PloS one 20100101 |
| Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. | Journal of oncology 20100101 |
| Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. | Molecular cancer 20100101 |
| A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. | Internal medicine (Tokyo, Japan) 20100101 |
| Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. | Journal of experimental & clinical cancer research : CR 20100101 |
| Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. | BMC health services research 20100101 |
| Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth. | BMC cancer 20100101 |
| Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. | Biologics : targets & therapy 20100101 |
| Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. | PloS one 20100101 |
| Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques. | BMC bioinformatics 20100101 |
| Clinical trials with anti-angiogenic agents in hematological malignancies. | Journal of angiogenesis research 20100101 |
| Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. | Molecular cancer 20100101 |
| Identifying differentially regulated subnetworks from phosphoproteomic data. | BMC bioinformatics 20100101 |
| Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. | Breast cancer research : BCR 20100101 |
| Update on options for treatment of metastatic castration-resistant prostate cancer. | OncoTargets and therapy 20100101 |
| Anti-angiogenesis therapies: their potential in cancer management. | OncoTargets and therapy 20100101 |
| RNA vaccines in cancer treatment. | Journal of biomedicine & biotechnology 20100101 |
| New targeted molecular therapies for dedifferentiated thyroid cancer. | Journal of oncology 20100101 |
| Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. | Journal of oncology 20100101 |
| Molecular and clinical aspects of targeting the VEGF pathway in tumors. | Journal of oncology 20100101 |
| Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. | Journal of experimental & clinical cancer research : CR 20100101 |
| Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. | Clinical drug investigation 20100101 |
| Targeted treatment for metastatic renal cell carcinoma and immune regulation. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101 |
| Advances in cellular therapy for the treatment of thyroid cancer. | Journal of oncology 20100101 |
| Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer. | Current gerontology and geriatrics research 20100101 |
| GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. | BMC cancer 20100101 |
| Angiogenesis inhibitors in the treatment of prostate cancer. | Journal of hematology & oncology 20100101 |
| Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results. | HPB surgery : a world journal of hepatic, pancreatic and biliary surgery 20100101 |
| Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. | Genome biology 20100101 |
| Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. | European journal of medical research 20100101 |
| The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. | Breast cancer : basic and clinical research 20100101 |
| Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. | Hepato-gastroenterology 20100101 |
| Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia? | Hepato-gastroenterology 20100101 |
| Targeting lymphatic vessel functions through tyrosine kinases. | Journal of angiogenesis research 20100101 |
| r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. | PloS one 20100101 |
| Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. | Genome medicine 20100101 |
| Potential role of sugar transporters in cancer and their relationship with anticancer therapy. | International journal of endocrinology 20100101 |
| Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology. | PloS one 20100101 |
| The challenge of metastatic colorectal cancer. | Clinical Medicine Insights. Oncology 20100101 |
| Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors. | Clinical Medicine Insights. Oncology 20100101 |
| Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. | Chemotherapy 20100101 |
| The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. | Biologics : targets & therapy 20100101 |
| Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. | Biologics : targets & therapy 20100101 |
| Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? | Dermatology (Basel, Switzerland) 20100101 |
| Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature. | Advances in urology 20100101 |
| Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia. | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20100101 |
| Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. | Oncology 20100101 |
| Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. | BMC cancer 20100101 |
| [Nexavar clinical registry]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101 |
| Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells. | Journal of carcinogenesis 20100101 |
| Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. | BMC cancer 20100101 |
| Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. | PloS one 20100101 |
| EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. | PloS one 20100101 |
| Cost-effectiveness analysis in markets with high fixed costs. | PharmacoEconomics 20100101 |
| Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma. | BMC cancer 20100101 |
| Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. | Journal of Cancer 20100101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| Current and emerging therapies for the treatment of pancreatic cancer. | OncoTargets and therapy 20100101 |
| Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. | Molecular cancer 20100101 |
| Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. | Journal of transplantation 20100101 |
| Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers. | Journal of oncology 20100101 |
| Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression. | Molecular cancer 20100101 |
| Role of surgery in advanced/metastatic renal cell carcinoma. | Indian journal of urology : IJU : journal of the Urological Society of India 20100101 |
| Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. | BMC cancer 20100101 |
| [Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20100101 |
| Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. | BMC cancer 20100101 |
| Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome? | BMC cancer 20100101 |
| Oral systemic therapy: Not all 'win-win'. | Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101 |
| Advanced inoperable type B3 thymoma: monitoring of a novel therapeutic approach with radio-chemotherapy and sorafenib by FDG-PET and CT. | Nuklearmedizin. Nuclear medicine 20100101 |
| Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy. | Acta haematologica 20100101 |
| A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient. | International journal of immunopathology and pharmacology 20100101 |
| Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice. | BMC pharmacology 20100101 |
| The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. | BMC cancer 20100101 |
| Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment. | European journal of dermatology : EJD 20100101 |
| Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment. | Therapeutics and clinical risk management 20100101 |
| Herbal compound 'Songyou Yin' reinforced the ability of interferon-alfa to inhibit the enhanced metastatic potential induced by palliative resection of hepatocellular carcinoma in nude mice. | BMC cancer 20100101 |
| Late presentation of sorafenib-associated rash: a case report. | Journal of medical case reports 20100101 |
| Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. | Urologia internationalis 20100101 |
| Pazopanib for the treatment of patients with advanced renal cell carcinoma. | Clinical Medicine Insights. Oncology 20100101 |
| Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. | Hepato-gastroenterology 20100101 |
| Right ventricular exclusion for hepatocellular carcinoma metastatic to the heart. | Journal of cardiothoracic surgery 20100101 |
| Sarcomatoid chromophobe renal cell carcinoma: Cytohistopathological correlation of a case. | Journal of cytology 20100101 |
| Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. | Journal of translational medicine 20100101 |
| Old and new insights in the treatment of thyroid carcinoma. | Journal of thyroid research 20100101 |
| New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. | OncoTargets and therapy 20100101 |
| The bevacizumab experience in advanced renal cell carcinoma. | OncoTargets and therapy 20100101 |
| Profile of temsirolimus in the treatment of advanced renal cell carcinoma. | OncoTargets and therapy 20100101 |
| Treatment with sorafenib in advanced thyroid cancer - a case report. | Endokrynologia Polska 20100101 |
| Present and future evolution of advanced breast cancer therapy. | Breast cancer research : BCR 20100101 |
| Triple-negative breast cancer. | Breast cancer research : BCR 20100101 |
| [Hand-foot syndrome after administration of tyrosinkinase inhibitors]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101 |
| Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. | BMC cancer 20100101 |
| Antiangiogenic therapy for breast cancer. | Breast cancer research : BCR 20100101 |
| Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. | Oncology 20100101 |
| Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. | Oncology 20100101 |
| Constructing the HBV-human protein interaction network to understand the relationship between HBV and hepatocellular carcinoma. | Journal of experimental & clinical cancer research : CR 20100101 |
| Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. | BMC cancer 20100101 |
| Targeted therapy in lymphoma. | Journal of hematology & oncology 20100101 |
| Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? | The oncologist 20100101 |
| Current and future technology for minimally invasive ablation of renal cell carcinoma. | Indian journal of urology : IJU : journal of the Urological Society of India 20100101 |
| Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. | BMC cancer 20100101 |
| The inefficacy of antiangiogenic therapies. | Journal of angiogenesis research 20100101 |
| A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. | Therapeutics and clinical risk management 20100101 |
| Activation of protein serine/threonine phosphatase PP2Cα efficiently prevents liver fibrosis. | PloS one 20100101 |
| Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers. | PloS one 20100101 |
| Do not say ever never more: the ins and outs of antiangiogenic therapies. | Current pharmaceutical design 20100101 |
| Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. | Journal of experimental & clinical cancer research : CR 20100101 |
| A comprehensive map of the mTOR signaling network. | Molecular systems biology 20100101 |
| Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. | PloS one 20100101 |
| Everolimus - a new approach in the treatment of renal cell carcinoma. | Cancer management and research 20100101 |
| Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. | Cancer management and research 20100101 |
| Management of metastatic renal cell carcinoma in patients with poor prognosis. | Cancer management and research 20100101 |
| Treatment of cutaneous melanoma: current approaches and future prospects. | Cancer management and research 20100101 |
| RAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development. | PloS one 20100101 |
| A phase II trial of sorafenib in metastatic melanoma with tissue correlates. | PloS one 20100101 |
| Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. | Biologics : targets & therapy 20100101 |
| Renal cell carcinoma: focus on safety and efficacy of temsirolimus. | Clinical Medicine Insights. Oncology 20100101 |
| [Task-orientated therapy (target-therapy) directed to patients with renal cell carcinoma]. | Likars'ka sprava 20100101 |
| Radionuclide therapy for hepatocellular carcinoma. | Acta gastro-enterologica Belgica 20100101 |
| Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma. | Tumori 20100101 |
| Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma? | Tumori 20100101 |
| Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. | Journal of biomedicine & biotechnology 20100101 |
| Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. | Case reports in oncology 20100101 |
| [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101 |
| Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). | Tumori 20100101 |
| Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma. | Gastroenterology research and practice 20100101 |
| Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma. | Case reports in oncology 20100101 |
| Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. | Clinical and experimental gastroenterology 20100101 |
| Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). | Drug, healthcare and patient safety 20100101 |
| Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. | Therapeutic advances in medical oncology 20100101 |
| TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. | World journal of gastroenterology 20091221 |
| Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk? | Pediatric blood & cancer 20091215 |
| Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4. | Bioorganic & medicinal chemistry letters 20091215 |
| Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. | British journal of cancer 20091215 |
| The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. | Journal of immunology (Baltimore, Md. : 1950) 20091215 |
| Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. | Journal of medicinal chemistry 20091210 |
| Novel treatments for hepatocellular cancer. | Cancer letters 20091201 |
| UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. | Cancer chemotherapy and pharmacology 20091201 |
| Rectal fistulae resulting from treatment with sorafenib and bevacizumab. | Gastrointestinal endoscopy 20091201 |
| A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection. | Medical oncology (Northwood, London, England) 20091201 |
| Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. | Cancer treatment reviews 20091201 |
| New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. | Gut 20091201 |
| Clinical pharmacokinetics of tyrosine kinase inhibitors. | Cancer treatment reviews 20091201 |
| Metastatic renal cell carcinoma: recent advances in the targeted therapy era. | European urology 20091201 |
| Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. | European journal of endocrinology 20091201 |
| Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. | Hepatology (Baltimore, Md.) 20091201 |
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091201 |
| Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091201 |
| Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line. | Bioorganic & medicinal chemistry letters 20091201 |
| Sorafenib-induced hepatic encephalopathy. | The Annals of pharmacotherapy 20091201 |
| Increase in tumour permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI. | British journal of cancer 20091201 |
| Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? | Targeted oncology 20091201 |
| Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. | British journal of cancer 20091201 |
| Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091201 |
| Combination systemic therapy for advanced renal cell carcinoma. | The oncologist 20091201 |
| Tyrosine kinase inhibitors and the thyroid. | Best practice & research. Clinical endocrinology & metabolism 20091201 |
| Sorafenib-induced acute myocardial infarction due to coronary artery spasm. | Journal of cardiology 20091201 |
| Metastatic renal cell carcinoma: current standards of care. | Clinical journal of oncology nursing 20091201 |
| Management of vascular endothelial growth factor and multikinase inhibitor side effects. | Clinical journal of oncology nursing 20091201 |
| Clinical characteristics of renal cell carcinoma in Korean patients with von Hippel-Lindau disease compared to sporadic bilateral or multifocal renal cell carcinoma. | Journal of Korean medical science 20091201 |
| Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. | Expert review of anticancer therapy 20091201 |
| Update on novel agents in renal cell carcinoma. | Expert review of anticancer therapy 20091201 |
| Health policy: The UK 'postcode lottery' in renal cell carcinoma. | Nature reviews. Urology 20091201 |
| Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data. | PLoS computational biology 20091201 |
| [Sorafenib-induced multiple eruptive keratoacanthomas]. | Annales de dermatologie et de venereologie 20091201 |
| Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases. | Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20091201 |
| Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20091201 |
| [Targeting KRAS pathway in NSCLC therapy]. | Bulletin du cancer 20091201 |
| Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. | Cancer biology & therapy 20091201 |
| Tyrosine kinase inhibitor-induced macrocytosis. | Anticancer research 20091201 |
| Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. | BJU international 20091201 |
| Hepatocellular carcinoma: the search for innovative adjuvant therapies. | Oncology (Williston Park, N.Y.) 20091201 |
| Targeted molecular therapies in thyroid carcinoma. | Arquivos brasileiros de endocrinologia e metabologia 20091201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091201 |
| Highlights from the Eigth International Kidney Cancer Symposium. | Clinical advances in hematology & oncology : H&O 20091201 |
| Baying for a flexible drug price. | Lancet (London, England) 20091128 |
| NICE rules that drug used in advanced liver cancer is not cost effective for the NHS. | BMJ (Clinical research ed.) 20091123 |
| Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. | British journal of cancer 20091117 |
| Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091115 |
| MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. | The Journal of biological chemistry 20091113 |
| C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). | Molecular cell 20091113 |
| Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. | The British journal of dermatology 20091101 |
| Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20091101 |
| Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. | Journal of hepatology 20091101 |
| New treatment approaches in renal cell carcinoma. | Anti-cancer drugs 20091101 |
| [Sorafenib in advanced hepatocellular carcinoma]. | Der Internist 20091101 |
| Therapy for metastatic RCC--questions remain. | Nature reviews. Urology 20091101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091101 |
| Targeted therapy in renal cancer. | Therapeutic advances in medical oncology 20091101 |
| Challenge and hope in radiotherapy of hepatocellular carcinoma. | Yonsei medical journal 20091031 |
| Everolimus: in advanced renal cell carcinoma. | Drugs 20091022 |
| Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. | British journal of cancer 20091020 |
| Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. | British journal of cancer 20091020 |
| Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). | Cancer 20091015 |
| Thrombotic events in patients with cancer receiving antiangiogenesis agents. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091010 |
| Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. | Journal of the National Cancer Institute 20091007 |
| Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. | British journal of cancer 20091006 |
| A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20091001 |
| Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. | Seminars in cancer biology 20091001 |
| Erythema multiforme induced by sorafenib. | Clinical and experimental dermatology 20091001 |
| Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. | International journal of cancer 20091001 |
| Novel treatment of medullary thyroid cancer. | Current opinion in endocrinology, diabetes, and obesity 20091001 |
| AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). | Blood 20091001 |
| Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. | Journal of hepatology 20091001 |
| Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20091001 |
| Hepatocellular carcinoma: The beginning of a long journey. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20091001 |
| Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. | Hepatology (Baltimore, Md.) 20091001 |
| Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. | American journal of hematology 20091001 |
| An overview of small-molecule inhibitors of VEGFR signaling. | Nature reviews. Clinical oncology 20091001 |
| Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. | The Lancet. Oncology 20091001 |
| Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. | AJR. American journal of roentgenology 20091001 |
| Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. | Cancer biology & therapy 20091001 |
| Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| [Palmoplantar cutaneous reaction to sorafenib]. | Actas dermo-sifiliograficas 20091001 |
| Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf. | Journal of pharmacological sciences 20091001 |
| Rapid development of hypertension by sorafenib: toxicity or target? | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. | Expert review of anticancer therapy 20091001 |
| Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient. | International journal of clinical oncology 20091001 |
| Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. | Breast (Edinburgh, Scotland) 20091001 |
| Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. | Journal of the American Chemical Society 20090923 |
| Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. | World journal of gastroenterology 20090921 |
| Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920 |
| Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920 |
| Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. | Neuroscience 20090915 |
| Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. | Cancer 20090915 |
| Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090915 |
| C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090915 |
| Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090915 |
| Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910 |
| Long-term response in primary renal cancer to sequential antiangiogenic therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910 |
| Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. | Journal of neurosurgery 20090901 |
| Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. | Current opinion in supportive and palliative care 20090901 |
| Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists. | Anti-cancer agents in medicinal chemistry 20090901 |
| Targeted therapies in the treatment of advanced/metastatic NSCLC. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. | Current opinion in oncology 20090901 |
| Surgical resection of renal cell carcinoma after targeted therapy. | The Journal of urology 20090901 |
| Sorafenib for hepatocellular carcinoma: global validation. | Gastroenterology 20090901 |
| Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. | Cancer biology & therapy 20090901 |
| A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. | Laboratory investigation; a journal of technical methods and pathology 20090901 |
| [Current state of systemic therapy of metastatic renal cell carcinoma]. | Der Urologe. Ausg. A 20090901 |
| The histologic spectrum of epithelial neoplasms induced by sorafenib. | Journal of the American Academy of Dermatology 20090901 |
| Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. | Nature reviews. Clinical oncology 20090901 |
| Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 1. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090901 |
| AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. | Molecular cancer therapeutics 20090901 |
| Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. | Neoplasia (New York, N.Y.) 20090901 |
| Molecular targeting for treatment of advanced hepatocellular carcinoma. | The Korean journal of hepatology 20090901 |
| Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. | Current oncology (Toronto, Ont.) 20090901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090901 |
| [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901 |
| [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901 |
| [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901 |
| Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. | Cancer 20090815 |
| Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. | Cancer research 20090815 |
| Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810 |
| [Molecular targeted drugs in the developmental stage: 2) Various molecular targets and therapeutic agents under investigation]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090810 |
| Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect. | Journal of the European Academy of Dermatology and Venereology : JEADV 20090801 |
| Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. | Journal of cellular and molecular medicine 20090801 |
| Hyperkeratosis of nipple skin during sorafenib treatment. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20090801 |
| Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. | Clinical and experimental nephrology 20090801 |
| Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. | Molecular pharmacology 20090801 |
| BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. | Molecular pharmacology 20090801 |
| Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. | Nature reviews. Clinical oncology 20090801 |
| Adverse effects of anticancer agents that target the VEGF pathway. | Nature reviews. Clinical oncology 20090801 |
| Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. | Current medical research and opinion 20090801 |
| Array of cutaneous adverse effects associated with sorafenib. | Journal of the American Academy of Dermatology 20090801 |
| Small molecules and targeted therapies in distant metastatic disease. | Annals of oncology : official journal of the European Society for Medical Oncology 20090801 |
| Tumor endothelial cells join the resistance. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090801 |
| Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090801 |
| Diagnosis and management of leptomeningeal disease. | Clinical journal of oncology nursing 20090801 |
| Sorafenib and sunitinib. | The oncologist 20090801 |
| Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. | Future oncology (London, England) 20090801 |
| Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? | Future oncology (London, England) 20090801 |
| [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402]. | Ai zheng = Aizheng = Chinese journal of cancer 20090801 |
| Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. | Molecular cancer therapeutics 20090801 |
| Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. | Molecular cancer therapeutics 20090801 |
| Re: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. | European urology 20090801 |
| Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. | Clinical genitourinary cancer 20090801 |
| The high-dose aldesleukin (IL-2) 'select' trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. | Clinical genitourinary cancer 20090801 |
| Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. | Anti-cancer drugs 20090801 |
| New directions in the systemic treatment of metastatic thyroid cancer. | Oncology (Williston Park, N.Y.) 20090801 |
| [Transarterial chemoembolization in hepatocellular carcinoma]. | Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti 20090801 |
| Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. | British journal of cancer 20090721 |
| Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715 |
| Targeting renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090710 |
| Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090710 |
| Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. | Journal of medicinal chemistry 20090709 |
| UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. | British journal of cancer 20090707 |
| Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib. | The British journal of ophthalmology 20090701 |
| Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. | Journal of cellular physiology 20090701 |
| Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. | BJU international 20090701 |
| Sorafenib tosylate in advanced kidney cancer: past, present and future. | Anti-cancer drugs 20090701 |
| Sequential sorafenib and sunitinib for renal cell carcinoma. | The Journal of urology 20090701 |
| Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701 |
| Aminoquinoline derivatives with antiproliferative activity against melanoma cell line. | Bioorganic & medicinal chemistry letters 20090701 |
| VEGF inhibition and metastasis: possible implications for antiangiogenic therapy. | Cancer biology & therapy 20090701 |
| Targeted therapy for hepatocellular carcinoma. | Nature reviews. Gastroenterology & hepatology 20090701 |
| Investigational agents in the management of non-small cell lung cancer. | Current oncology reports 20090701 |
| Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. | Nuclear medicine communications 20090701 |
| Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. | Nature reviews. Urology 20090701 |
| Multiple Histology Phase II Trials. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090701 |
| Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. | Deutsche medizinische Wochenschrift (1946) 20090701 |
| Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. | The American journal of gastroenterology 20090701 |
| Current management of hepatocellular carcinoma. | The Medical clinics of North America 20090701 |
| Systemic therapy for advanced renal cell carcinoma. | Therapeutic advances in medical oncology 20090701 |
| Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. | Blood 20090625 |
| NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. | Cancer letters 20090618 |
| The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. | Biochemistry 20090616 |
| How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. | Journal of the National Cancer Institute 20090616 |
| Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. | Blood 20090611 |
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090610 |
| Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. | Annals of the rheumatic diseases 20090601 |
| Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. | Cancer immunology, immunotherapy : CII 20090601 |
| Publication biases and phase II trials investigating anticancer targeted therapies. | Investigational new drugs 20090601 |
| Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. | European urology 20090601 |
| Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. | European urology 20090601 |
| Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. | BJU international 20090601 |
| A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. | Allergy 20090601 |
| [Prognostic factors for survival of patients with metastatic renal cell carcinoma]. | Der Urologe. Ausg. A 20090601 |
| Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. | Minerva gastroenterologica e dietologica 20090601 |
| Treatment of metastatic renal cell carcinoma. | Cancer chemotherapy and pharmacology 20090601 |
| [Toxicity of radiation therapy and antiangiogenics combination: a case report]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20090601 |
| A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. | Journal of hepatology 20090601 |
| Sunitinib in solid tumors. | Expert opinion on investigational drugs 20090601 |
| Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090601 |
| BRAF signaling and targeted therapies in melanoma. | Hematology/oncology clinics of North America 20090601 |
| Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? | Radiology 20090601 |
| Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. | Expert review of anticancer therapy 20090601 |
| Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. | Expert review of anticancer therapy 20090601 |
| The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. | Annals of oncology : official journal of the European Society for Medical Oncology 20090601 |
| Targeted therapies in the treatment of advanced renal cell carcinoma. | Recent patents on anti-cancer drug discovery 20090601 |
| The role of antiangiogenesis therapy: bevacizumab and beyond. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090601 |
| Old disease, new targets--part-I, solid malignancies. | JPMA. The Journal of the Pakistan Medical Association 20090601 |
| Localized dyskeratotic plaque with milia associated with sorafenib. | Journal of drugs in dermatology : JDD 20090601 |
| [Sorafenib(Nexavar)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090601 |
| New treatments for renal cell carcinoma: targeted therapies. | Journal of the National Comprehensive Cancer Network : JNCCN 20090601 |
| Non-clear cell renal cancer: features and medical management. | Journal of the National Comprehensive Cancer Network : JNCCN 20090601 |
| [Current advances in molecular targeted therapy of primary hepatocellular carcinoma]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090601 |
| [Interferon alpha and half-dose sorafenib is an effective treatment modality for interferon alpha-resistant metastatic renal cell carcinoma: a case report]. | Hinyokika kiyo. Acta urologica Japonica 20090601 |
| VEGF inhibitors and prostate cancer therapy. | Current molecular pharmacology 20090601 |
| [Expert consensus on standardization of the management of primary liver cancer]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090601 |
| Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. | Current drug metabolism 20090601 |
| Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT. | Cancer research and treatment : official journal of Korean Cancer Association 20090601 |
| Molecular markers of tumor progression in melanoma. | Current genomics 20090601 |
| Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. | Cancer letters 20090518 |
| Novel therapeutics for metastatic renal cell carcinoma. | Cancer 20090515 |
| Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. | Cancer 20090515 |
| Sequential therapy in renal cell carcinoma. | Cancer 20090515 |
| Treatment selection for patients with metastatic renal cell carcinoma. | Cancer 20090515 |
| Targeting mTOR in renal cell carcinoma. | Cancer 20090515 |
| Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. | Cancer 20090515 |
| Hereditary kidney cancer: unique opportunity for disease-based therapy. | Cancer 20090515 |
| Management of hypertension in angiogenesis inhibitor-treated patients. | Annals of oncology : official journal of the European Society for Medical Oncology 20090501 |
| Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. | Journal of gastroenterology and hepatology 20090501 |
| Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20090501 |
| FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. | Leukemia 20090501 |
| Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. | The Journal of clinical endocrinology and metabolism 20090501 |
| Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. | Journal of pharmaceutical and biomedical analysis 20090501 |
| Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. | International journal of urology : official journal of the Japanese Urological Association 20090501 |
| [Targeted therapies and their indications in solid neoplasias]. | La Revue de medecine interne 20090501 |
| Sorafenib in advanced hepatocellular carcinoma: a further step toward personalized therapy of liver cancer. | Gastroenterology 20090501 |
| Optimizing recent advances in metastatic renal cell carcinoma. | Current oncology reports 20090501 |
| Targeting angiogenesis in bladder cancer. | Current oncology reports 20090501 |
| Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. | Japanese journal of clinical oncology 20090501 |
| Targeted therapies in metastatic renal cancer in 2009. | BJU international 20090501 |
| Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. | British journal of pharmacology 20090501 |
| Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. | Cancer research 20090501 |
| Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. | Current cardiology reports 20090501 |
| Pathogenesis of hepatocellular carcinoma and molecular therapies. | Current opinion in gastroenterology 20090501 |
| Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20090501 |
| Prognostic markers and new, innovative treatments in renal cell carcinoma. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20090501 |
| Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? | Thyroid : official journal of the American Thyroid Association 20090501 |
| Future developments in renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20090501 |
| [Sorafenib reverses multidrug resistance of hepatoma cells in vitro]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090501 |
| Sorafenib in the management of metastatic renal cell carcinoma. | Current oncology (Toronto, Ont.) 20090501 |
| Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. | Current oncology (Toronto, Ont.) 20090501 |
| State-of-the-art treatment of metastatic renal cell carcinoma. | Current oncology (Toronto, Ont.) 20090501 |
| Targeted therapies for renal cell carcinoma: more gains from using them again. | Current oncology (Toronto, Ont.) 20090501 |
| Inhibition of mTOR in kidney cancer. | Current oncology (Toronto, Ont.) 20090501 |
| The contemporary role of surgery in kidney cancer. | Current oncology (Toronto, Ont.) 20090501 |
| Review of guidelines on the treatment of metastatic renal cell carcinoma. | Current oncology (Toronto, Ont.) 20090501 |
| Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. | Current oncology (Toronto, Ont.) 20090501 |
| First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from ASCO 2008. | Current oncology (Toronto, Ont.) 20090501 |
| Angiogenesis regulated by VEGF and its receptors and its clinical application. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20090501 |
| Novel developments in angiogenesis cancer therapy. | Current oncology (Toronto, Ont.) 20090501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090501 |
| [New therapeutic opportunities in metastatic renal cell carcinoma]. | Praxis 20090429 |
| Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). | Journal of medicinal chemistry 20090423 |
| Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. | Journal of the National Cancer Institute 20090415 |
| Facial acneiform rash associated with sorafenib. | Dermatology online journal 20090415 |
| Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410 |
| Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. | British journal of cancer 20090407 |
| [The treatment of hepatocellular carcinoma. New developments]. | Nederlands tijdschrift voor geneeskunde 20090404 |
| Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. | Journal of cancer research and clinical oncology 20090401 |
| Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. | European urology 20090401 |
| Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. | Hepatology (Baltimore, Md.) 20090401 |
| Phase II trial of sorafenib in metastatic thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090401 |
| Efficient exploration of large combinatorial chemistry spaces by monomer-based similarity searching. | Journal of chemical information and modeling 20090401 |
| FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. | Cancer research 20090401 |
| [Hepatocellular carcinoma management in the era of sorafenib]. | Gastroenterologie clinique et biologique 20090401 |
| Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. | Pharmacotherapy 20090401 |
| Antiangiogenic therapy: not just for cancer anymore? | Hepatology (Baltimore, Md.) 20090401 |
| Renal effects of anti-angiogenesis therapy: update for the internist. | The American journal of medicine 20090401 |
| Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. | Nature reviews. Clinical oncology 20090401 |
| PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? | Expert opinion on therapeutic targets 20090401 |
| [Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib]. | Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20090401 |
| The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. | Thyroid : official journal of the American Thyroid Association 20090401 |
| Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). | Biochimica et biophysica acta 20090401 |
| Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. | Targeted oncology 20090401 |
| Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. | Expert review of anticancer therapy 20090401 |
| [Strategy for patients with GIST after failure of imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090401 |
| Selection of patients with hepatocellular carcinoma for sorafenib. | Journal of the National Comprehensive Cancer Network : JNCCN 20090401 |
| Renal toxicity of targeted therapies. | Targeted oncology 20090401 |
| Clinical management of adrenocortical carcinoma. | Best practice & research. Clinical endocrinology & metabolism 20090401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090401 |
| Sorafenib: new indication. For some patients with liver cancer. | Prescrire international 20090401 |
| Sorafenib: gastrointestinal perforation. Known reactions to VEGF inhibitors. | Prescrire international 20090401 |
| Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090310 |
| Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways. | Purinergic signalling 20090301 |
| Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas. | European journal of medicinal chemistry 20090301 |
| Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. | European journal of cancer (Oxford, England : 1990) 20090301 |
| The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. | BJU international 20090301 |
| EORTC-GU group expert opinion on metastatic renal cell cancer. | European journal of cancer (Oxford, England : 1990) 20090301 |
| Multimodal approaches to the treatment of hepatocellular carcinoma. | Nature clinical practice. Gastroenterology & hepatology 20090301 |
| Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma. | The Journal of investigative dermatology 20090301 |
| Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy. | Expert opinion on investigational drugs 20090301 |
| Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. | Cancer chemotherapy and pharmacology 20090301 |
| Recent advances in the systemic treatment of metastatic papillary renal cancer. | Expert review of anticancer therapy 20090301 |
| Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. | Molecular cancer therapeutics 20090301 |
| Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy. | Molecular cancer research : MCR 20090301 |
| Thrombosis associated with angiogenesis inhibitors. | Best practice & research. Clinical haematology 20090301 |
| Systemic treatment in hepatocellular carcinoma; 'A small step for man...'. | The Netherlands journal of medicine 20090301 |
| Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. | Clinical lung cancer 20090301 |
| Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. | Marine drugs 20090301 |
| Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach. | Current oncology (Toronto, Ont.) 20090301 |
| [Treatment of (unresectable) hepatocellular carcinoma at an intermediate or advanced stage]. | Revue medicale de Liege 20090301 |
| [Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)]. | Revue medicale de Liege 20090301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090301 |
| [Diagnosis and treatment of hepatocellular carcinoma]. | Medicina clinica 20090227 |
| Major achievements in hepatocellular carcinoma. | Lancet (London, England) 20090221 |
| Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090220 |
| Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| Integrating BRAF/MEK inhibitors into combination therapy for melanoma. | British journal of cancer 20090210 |
| Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090201 |
| Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. | Leukemia research 20090201 |
| Dermatologic symptoms associated with the multikinase inhibitor sorafenib. | Journal of the American Academy of Dermatology 20090201 |
| Targeting RET for thyroid cancer therapy. | Biochemical pharmacology 20090201 |
| Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090201 |
| Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma? | Nature clinical practice. Oncology 20090201 |
| Treating hepatocellular carcinoma without liver transplantation. | Current gastroenterology reports 20090201 |
| Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090201 |
| MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. | Molecular cancer therapeutics 20090201 |
| Potential and future strategies for radiotherapy in hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20090201 |
| Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. | Onkologie 20090201 |
| Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib. | Onkologie 20090201 |
| Sorafenib is active on lung metastases from synovial sarcoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20090201 |
| [Hand-foot syndrome and sorafenib]. | Bulletin du cancer 20090201 |
| Protein kinase inhibitors: contributions from structure to clinical compounds. | Quarterly reviews of biophysics 20090201 |
| [Highlights in hepatology]. | Revue medicale suisse 20090121 |
| Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. | Cancer 20090115 |
| Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090115 |
| Antiangiogenic drugs in ovarian cancer. | British journal of cancer 20090113 |
| Molecular therapy for the treatment of hepatocellular carcinoma. | British journal of cancer 20090113 |
| Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110 |
| CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. | Oncogene 20090108 |
| Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. | Journal of cancer research and clinical oncology 20090101 |
| Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. | Journal of neuro-oncology 20090101 |
| New therapeutic developments in renal cell cancer. | Critical reviews in oncology/hematology 20090101 |
| The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. | Critical reviews in oncology/hematology 20090101 |
| Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. | Medical oncology (Northwood, London, England) 20090101 |
| Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. | Cancer science 20090101 |
| Molecularly targeted therapy for hepatocellular carcinoma. | Cancer science 20090101 |
| Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090101 |
| Quo vadis with targeted drugs in the 21st century? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090101 |
| Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. | Cancer 20090101 |
| Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. | Clinical drug investigation 20090101 |
| Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. | Cancer control : journal of the Moffitt Cancer Center 20090101 |
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. | The Lancet. Oncology 20090101 |
| Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. | The American journal of gastroenterology 20090101 |
| Lessons learned from independent central review. | European journal of cancer (Oxford, England : 1990) 20090101 |
| Early development of sunitinib in hepatocellular carcinoma. | Expert review of anticancer therapy 20090101 |
| Sorafenib for liver cancer: the horizon broadens. | The Lancet. Oncology 20090101 |
| Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma? | Hepatology (Baltimore, Md.) 20090101 |
| Management of advanced hepatocellular carcinoma in the era of targeted therapy. | Liver international : official journal of the International Association for the Study of the Liver 20090101 |
| Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. | Molecular cancer therapeutics 20090101 |
| Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. | Molecular cancer therapeutics 20090101 |
| Sorafenib for the treatment of unresectable hepatocellular carcinoma. | The oncologist 20090101 |
| Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning? | The oncologist 20090101 |
| Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. | The oncologist 20090101 |
| Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. | The oncologist 20090101 |
| Molecular targeted therapy for hepatocellular carcinoma. | Journal of gastroenterology 20090101 |
| Tyrosine kinase blockers: new hope for successful cancer therapy. | Anti-cancer agents in medicinal chemistry 20090101 |
| Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090101 |
| Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report. | Zeitschrift fur Gastroenterologie 20090101 |
| [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC]. | Zeitschrift fur Gastroenterologie 20090101 |
| [New surgical approaches in the treatment of hepatocellular carcinoma]. | Zeitschrift fur Gastroenterologie 20090101 |
| Recent advances of novel targeted therapy in non-small cell lung cancer. | Journal of hematology & oncology 20090101 |
| Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. | BMC cancer 20090101 |
| [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. | Aktuelle Urologie 20090101 |
| [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. | Aktuelle Urologie 20090101 |
| Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. | International journal of clinical pharmacology and therapeutics 20090101 |
| New drugs for the treatment of hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20090101 |
| [Management of hepatocellular carcinoma. Where are we now? What's next?]. | Bulletin du cancer 20090101 |
| [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies]. | Bulletin du cancer 20090101 |
| Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm. | Clinical genitourinary cancer 20090101 |
| Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. | Clinical genitourinary cancer 20090101 |
| Compassionate use of sorafenib in patients with advanced renal cell cancer. | Clinical genitourinary cancer 20090101 |
| Sorafenib: a review of its use in advanced hepatocellular carcinoma. | Drugs 20090101 |
| Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. | Journal of hematology & oncology 20090101 |
| Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20090101 |
| Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. | Journal of clinical gastroenterology 20090101 |
| Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. | Journal of experimental & clinical cancer research : CR 20090101 |
| Gallbladder metastasis from renal cell carcinoma mimicking acute cholecystitis. | European journal of medical research 20090101 |
| Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. | PloS one 20090101 |
| Novel agents on the horizon for cancer therapy. | CA: a cancer journal for clinicians 20090101 |
| Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. | Head & neck oncology 20090101 |
| Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. | BMC cancer 20090101 |
| Toxicity of targeted therapy in non-small-cell lung cancer management. | Clinical lung cancer 20090101 |
| From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. | Molecular cancer 20090101 |
| Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. | Oncology 20090101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090101 |
| Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. | BMC pharmacology 20090101 |
| Selecting promising treatments in randomized Phase II cancer trials with an active control. | Journal of biopharmaceutical statistics 20090101 |
| [Prospect of hepatocellular carcinoma in 2008]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090101 |
| Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. | Journal of oncology 20090101 |
| Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. | Molecular cancer 20090101 |
| Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology. | The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20090101 |
| The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. | Acta oncologica (Stockholm, Sweden) 20090101 |
| Targeting targeted agents: open issues for clinical trial design. | Journal of experimental & clinical cancer research : CR 20090101 |
| Medullary thyroid cancer: molecular biology and novel molecular therapies. | Neuroendocrinology 20090101 |
| Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. | BMC cancer 20090101 |
| HCC heterogeneity: molecular pathogenesis and clinical implications. | Cellular oncology : the official journal of the International Society for Cellular Oncology 20090101 |
| A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer. | Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg 20090101 |
| Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma. | Cutaneous and ocular toxicology 20090101 |
| Metastatic renal cell carcinoma management. | International braz j urol : official journal of the Brazilian Society of Urology 20090101 |
| [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090101 |
| [Hepatocellular carcinoma: increasing incidence and optimized management]. | Gastroenterologie clinique et biologique 20090101 |
| A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. | Angiogenesis 20090101 |
| Neurofibromatosis type 2 (NF2): a clinical and molecular review. | Orphanet journal of rare diseases 20090101 |
| Systemic therapies in hepatocellular carcinoma. | Digestive diseases (Basel, Switzerland) 20090101 |
| Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. | BMC cancer 20090101 |
| A genetic screen in Drosophila reveals novel cytoprotective functions of the autophagy-lysosome pathway. | PloS one 20090101 |
| Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. | BMC cancer 20090101 |
| Target therapy for hepatocellular carcinoma: is sorafenib for everybody? | Journal of clinical gastroenterology 20090101 |
| Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects? | BMC cancer 20090101 |
| Ras signaling and therapies. | Advances in cancer research 20090101 |
| How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy? | Oncology 20090101 |
| Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. | BMC cancer 20090101 |
| An in silico study of the molecular basis of B-RAF activation and conformational stability. | BMC structural biology 20090101 |
| Vorinostat in solid and hematologic malignancies. | Journal of hematology & oncology 20090101 |
| Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization. | Clinical ophthalmology (Auckland, N.Z.) 20090101 |
| Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. | Cancer journal (Sudbury, Mass.) 20090101 |
| Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. | German medical science : GMS e-journal 20090101 |
| Tumor biology and cancer therapy - an evolving relationship. | Cell communication and signaling : CCS 20090101 |
| A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from renal cell carcinoma 17 years from diagnosis. | Tumori 20090101 |
| [Treatment of extensive disease]. | Wiener medizinische Wochenschrift (1946) 20090101 |
| ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. | Journal of translational medicine 20090101 |
| Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. | BMC medicine 20090101 |
| Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? | BMC medicine 20090101 |
| Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma. | Pediatric dermatology 20090101 |
| Current available therapies and future directions in the treatment of malignant gliomas. | Biologics : targets & therapy 20090101 |
| [Dermatologic toxicity to sorafenib]. | Actas dermo-sifiliograficas 20090101 |
| Cardiotoxicity induced by tyrosine kinase inhibitors. | Acta oncologica (Stockholm, Sweden) 20090101 |
| Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. | Breast cancer research : BCR 20090101 |
| Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. | Current medicinal chemistry 20090101 |
| VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. | PloS one 20090101 |
| Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. | Biologics : targets & therapy 20090101 |
| Role of everolimus in the treatment of renal cell carcinoma. | Therapeutics and clinical risk management 20090101 |
| [Sorafenib: effectiveness versus safety. Prevention of hand-foot syndrome]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101 |
| Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells. | Molecular cancer 20090101 |
| The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer. | Molecular diagnosis & therapy 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090101 |
| New therapeutic approaches in the management of metastatic renal cell carcinoma. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090101 |
| Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. | Journal of experimental & clinical cancer research : CR 20090101 |
| Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1. | PloS one 20090101 |
| Successful management of bulky osseous metastasis of renal cell carcinoma with selective arterial embolization and radiofrequency ablation: a case report. | Cases journal 20090101 |
| Different responses to two types of 5-fluorouracil prodrugs in combination with interferon-alpha in pulmonary metastases of renal cell carcinoma: a case report. | Cases journal 20090101 |
| Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report. | Cases journal 20090101 |
| Renal cell carcinoma metastasis to the ovary: a case report. | Cases journal 20090101 |
| Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. | Tumori 20090101 |
| Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. | Journal of hematology & oncology 20090101 |
| Proteomics, pathway array and signaling network-based medicine in cancer. | Cell division 20090101 |
| Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. | BMC cancer 20090101 |
| Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. | Journal of experimental & clinical cancer research : CR 20090101 |
| Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. | PloS one 20090101 |
| Successful treatment of a brain-metastasized renal cell carcinoma. | German medical science : GMS e-journal 20090101 |
| Sternal metastasis as an initial presentation of renal cell carcinoma: a case report. | Cases journal 20090101 |
| Cutaneous metastases in renal cell carcinoma: a case report. | Cases journal 20090101 |
| A unique case of spontaneous regression of metastatic papillary renal cell carcinoma: a case report. | Cases journal 20090101 |
| Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report. | Cases journal 20090101 |
| CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. | BMC clinical pathology 20090101 |
| Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. | Oncology 20090101 |
| Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma. | Acta oncologica (Stockholm, Sweden) 20090101 |
| Generalized convulsions due to sorafenib-induced hypocalcemia. | Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20090101 |
| New pharmacological developments in the treatment of hepatocellular cancer. | Drugs 20090101 |
| A predictive phosphorylation signature of lung cancer. | PloS one 20090101 |
| Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. | Molecular systems biology 20090101 |
| Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future. | Indian journal of urology : IJU : journal of the Urological Society of India 20090101 |
| Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. | PloS one 20090101 |
| Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. | Molecular cancer 20090101 |
| Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. | PloS one 20090101 |
| The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. | Molecular cancer 20090101 |
| Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. | Health and quality of life outcomes 20090101 |
| Next-generation sequencing. | Breast cancer research : BCR 20090101 |
| Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma. | PloS one 20090101 |
| Targeted therapy in melanoma. | Biologics : targets & therapy 20090101 |
| Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. | Cases journal 20090101 |
| Medullary thyroid carcinoma: targeted therapies and future directions. | Journal of oncology 20090101 |
| Tumor-derived VEGF modulates hematopoiesis. | Journal of angiogenesis research 20090101 |
| Treatment of hepatocellular carcinoma. | Oncology 20090101 |
| New agents in advanced non-small-cell lung cancer treatment. | Oncology 20090101 |
| Targeted therapy in the treatment of metastatic renal cell cancer. | Oncology 20090101 |
| Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. | OncoTargets and therapy 20090101 |
| Targeted therapy in the treatment of malignant gliomas. | OncoTargets and therapy 20090101 |
| Multiple roles and therapeutic implications of Akt signaling in cancer. | OncoTargets and therapy 20090101 |
| Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. | OncoTargets and therapy 20090101 |
| Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. | Core evidence 20090101 |
| Emerging technologies for the genomic analysis of cancer. | F1000 biology reports 20090101 |
| New therapies for recurrent glioblastomas. | F1000 medicine reports 20090101 |
| Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going. | F1000 medicine reports 20090101 |
| Recent advances in management of renal cancer. | F1000 medicine reports 20090101 |
| Current status of maintenance therapy for advanced ovarian cancer. | International journal of women's health 20090101 |
| Current status of therapy for hepatocellular carcinoma. | Therapeutic advances in gastroenterology 20090101 |
| Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns. | Cancer management and research 20090101 |
| Medical treatment of hepatocellular carcinoma. | Mediterranean journal of hematology and infectious diseases 20090101 |
| The use of everolimus in renal-transplant patients. | International journal of nephrology and renovascular disease 20090101 |
| New onset of multiple keratoacanthomas and palmoplantar hyperkeratosis caused by the treatment of metastatic renal cell carcinoma with a new generation multi-kinase inhibitor. | BMJ case reports 20090101 |
| Sorafenib in hepatocellular carcinoma: separating the hype from the hope. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081220 |
| Targeting metastatic melanoma. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081215 |
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081210 |
| Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. | British journal of cancer 20081209 |
| Sorafenib in advanced hepatocellular carcinoma. | The New England journal of medicine 20081204 |
| Sorafenib in advanced hepatocellular carcinoma. | The New England journal of medicine 20081204 |
| Sorafenib in advanced hepatocellular carcinoma. | The New England journal of medicine 20081204 |
| Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. | Digestive diseases and sciences 20081201 |
| Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. | Gynecologic oncology 20081201 |
| Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. | European urology 20081201 |
| Exploring the role of novel agents in the treatment of renal cell carcinoma. | Cancer treatment reviews 20081201 |
| Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. | Alimentary pharmacology & therapeutics 20081201 |
| Vascular complications of selected cancer therapies. | Nature clinical practice. Cardiovascular medicine 20081201 |
| Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. | Nature clinical practice. Oncology 20081201 |
| [Vascular and renal effects of anti-angiogenic therapy]. | Nephrologie & therapeutique 20081201 |
| Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. | Current medical research and opinion 20081201 |
| Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. | Cancer research 20081201 |
| Potential role of sorafenib in the treatment of acute myeloid leukemia. | Leukemia & lymphoma 20081201 |
| Treatment of adult rhabdoid renal cell carcinoma with sorafenib. | Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20081201 |
| Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20081201 |
| Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. | Current cancer drug targets 20081201 |
| Small-molecule Bcl-2 antagonists as targeted therapy in oncology. | Current oncology (Toronto, Ont.) 20081201 |
| Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. | Biomedical research (Tokyo, Japan) 20081201 |
| Gateways to clinical trials. December 2008. | Methods and findings in experimental and clinical pharmacology 20081201 |
| Small molecule tyrosine kinase inhibitors in pancreatic cancer. | Biologics : targets & therapy 20081201 |
| Sorafenib for the treatment of unresectable hepatocellular carcinoma. | Biologics : targets & therapy 20081201 |
| Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. | Clinical genitourinary cancer 20081201 |
| What role do combinations of interferon and targeted agents play in the first-line therapy of metastatic renal cell carcinoma? | Clinical genitourinary cancer 20081201 |
| Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. | Clinical genitourinary cancer 20081201 |
| Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. | Clinical genitourinary cancer 20081201 |
| Characterization of Ser338 phosphorylation for Raf-1 activation. | The Journal of biological chemistry 20081114 |
| Evolution of systemic therapy of advanced hepatocellular carcinoma. | World journal of gastroenterology 20081114 |
| Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. | Circulation 20081111 |
| Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110 |
| Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110 |
| Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. | British journal of cancer 20081104 |
| Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. | Annals of oncology : official journal of the European Society for Medical Oncology 20081101 |
| Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. | Toxicological sciences : an official journal of the Society of Toxicology 20081101 |
| Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20081101 |
| [Molecular basis of targeted therapy in metastatic renal cancer]. | Der Pathologe 20081101 |
| Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war. | Journal of hepatology 20081101 |
| Hemostatic complications of angiogenesis inhibitors in cancer patients. | American journal of hematology 20081101 |
| Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. | Nature chemical biology 20081101 |
| Experimental therapy for advanced renal cell carcinoma. | Expert opinion on investigational drugs 20081101 |
| Systemic therapy of hepatocellular carcinoma: are we making progress? | Advances in therapy 20081101 |
| Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. | Expert review of anticancer therapy 20081101 |
| Systemic therapy for metastatic renal cell carcinoma. | The Urologic clinics of North America 20081101 |
| Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. | Molecular cancer therapeutics 20081101 |
| Words of wisdom. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. | European urology 20081101 |
| [Prise en charge of metastatic renal carcinoma]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20081101 |
| mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? | British journal of cancer 20081021 |
| Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. | Journal of the National Cancer Institute 20081015 |
| Phase II trial of sorafenib in advanced thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010 |
| Identification of BRAF inhibitors through in silico screening. | Journal of medicinal chemistry 20081009 |
| [Targeted therapy for metastatic bladder cancer]. | Der Urologe. Ausg. A 20081001 |
| [Value of targeted therapies for renal cell cancer]. | Der Urologe. Ausg. A 20081001 |
| [Targeted therapy - point blank or single shot]. | Der Urologe. Ausg. A 20081001 |
| Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. | Urology 20081001 |
| About sorafenib in castration-resistant prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20081001 |
| Searching for the Achilles' heel of melanoma cells: new treatment modalities. | Pigment cell & melanoma research 20081001 |
| Choosing the best endpoint. | Journal of hepatology 20081001 |
| Regulation of autophagy by ceramide-CD95-PERK signaling. | Autophagy 20081001 |
| [Cutaneous reactions to molecular targeted therapies]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20081001 |
| Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. | Cancer biology & therapy 20081001 |
| Novel drugs for renal cell carcinoma. | Expert opinion on investigational drugs 20081001 |
| Molecular targeted therapies in hepatocellular carcinoma. | Hepatology (Baltimore, Md.) 20081001 |
| Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001 |
| [Systemic therapy of metastasizing renal cell carcinoma]. | Der Urologe. Ausg. A 20081001 |
| Targeting angiogenesis in the treatment of lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081001 |
| Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. | European journal of cancer (Oxford, England : 1990) 20081001 |
| Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. | The oncologist 20081001 |
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. | Molecular cancer therapeutics 20081001 |
| Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. | Onkologie 20081001 |
| [Eruptive nevi associated with sorafenib treatment]. | Annales de dermatologie et de venereologie 20081001 |
| [Cutaneous toxicities]. | Gan to kagaku ryoho. Cancer & chemotherapy 20081001 |
| Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. | Current pharmaceutical design 20081001 |
| Multi-targeted approach in the treatment of thyroid cancer. | Therapeutics and clinical risk management 20081001 |
| Drug essentials. Small molecule multitargeted TKI therapy. | Oncology (Williston Park, N.Y.) 20081001 |
| CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. | Molecular cell 20080926 |
| Survival from melanoma of the skin in England and Wales up to 2001. | British journal of cancer 20080923 |
| Survival from kidney cancer in England and Wales up to 2001. | British journal of cancer 20080923 |
| Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. | Cancer 20080915 |
| Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080915 |
| Major treatment improvements encourage kidney cancer researchers to seek further gains. | Journal of the National Cancer Institute 20080903 |
| Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? | British journal of cancer 20080902 |
| Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. | BJU international 20080901 |
| Update on novel therapeutic agents for cervical cancer. | Gynecologic oncology 20080901 |
| Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells. | Carcinogenesis 20080901 |
| Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20080901 |
| Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. | Cancer science 20080901 |
| von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. | The Journal of urology 20080901 |
| A Kaposi's sarcoma complete clinical response after sorafenib administration. | Annals of oncology : official journal of the European Society for Medical Oncology 20080901 |
| Targeted therapy in renal cell carcinoma. | Current opinion in urology 20080901 |
| Novel chemotherapy approaches in chemoradiation protocols. | Gynecologic oncology 20080901 |
| Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. | Current opinion in supportive and palliative care 20080901 |
| Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma. | Expert opinion on pharmacotherapy 20080901 |
| Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080901 |
| Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. | The oncologist 20080901 |
| Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood. | Journal of internal medicine 20080901 |
| [Renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20080901 |
| [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma]. | Bulletin du cancer 20080901 |
| [Tumor vasculature as a therapeutic target in non-small cell lung cancer]. | Magyar onkologia 20080901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080901 |
| Cutaneous drug eruptions induced by sorafenib: a case series. | Journal of drugs in dermatology : JDD 20080901 |
| Evolving therapies in the treatment of hepatocellular carcinoma. | Biologics : targets & therapy 20080901 |
| Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. | Biologics : targets & therapy 20080901 |
| Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080820 |
| Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080815 |
| Watchdog set to reject four drugs for kidney cancer on the NHS. | BMJ (Clinical research ed.) 20080814 |
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. | Lancet (London, England) 20080809 |
| The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. | British journal of cancer 20080805 |
| Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. | The Journal of investigative dermatology 20080801 |
| Update on the medical treatment of metastatic renal cell carcinoma. | European urology 20080801 |
| Challenges and pitfalls of combining targeted agents in phase I studies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080801 |
| Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080801 |
| A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080801 |
| Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080801 |
| Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. | Cancer research 20080801 |
| Targeting angiogenesis in renal cell carcinoma. | Current cancer drug targets 20080801 |
| Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. | Current cancer drug targets 20080801 |
| Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. | The oncologist 20080801 |
| Effectively targeting BRAF in melanoma: a formidable challenge. | Pigment cell & melanoma research 20080801 |
| Contemporary management of hepatocellular carcinoma. | Clinical medicine (London, England) 20080801 |
| Side effects related to systemic cancer treatment: are we changing the Promethean experience with molecularly targeted therapies? | Current oncology (Toronto, Ont.) 20080801 |
| Sorafenib-induced liver failure. | The American journal of gastroenterology 20080801 |
| [Molecular targeted therapy for renal cell carcinoma]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20080801 |
| [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080801 |
| Medical therapies to extend survival in hepatocellular carcinoma. | Clinical advances in hematology & oncology : H&O 20080801 |
| Sorafenib in advanced hepatocellular carcinoma. | The New England journal of medicine 20080724 |
| Sorafenib in liver cancer--just the beginning. | The New England journal of medicine 20080724 |
| Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. | British journal of cancer 20080722 |
| [The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008]. | Orvosi hetilap 20080713 |
| Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710 |
| Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on. | BJU international 20080701 |
| Growth factors as therapeutic targets in HCC. | Critical reviews in oncology/hematology 20080701 |
| Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. | Cancer science 20080701 |
| Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. | The Journal of urology 20080701 |
| Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. | Current opinion in oncology 20080701 |
| Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? | Nature clinical practice. Oncology 20080701 |
| Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. | AJR. American journal of roentgenology 20080701 |
| Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications. | Oncology nursing forum 20080701 |
| Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. | Cancer research 20080701 |
| Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. | Onkologie 20080701 |
| [Regression of vena cava tumour thrombus in response to sorafenib]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701 |
| A distinct cutaneous reaction to sorafenib and a multikinase inhibitor. | International journal of dermatology 20080701 |
| Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. | Archives of dermatology 20080701 |
| [Antiangiogenics: new therapeutic standards in metastatic kidney cancer]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701 |
| [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701 |
| Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know? | Sultan Qaboos University medical journal 20080701 |
| Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. | British journal of cancer 20080617 |
| Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. | Blood 20080615 |
| Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold. | Journal of medicinal chemistry 20080612 |
| Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. | Acta ophthalmologica 20080601 |
| Metastatic non-clear cell renal cell carcinoma: current therapeutic options. | BJU international 20080601 |
| Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. | Leukemia 20080601 |
| Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. | Cancer biology & therapy 20080601 |
| Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. | Bioorganic & medicinal chemistry letters 20080601 |
| Early clinical studies of novel therapies for thyroid cancers. | Endocrinology and metabolism clinics of North America 20080601 |
| Targeted therapy in advanced non-small-cell lung cancer. | Seminars in respiratory and critical care medicine 20080601 |
| Targeted therapy of renal cell cancer. | Current opinion in investigational drugs (London, England : 2000) 20080601 |
| Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080601 |
| Sorafenib in lung cancer: clinical developments and future directions. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601 |
| K-ras as a target for lung cancer therapy. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601 |
| [Oncology 2008]. | Deutsche medizinische Wochenschrift (1946) 20080601 |
| Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. | American journal of clinical oncology 20080601 |
| Targeting angiogenesis in head and neck cancer. | Seminars in oncology 20080601 |
| Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. | Archives of dermatology 20080601 |
| Sorafenib-induced eruptive melanocytic lesions. | Archives of dermatology 20080601 |
| Sorafenib-induced palmoplantar hyperkeratosis. | Journal of drugs in dermatology : JDD 20080601 |
| Reader seeks clarification on hand-foot skin reaction. | Clinical journal of oncology nursing 20080601 |
| 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. | The oncologist 20080601 |
| Systemic treatments for mesothelioma: standard and novel. | Current treatment options in oncology 20080601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080601 |
| Design and endpoints of clinical trials in hepatocellular carcinoma. | Journal of the National Cancer Institute 20080521 |
| Molecular characterization of pediatric gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080515 |
| [Lung cancer]. | Medizinische Klinik (Munich, Germany : 1983) 20080515 |
| Bowel perforation after radiotherapy in a patient receiving sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510 |
| Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. | European urology 20080501 |
| Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81. | European urology 20080501 |
| Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. | Cancer treatment reviews 20080501 |
| Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. | Hepatology (Baltimore, Md.) 20080501 |
| Renal cell carcinoma. | Current opinion in oncology 20080501 |
| Dual binding site inhibitors of B-RAF kinase. | Bioorganic & medicinal chemistry letters 20080501 |
| Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. | Molecular cancer therapeutics 20080501 |
| Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080501 |
| Axitinib for renal cell carcinoma. | Expert opinion on investigational drugs 20080501 |
| Diagnosis and treatment of hepatocellular carcinoma. | Gastroenterology 20080501 |
| [Antiangiogenic agents and gastrointestinal cancers]. | Gastroenterologie clinique et biologique 20080501 |
| New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. | Reviews on recent clinical trials 20080501 |
| Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. | Molecular cancer therapeutics 20080501 |
| Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. | European urology 20080501 |
| [Metachronic testicular metastasis secondary to clear cell renal adenocarcinoma]. | Archivos espanoles de urologia 20080501 |
| The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. | Current clinical pharmacology 20080501 |
| The impact of new data in the treatment of advanced hepatocellular carcinoma. | Current oncology reports 20080501 |
| The future of tyrosine kinase inhibitors: single agent or combination? | Current oncology reports 20080501 |
| Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. | Physiological genomics 20080422 |
| Targeted therapy for advanced renal cell carcinoma. | The Cochrane database of systematic reviews 20080416 |
| Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. | Cancer 20080415 |
| Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? | Oncology (Williston Park, N.Y.) 20080415 |
| Minimising treatment-associated risks in systemic cancer therapy. | Pharmacy world & science : PWS 20080401 |
| Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. | Cancer chemotherapy and pharmacology 20080401 |
| [Renal cell carcinoma and antiangiogenic therapies]. | Presse medicale (Paris, France : 1983) 20080401 |
| A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20080401 |
| Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. | Leukemia 20080401 |
| Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. | Cancer biology & therapy 20080401 |
| Targeted therapy in renal cell carcinoma. | World journal of urology 20080401 |
| Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy. | Melanoma research 20080401 |
| Chemotherapeutic agents and the skin: An update. | Journal of the American Academy of Dermatology 20080401 |
| Mcl-1: a gateway to TRAIL sensitization. | Cancer research 20080401 |
| Sorafenib for metastatic renal cancer: the Princess Margaret experience. | American journal of clinical oncology 20080401 |
| Treatment options for metastatic renal cell carcinoma: a review. | The Canadian journal of urology 20080401 |
| Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Molecular cancer therapeutics 20080401 |
| [Anti-angiogenesis targeting drugs: a review]. | Ai zheng = Aizheng = Chinese journal of cancer 20080401 |
| [Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080401 |
| Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma. | Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20080401 |
| Is human hepatocellular carcinoma a hormone-responsive tumor? | World journal of gastroenterology 20080321 |
| Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer. | Journal of the National Cancer Institute 20080319 |
| Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. | British journal of cancer 20080311 |
| Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. | British journal of cancer 20080311 |
| Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. | The British journal of dermatology 20080301 |
| Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma? | Nature clinical practice. Urology 20080301 |
| The MAPK pathway in melanoma. | Current opinion in oncology 20080301 |
| Hepatocellular carcinoma (HCC): current and evolving therapies. | IDrugs : the investigational drugs journal 20080301 |
| Improving outcomes in patients with advanced renal cell carcinoma. | Expert review of anticancer therapy 20080301 |
| New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. | The oncologist 20080301 |
| Targeted therapies for hepatocellular carcinoma. | Clinical advances in hematology & oncology : H&O 20080301 |
| Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. | Deutsches Arzteblatt international 20080301 |
| Sunitinib for advanced renal cell cancer. | Biologics : targets & therapy 20080301 |
| Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer. | Clinical lung cancer 20080301 |
| Clinical implications of mutational analysis in gastrointestinal stromal tumours. | British journal of cancer 20080226 |
| [New drugs; sunitinib and sorafenib]. | Nederlands tijdschrift voor geneeskunde 20080223 |
| A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. | Journal of the National Cancer Institute 20080220 |
| [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. | Nederlands tijdschrift voor geneeskunde 20080216 |
| Examining heterogeneity in phase II trial designs may improve success in phase III. | Journal of the National Cancer Institute 20080206 |
| Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. | Journal of the National Cancer Institute 20080206 |
| High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. | European urology 20080201 |
| Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20080201 |
| New developments in multitargeted therapy for patients with solid tumours. | Cancer treatment reviews 20080201 |
| Tumoral angiogenesis: review of the literature. | Cancer investigation 20080201 |
| Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. | The Lancet. Oncology 20080201 |
| Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. | Expert opinion on investigational drugs 20080201 |
| Quantifying hypertension in patients with cancer treated with sorafenib. | The Lancet. Oncology 20080201 |
| Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. | Mayo Clinic proceedings 20080201 |
| FDA approves sorafenib for patients with inoperable liver cancer. | Gastroenterology 20080201 |
| [Cutaneous side effects of sorafenib and sunitinib]. | Annales de dermatologie et de venereologie 20080201 |
| Off-label uses of sorafenib and sunitinib. | Technology Evaluation Center Assessment Program. Executive summary 20080201 |
| Early detection of liver cancer: diagnosis and management. | Current gastroenterology reports 20080201 |
| Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. | Therapeutics and clinical risk management 20080201 |
| Treatment options for hepatocellular carcinoma. | Expert review of gastroenterology & hepatology 20080201 |
| Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. | Journal of pharmaceutical and biomedical analysis 20080122 |
| Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. | Cancer 20080115 |
| Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080115 |
| GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. | The Journal of biological chemistry 20080111 |
| Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. | World journal of gastroenterology 20080107 |
| Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. | Cancer science 20080101 |
| Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. | The Journal of urology 20080101 |
| Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. | Current opinion in oncology 20080101 |
| Will targeted therapy hold its promise? An evidence-based review. | Current opinion in oncology 20080101 |
| Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080101 |
| A phase II clinical trial of sorafenib in androgen-independent prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080101 |
| A quantitative analysis of kinase inhibitor selectivity. | Nature biotechnology 20080101 |
| Sorafenib: in hepatocellular carcinoma. | Drugs 20080101 |
| Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature. | Medical oncology (Northwood, London, England) 20080101 |
| Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. | Acta oncologica (Stockholm, Sweden) 20080101 |
| Cheiradone: a vascular endothelial cell growth factor receptor antagonist. | BMC cell biology 20080101 |
| [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. | Bulletin du cancer 20080101 |
| [News in digestive oncology]. | Bulletin du cancer 20080101 |
| Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. | PLoS medicine 20080101 |
| [Molecular targeted therapy for renal cell carcinoma]. | Hinyokika kiyo. Acta urologica Japonica 20080101 |
| Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. | The oncologist 20080101 |
| From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. | Current medicinal chemistry 20080101 |
| The role of angiogenesis inhibitors in prostate cancer. | Cancer journal (Sudbury, Mass.) 20080101 |
| Novel advancements in the management of hepatocellular carcinoma in 2008. | Journal of hepatology 20080101 |
| Extensive necrosis of visceral melanoma metastases after immunotherapy. | World journal of surgical oncology 20080101 |
| Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. | Toxicologic pathology 20080101 |
| [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations]. | Gastroenterologie clinique et biologique 20080101 |
| [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. | Annales de dermatologie et de venereologie 20080101 |
| Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. | BMC cancer 20080101 |
| Reversible posterior leukoencephalopathy syndrome in cancer. | Current oncology reports 20080101 |
| Sorafenib, a systemic therapy for hepatocellular carcinoma. | Annals of hepatology 20080101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080101 |
| Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. | Cancer journal (Sudbury, Mass.) 20080101 |
| [Skin metastasis during follow-up of a clear cell renal carcinoma]. | Archivos espanoles de urologia 20080101 |
| Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease course. | World journal of surgical oncology 20080101 |
| [The role of angiogenesis in renal carcinoma]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20080101 |
| Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. | Genome biology 20080101 |
| Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model. | BMC genomics 20080101 |
| Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumor. | Sarcoma 20080101 |
| Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. | Urologia internationalis 20080101 |
| Comment on Di Silverio et al.: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451-453. | Urologia internationalis 20080101 |
| PPARgamma and MEK Interactions in Cancer. | PPAR research 20080101 |
| An update on the medical therapy of advanced metastatic renal cell carcinoma. | Scandinavian journal of urology and nephrology 20080101 |
| The role of microRNAs in primary liver cancer. | Annals of hepatology 20080101 |
| Tongue metastasis as an initial presentation of renal cell carcinoma: a case report and literature review. | Journal of medical case reports 20080101 |
| Promising newer molecular-targeted therapies in head and neck cancer. | Drugs 20080101 |
| Novel therapies in genitourinary cancer: an update. | Journal of hematology & oncology 20080101 |
| [New therapeutic regimes in metastasic renal-cell carcinoma]. | Der Internist 20080101 |
| Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. | Oncology 20080101 |
| Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. | Oncology 20080101 |
| Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma. | Anticancer research 20080101 |
| Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. | Urologic oncology 20080101 |
| Major liver resection for hepatocellular carcinoma in the morbidly obese: a proposed strategy to improve outcome. | World journal of surgical oncology 20080101 |
| Oral cavity metastasis of renal cell carcinoma: a case report. | Journal of medical case reports 20080101 |
| Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. | Journal of translational medicine 20080101 |
| EGFR expression in gallbladder carcinoma in North America. | International journal of medical sciences 20080101 |
| Signaling inhibitors in metastatic renal cell carcinoma. | Cancer journal (Sudbury, Mass.) 20080101 |
| Adjuvant treatments for resectable hepatocellular carcinoma. | Journal of hepato-biliary-pancreatic surgery 20080101 |
| Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. | Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20080101 |
| Gateways to clinical trials. July-August 2008. | Methods and findings in experimental and clinical pharmacology 20080101 |
| Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. | BMC cancer 20080101 |
| Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. | Journal of hematology & oncology 20080101 |
| NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. | Journal of experimental & clinical cancer research : CR 20080101 |
| Vascular involvement in rheumatic diseases: 'vascular rheumatology'. | Arthritis research & therapy 20080101 |
| Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib. | Clinical drug investigation 20080101 |
| Severe cutaneous reaction to sorafenib: induction of tolerance. | Acta dermato-venereologica 20080101 |
| Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. | BMC cancer 20080101 |
| The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. | BMC cancer 20080101 |
| PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments. | PPAR research 20080101 |
| Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. | Oncology 20080101 |
| Systemic chemotherapy of hepatocellular carcinoma--Korean experience. | Oncology 20080101 |
| The management of cancer in the elderly: targeted therapies in oncology. | Immunity & ageing : I & A 20080101 |
| Molecular underpinnings of the targeted therapy for cancer. | Acta poloniae pharmaceutica 20080101 |
| Current management of advanced hepatocellular carcinoma. | Gastrointestinal cancer research : GCR 20080101 |
| Treatment of Inoperable HCC After Sorafenib: Where Will The New Paradigm Take Us? | Gastrointestinal cancer research : GCR 20080101 |
| Liver stem cells and tgf-Beta in hepatic carcinogenesis. | Gastrointestinal cancer research : GCR 20080101 |
| Prognostic biomarkers of renal cell carcinoma: Recent advances. | Indian journal of urology : IJU : journal of the Urological Society of India 20080101 |
| Sorafenib in the treatment of advanced hepatocellular carcinoma. | Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20080101 |
| Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. | Drug design, development and therapy 20080101 |
| Fluorescent cascade and direct assays for characterization of RAF signaling pathway inhibitors. | Current chemical genomics 20080101 |
| Cellular Ser/Thr-kinase assays using generic peptide substrates. | Current chemical genomics 20080101 |
| The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer. | OncoTargets and therapy 20080101 |
| Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib. | OncoTargets and therapy 20080101 |
| Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. | OncoTargets and therapy 20080101 |
| [New drugs; sunitinib and sorafenib]. | Nederlands tijdschrift voor geneeskunde 20071229 |
| The selectivity of protein kinase inhibitors: a further update. | The Biochemical journal 20071215 |
| Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. | British journal of cancer 20071203 |
| A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. | British journal of cancer 20071203 |
| Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. | Current opinion in investigational drugs (London, England : 2000) 20071201 |
| Role of vaccine therapy in cancer: biology and practice. | Current oncology (Toronto, Ont.) 20071201 |
| Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. | The oncologist 20071201 |
| Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. | The oncologist 20071201 |
| Allergic interstitial nephritis possibly related to sunitinib use. | The American journal of geriatric pharmacotherapy 20071201 |
| Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. | Clinical and experimental medicine 20071201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071201 |
| FLT3 kinase inhibitors in the management of acute myeloid leukemia. | Clinical lymphoma & myeloma 20071201 |
| Imatinib in the treatment of dermatofibrosarcoma protuberans. | Biologics : targets & therapy 20071201 |
| Targeted therapies in the management of metastatic bladder cancer. | Biologics : targets & therapy 20071201 |
| The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. | Biologics : targets & therapy 20071201 |
| Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. | Biologics : targets & therapy 20071201 |
| Exploiting novel molecular targets in gastrointestinal cancers. | World journal of gastroenterology 20071128 |
| Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. | BioEssays : news and reviews in molecular, cellular and developmental biology 20071101 |
| Emerging drugs for the treatment of metastatic renal cancer. | Expert opinion on emerging drugs 20071101 |
| Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20071101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071101 |
| Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. | Dermatology online journal 20071013 |
| Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. | The Journal of biological chemistry 20071012 |
| Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. | British journal of cancer 20071008 |
| Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. | The Journal of biological chemistry 20071005 |
| Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. | Journal of the National Cancer Institute 20071003 |
| [Inductive systemic therapy of urological tumors with curative intent]. | Der Urologe. Ausg. A 20071001 |
| Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. | Experimental hematology 20071001 |
| Managing side effects of angiogenesis inhibitors in renal cell carcinoma. | Onkologie 20071001 |
| Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. | Cancer research 20071001 |
| The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. | Cancer research 20071001 |
| Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. | Japanese journal of clinical oncology 20071001 |
| Sorafenib: a promising new targeted therapy for renal cell carcinoma. | Clinical journal of oncology nursing 20071001 |
| Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. | The oncologist 20071001 |
| [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. | Bulletin du cancer 20071001 |
| Sorafenib TARGET trial results in Spanish patients. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20071001 |
| Current immunotherapeutic strategies in renal cell carcinoma. | Surgical oncology clinics of North America 20071001 |
| New therapies in renal cell carcinoma. | Current opinion in supportive and palliative care 20071001 |
| Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. | World journal of gastroenterology 20070907 |
| Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10. | European urology 20070901 |
| The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. | Molecular pharmacology 20070901 |
| [Application monitoring of the use of sorafenib in papillary renal cell carcinoma]. | Der Urologe. Ausg. A 20070901 |
| Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients. | Current oncology reports 20070901 |
| From cell signaling to cancer therapy. | Acta pharmacologica Sinica 20070901 |
| Treatment options in renal cell carcinoma: past, present and future. | Annals of oncology : official journal of the European Society for Medical Oncology 20070901 |
| Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20070901 |
| Antiangiogenic therapy for ovarian cancer. | Current opinion in oncology 20070901 |
| Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. | Onkologie 20070901 |
| Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. | Expert review of anticancer therapy 20070901 |
| Acute pancreatitis associated with sorafenib. | Southern medical journal 20070901 |
| Evolving role of novel targeted agents in renal cell carcinoma. | Oncology (Williston Park, N.Y.) 20070901 |
| Sunitinib, sorafenib and mTOR inhibitors in renal cancer. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901 |
| Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070901 |
| Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070820 |
| Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070815 |
| Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070815 |
| Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report. | European urology 20070801 |
| Interstitial nephritis in a patient taking sorafenib. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070801 |
| Are MAP kinases drug targets? Yes, but difficult ones. | ChemMedChem 20070801 |
| The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. | Molecular and cellular biology 20070801 |
| Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. | Bioorganic & medicinal chemistry letters 20070801 |
| Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. | Cancer 20070801 |
| What are the indications for sorafenib treatment in patients with renal cell carcinoma? | Nature clinical practice. Oncology 20070801 |
| Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. | Radiology 20070801 |
| Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. | Pharmacotherapy 20070801 |
| Drug insight: advances in renal cell carcinoma and the role of targeted therapies. | Nature clinical practice. Oncology 20070801 |
| Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801 |
| Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801 |
| American Society of Clinical Oncology--43rd annual meeting. Translating research into practice. | IDrugs : the investigational drugs journal 20070801 |
| Vascular endothelial growth factor trap in non small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070801 |
| [The hepatocellular carcinoma: alternative therapeutical strategies]. | Zentralblatt fur Chirurgie 20070801 |
| Sunitinib: new drug. For some gastrointestinal stromal tumours. | Prescrire international 20070801 |
| Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib. | Prescrire international 20070801 |
| Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach? | Oncology (Williston Park, N.Y.) 20070801 |
| Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers. | JAMA 20070718 |
| Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070715 |
| CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070701 |
| Clearing the TRAIL for Cancer Therapy. | Cancer cell 20070701 |
| Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. | Cancer cell 20070701 |
| Sorafenib [corrected] in kidney cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20070701 |
| Targeted therapy for renal cell carcinoma: a new treatment paradigm. | Proceedings (Baylor University. Medical Center) 20070701 |
| [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma]. | Aktuelle Urologie 20070701 |
| [Oral drugs inhibiting the VEGF pathway]. | Bulletin du cancer 20070701 |
| [Angiogenesis and renal cell carcinoma]. | Bulletin du cancer 20070701 |
| [Cutaneous side effects of antiangiogenic agents]. | Bulletin du cancer 20070701 |
| Targeting ELF in therapy of liver cancer. | Cancer biology & therapy 20070701 |
| Mechanisms of adverse effects of anti-VEGF therapy for cancer. | British journal of cancer 20070618 |
| 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. | Oncogene 20070607 |
| ASCO 2006 highlights: targeted therapy for renal cell carcinoma. | Cancer treatment reviews 20070601 |
| Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. | The British journal of dermatology 20070601 |
| Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070601 |
| Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. | American journal of clinical oncology 20070601 |
| Outcomes and prognosis in advanced renal cell carcinoma. | Expert review of anticancer therapy 20070601 |
| Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. | Molecular cancer therapeutics 20070601 |
| Integrated therapy of kidney cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20070601 |
| Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20070601 |
| Can sorafenib cause hypothyroidism? | Journal of chemotherapy (Florence, Italy) 20070601 |
| B-Raf kinase inhibitors for cancer treatment. | Current opinion in investigational drugs (London, England : 2000) 20070601 |
| ASCO 2007: plenary top 5. | Oncology (Williston Park, N.Y.) 20070601 |
| Take-home message: are we 'off target'? | Drug news & perspectives 20070601 |
| [Promising new treatment options for metastatic androgen-independent prostate cancer]. | Actas urologicas espanolas 20070601 |
| Molecular targets in squamous cell carcinoma of the head and neck. | Current treatment options in oncology 20070601 |
| Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). | Therapeutics and clinical risk management 20070601 |
| Systemic therapy for patients with advanced, unresectable ormetastatic renal cell carcinoma: moving to guidelines. | Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20070601 |
| Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists. | Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20070601 |
| [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. | Praxis 20070502 |
| Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. | Biochemical pharmacology 20070501 |
| [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot]. | Der Urologe. Ausg. A 20070501 |
| Genetic basis of kidney cancer: a model for developing molecular-targeted therapies. | BJU international 20070501 |
| Combination of target agents: challenges and opportunities. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070501 |
| Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. | Nature reviews. Cancer 20070501 |
| Angiogenesis in cancer: molecular mechanisms, clinical impact. | Langenbeck's archives of surgery 20070501 |
| Do the results of the new trials change the standard treatment of metastatic renal cell cancer? | Onkologie 20070501 |
| Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070501 |
| Sorafenib: delivering a targeted drug to the right targets. | Expert review of anticancer therapy 20070501 |
| A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. | Clinical lung cancer 20070501 |
| Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. | Reviews on recent clinical trials 20070501 |
| Therapeutic strategies for targeting BRAF in human cancer. | Reviews on recent clinical trials 20070501 |
| Vascular disrupting agents in clinical development. | British journal of cancer 20070423 |
| Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. | Cancer chemotherapy and pharmacology 20070401 |
| [Clinical studies with sorafenib (Nexavar) in metastatic melanoma]. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20070401 |
| Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. | Cancer research 20070401 |
| Pulmonary blastoma with renal metastasis responds to sorafenib. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401 |
| Sorafenib-induced pancreatitis. | Mayo Clinic proceedings 20070401 |
| Laparoscopic radical nephrectomy for renal carcinoma with known level I renal vein tumor thrombus. | Urology 20070401 |
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. | The oncologist 20070401 |
| Design of clinical trials of radiation combined with antiangiogenic therapy. | The oncologist 20070401 |
| The effect of recent drug approvals on translational research and drug development. | Clinical advances in hematology & oncology : H&O 20070401 |
| Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. | British journal of cancer 20070326 |
| Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070315 |
| Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. | British journal of cancer 20070312 |
| Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007. | JOP : Journal of the pancreas 20070310 |
| Antitumor activity of sorafenib in FLT3-driven leukemic cells. | Leukemia 20070301 |
| Sorafenib-induced erythema multiforme. | Journal of the American Academy of Dermatology 20070301 |
| Combined targeted therapies in non-small cell lung cancer: a winner strategy? | Current opinion in oncology 20070301 |
| Drug insight: VEGF as a therapeutic target for breast cancer. | Nature clinical practice. Oncology 20070301 |
| Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. | Southern medical journal 20070301 |
| Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. | Clinical genitourinary cancer 20070301 |
| Two new drugs for renal cell carcinoma. | The Medical letter on drugs and therapeutics 20070226 |
| Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070215 |
| Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. | British journal of cancer 20070212 |
| Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. | Cancer chemotherapy and pharmacology 20070201 |
| A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070201 |
| Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. | BJU international 20070201 |
| Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. | Annals of surgical oncology 20070201 |
| Recent advances in the therapy of renal cancer. | Expert opinion on biological therapy 20070201 |
| European Society for Medical Oncology 2006: meeting highlights on targeted therapies. Istanbul, Turkey, 29 September-3 October 2006. | Expert opinion on biological therapy 20070201 |
| New drugs 07, part I. | Nursing 20070201 |
| American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA. | IDrugs : the investigational drugs journal 20070201 |
| Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. | The oncologist 20070201 |
| [Clinical results of Nexavar for the treatment of kidney cancer]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20070201 |
| Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. | Current treatment options in oncology 20070201 |
| Hand-foot and stump syndrome to sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070120 |
| Evaluating the activity of temsirolimus in neuroendocrine cancer. | British journal of cancer 20070115 |
| Targeting BRAF in thyroid cancer. | British journal of cancer 20070115 |
| Sorafenib in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070115 |
| Opportunities and obstacles to combination targeted therapy in renal cell cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070115 |
| Sorafenib in advanced clear-cell renal-cell carcinoma. | The New England journal of medicine 20070111 |
| Renal-cell carcinoma--molecular pathways and therapies. | The New England journal of medicine 20070111 |
| [Medical oncology]. | Revue medicale suisse 20070110 |
| Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. | Clinical and experimental dermatology 20070101 |
| Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. | European journal of cancer (Oxford, England : 1990) 20070101 |
| Keratoacanthomas associated with sorafenib therapy. | Journal of the American Academy of Dermatology 20070101 |
| The role of PDGF in radiation oncology. | Radiation oncology (London, England) 20070101 |
| The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. | Haematologica 20070101 |
| [Therapy sequence for renal cell carcinoma--new aspects!]. | Aktuelle Urologie 20070101 |
| B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. | PloS one 20070101 |
| Sorafenib: in advanced renal cancer. | Drugs 20070101 |
| Newly approved therapies for RCC and their effect on the standard of care. | Clinical advances in hematology & oncology : H&O 20070101 |
| Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. | Neuroendocrinology 20070101 |
| Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. | Medical hypotheses 20070101 |
| Recent progress in the management of advanced renal cell carcinoma. | CA: a cancer journal for clinicians 20070101 |
| PDGF receptors as targets in tumor treatment. | Advances in cancer research 20070101 |
| Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. | Anticancer research 20070101 |
| Atrial and placental melanoma metastasis: a case report and literature review. | Journal of medical case reports 20070101 |
| Rationale and clinical results of multi-target treatments in oncology. | The International journal of biological markers 20070101 |
| Vascular endothelial growth factor: biology and therapeutic applications. | The international journal of biochemistry & cell biology 20070101 |
| Advanced renal cell carcinoma: current and emerging management strategies. | Drugs 20070101 |
| Renal cell cancer and sorafenib: skin toxicity and treatment outcome. | Tumori 20070101 |
| The role of targeted therapy in metastatic renal cell carcinoma. | TheScientificWorldJournal 20070101 |
| Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. | TheScientificWorldJournal 20070101 |
| Molecular therapy in urologic oncology. | Urologia internationalis 20070101 |
| Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. | Journal of translational medicine 20070101 |
| [Effect of angiogenesis inhibitors on renal cell carcinoma]. | Magyar onkologia 20070101 |
| Molecular design and clinical development of VEGFR kinase inhibitors. | Current topics in medicinal chemistry 20070101 |
| A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. | Journal of neuroinflammation 20070101 |
| Targeted therapies for kidney cancer in urologic practice. | Urologic oncology 20070101 |
| Hypereosinophilic syndromes. | Orphanet journal of rare diseases 20070101 |
| A Belgian registry of interleukin-2 administration for treatment of metastatic renal cell cancer and confrontation with literature data. | Acta clinica Belgica 20070101 |
| Renal cell cancer. | Cancer journal (Sudbury, Mass.) 20070101 |
| Sorafenib: atypical cutaneous side effects. | European journal of dermatology : EJD 20070101 |
| [Angiogenesis targeting in gastro-intestinal cancers]. | Bulletin du cancer 20070101 |
| [Angiogenesis targeting in renal carcinomas]. | Bulletin du cancer 20070101 |
| Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. | Breast cancer research : BCR 20070101 |
| Role of the ubiquitin proteasome system in renal cell carcinoma. | BMC biochemistry 20070101 |
| Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. | Molecular systems biology 20070101 |
| Breast tumour angiogenesis. | Breast cancer research : BCR 20070101 |
| [New treatments for renal carcinoma]. | Anales del sistema sanitario de Navarra 20070101 |
| Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. | Oncology 20070101 |
| [Current progress and problems in oncourology]. | Khirurgiia 20070101 |
| Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. | Journal of gastrointestinal cancer 20070101 |
| Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology. | Gastrointestinal cancer research : GCR 20070101 |
| Prognostic stratification of renal cell carcinoma using a pathological triad of microvascular invasion, Fuhrman's grade and tumor size. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| Temsirolimus, interferon alfa or both in advanced renal-cell carcinoma: One plus one does not always equal two. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| Computational systems biology in cancer: modeling methods and applications. | Gene regulation and systems biology 20070101 |
| Signaling mechanisms of endogenous angiogenesis inhibitors derived from type IV collagen. | Gene regulation and systems biology 20070101 |
| Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. | Core evidence 20070101 |
| The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). | Biomedical imaging and intervention journal 20070101 |
| The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. | Drug target insights 20070101 |
| Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. | British journal of cancer 20061218 |
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Cancer research 20061215 |
| Targeting von Hippel-Lindau pathway in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061215 |
| Sorafenib for the treatment of advanced renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061215 |
| Targeted therapy for metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061210 |
| Kinase inhibitors in the treatment of renal cell carcinoma. | Critical reviews in oncology/hematology 20061201 |
| Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. | The Journal of pharmacology and experimental therapeutics 20061201 |
| New weapons to snuff out kidney cancer. | Nursing 20061201 |
| Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery. | Nature clinical practice. Oncology 20061201 |
| Molecularly targeted therapy in renal cell carcinoma: where do we go from here? | Expert review of anticancer therapy 20061201 |
| Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. | Expert review of anticancer therapy 20061201 |
| Update on the epidemiology and biology of renal cortical neoplasms. | Journal of endourology 20061201 |
| Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects. | Clinical genitourinary cancer 20061201 |
| Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. | Clinical genitourinary cancer 20061201 |
| Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. | Clinical genitourinary cancer 20061201 |
| Toxicities of antiangiogenic therapy in non-small-cell lung cancer. | Clinical lung cancer 20061201 |
| Raf kinases: oncogenesis and drug discovery. | International journal of cancer 20061115 |
| Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. | Cancer 20061115 |
| Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. | Clinical and experimental dermatology 20061101 |
| Sorafenib. | Current opinion in oncology 20061101 |
| Therapeutic options to target angiogenesis in human malignancies. | Expert opinion on emerging drugs 20061101 |
| Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). | The American journal of pathology 20061101 |
| Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. | Nature clinical practice. Oncology 20061101 |
| Protein kinases as drug targets in cancer. | Current cancer drug targets 20061101 |
| Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. | Archives of dermatology 20061101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061101 |
| [Metastatic renal cell carcinoma and its treatments]. | Annales d'urologie 20061101 |
| Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress? | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101 |
| Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants. | Oncogene 20061026 |
| To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. | European journal of cancer (Oxford, England : 1990) 20061001 |
| Randomized discontinuation trial of sorafenib (BAY 43-9006). | Cancer biology & therapy 20061001 |
| Novel targets in prostate cancer. | Expert opinion on therapeutic targets 20061001 |
| Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061001 |
| Problems with the randomized discontinuation design. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061001 |
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Nature reviews. Drug discovery 20061001 |
| [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma]. | Der Urologe. Ausg. A 20061001 |
| Speeding up cancer-drug development. | The Lancet. Oncology 20061001 |
| Molecular biology of renal cell carcinoma. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061001 |
| A tale of two drugs. | Nature reviews. Drug discovery 20061001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061001 |
| Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? | British journal of cancer 20060918 |
| Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. | British journal of cancer 20060918 |
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060910 |
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. | British journal of cancer 20060904 |
| Therapeutic targets in melanoma: map kinase pathway. | Current oncology reports 20060901 |
| New treatment approaches in metastatic renal cell carcinoma. | Current opinion in urology 20060901 |
| New molecular targeted therapies in thyroid cancer. | Anti-cancer drugs 20060901 |
| Targeted approaches for treating advanced clear cell renal carcinoma. | Onkologie 20060901 |
| Pharmacy benefit spending on oral chemotherapy drugs. | Journal of managed care pharmacy : JMCP 20060901 |
| Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. | Molecular cancer therapeutics 20060901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060901 |
| Adjuvant therapy of renal cell carcinoma. | Clinical genitourinary cancer 20060901 |
| Sorafenib (BAY 43-9006): review of clinical development. | Current clinical pharmacology 20060901 |
| Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. | Blood 20060815 |
| Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. | Annals of oncology : official journal of the European Society for Medical Oncology 20060801 |
| Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. | Seminars in oncology 20060801 |
| Current and future management of GIST. | Clinical advances in hematology & oncology : H&O 20060801 |
| Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? | Annals of the New York Academy of Sciences 20060801 |
| Trials probe new agents for kidney cancer. | JAMA 20060712 |
| Rational design of inhibitors that bind to inactive kinase conformations. | Nature chemical biology 20060701 |
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060601 |
| Comparative integromics on VEGF family members. | International journal of oncology 20060601 |
| Targeting Raf-kinase: molecular rationales and translational issues. | Annals of oncology : official journal of the European Society for Medical Oncology 20060601 |
| Molecular targeting therapy for renal cell carcinoma. | International journal of clinical oncology 20060601 |
| Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. | Clinical genitourinary cancer 20060601 |
| New therapeutic options for renal cell carcinoma. | Clinical advances in hematology & oncology : H&O 20060601 |
| The place of VEGF inhibition in the current management of renal cell carcinoma. | British journal of cancer 20060508 |
| Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. | Cancer chemotherapy and pharmacology 20060501 |
| Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. | Cytometry. Part B, Clinical cytometry 20060501 |
| Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20060501 |
| Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. | Oncology (Williston Park, N.Y.) 20060501 |
| Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community. | Oncology (Williston Park, N.Y.) 20060501 |
| What's new in pancreatic cancer treatment pipeline? | Best practice & research. Clinical gastroenterology 20060401 |
| Chemotherapy and targeted therapy combinations in advanced melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060401 |
| Molecular targets in melanoma from angiogenesis to apoptosis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060401 |
| The role of adjuvant therapy in non-metastatic RCC. | The Canadian journal of urology 20060401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060401 |
| Mechanisms of hypertension associated with BAY 43-9006. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060320 |
| Targeted therapy for metastatic renal cell carcinoma. | British journal of cancer 20060313 |
| Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? | European journal of cancer (Oxford, England : 1990) 20060301 |
| Sorafenib. | Expert opinion on pharmacotherapy 20060301 |
| VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. | Current oncology reports 20060301 |
| BAY 43-9006 inhibition of oncogenic RET mutants. | Journal of the National Cancer Institute 20060301 |
| BRAF is a therapeutic target in aggressive thyroid carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060301 |
| Multi-target inhibitors in non-small cell lung cancer (NSCLC). | Annals of oncology : official journal of the European Society for Medical Oncology 20060301 |
| Molecule of the month. Sorafenib. | Drug news & perspectives 20060301 |
| Emerging antiangiogenic agents in lung cancer. | Clinical lung cancer 20060301 |
| Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. | Clinical genitourinary cancer 20060301 |
| Editorial foreword. | Therapeutics and clinical risk management 20060301 |
| Renal cell carcinoma and the use of sorafenib. | Therapeutics and clinical risk management 20060301 |
| The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. | Cancer research 20060201 |
| [Progress in therapeutic strategy for renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060201 |
| Drug approval triggers debate on future direction for cancer treatments. | Nature reviews. Drug discovery 20060201 |
| Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. | FEBS letters 20060123 |
| Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. | Journal of medicinal chemistry 20060112 |
| Second- and third-line treatments in non-small cell lung cancer. | Current treatment options in oncology 20060101 |
| [Therapy strategies for advanced renal cell carcinoma]. | Der Urologe. Ausg. A 20060101 |
| Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060101 |
| New drugs: abatacept, sorafenib, and nelarabine. | Journal of the American Pharmacists Association : JAPhA 20060101 |
| Treatment for advanced kidney cancer. | FDA consumer 20060101 |
| Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. | Methods in enzymology 20060101 |
| Recent advances in the research and development of RAF kinase inhibitors. | Current topics in medicinal chemistry 20060101 |
| Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. | The oncologist 20060101 |
| Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes. | ONS news 20060101 |
| Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses. | ONS news 20060101 |
| A brief symptom index for advanced renal cell carcinoma. | Health and quality of life outcomes 20060101 |
| Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. | BMC cancer 20060101 |
| Report of the 2006 APhA House of Delegates. | Journal of the American Pharmacists Association : JAPhA 20060101 |
| C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation. | Biomarker insights 20060101 |
| Role of tyrosine kinase inhibitors in cancer therapy. | The Journal of pharmacology and experimental therapeutics 20051201 |
| Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. | Clinical genitourinary cancer 20051201 |
| Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. | Drugs of today (Barcelona, Spain : 1998) 20051201 |
| Update on angiogenesis inhibitors. | Current opinion in oncology 20051101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20051101 |
| Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. | The Journal of biological chemistry 20051021 |
| The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. | Oncogene 20051020 |
| Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20051001 |
| Targeted therapy in renal cell carcinoma. | Expert opinion on investigational drugs 20051001 |
| Raf: a strategic target for therapeutic development against cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050920 |
| Promising systemic therapy for renal cell carcinoma. | Current treatment options in oncology 20050901 |
| Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. | Clinical lung cancer 20050901 |
| Targeting multiple signal transduction pathways in lung cancer. | Clinical lung cancer 20050901 |
| Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor. | Journal of neuro-oncology 20050901 |
| Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. | Clinical colorectal cancer 20050901 |
| Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? | Annals of internal medicine 20050816 |
| Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. | Current opinion in pharmacology 20050801 |
| Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. | BJU international 20050801 |
| Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050801 |
| Cutaneous side-effects of kinase inhibitors and blocking antibodies. | The Lancet. Oncology 20050701 |
| Multi-kinase inhibitors create buzz at ASCO. | Nature biotechnology 20050601 |
| Features of selective kinase inhibitors. | Chemistry & biology 20050601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050601 |
| Cancer. Encouraging results for second-generation antiangiogenesis drugs. | Science (New York, N.Y.) 20050527 |
| Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. | British journal of cancer 20050523 |
| Angiogenesis and lung cancer: prognostic and therapeutic implications. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050510 |
| Clinical trials referral resource. | Oncology (Williston Park, N.Y.) 20050501 |
| Raf kinase as a target for anticancer therapeutics. | Molecular cancer therapeutics 20050401 |
| Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1. | Oncology (Williston Park, N.Y.) 20050401 |
| Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. | Cancer research 20050315 |
| A small molecule-kinase interaction map for clinical kinase inhibitors. | Nature biotechnology 20050301 |
| Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. | Current oncology reports 20050301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050301 |
| Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050210 |
| The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. | Anti-cancer drugs 20050201 |
| Raf kinase inhibitors in oncology. | Onkologie 20050201 |
| Improving outcomes in advanced malignant melanoma: update on systemic therapy. | Drugs 20050101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050101 |
| Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. | Journal of translational medicine 20050101 |
| Cancer targets in the Ras pathway. | Cold Spring Harbor symposia on quantitative biology 20050101 |
| How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. | The Journal of endocrinology 20041101 |
| Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. | International journal of clinical pharmacology and therapeutics 20041101 |
| Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. | International journal of clinical pharmacology and therapeutics 20041101 |
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. | Cancer research 20041001 |
| Novel agents for the treatment of advanced kidney cancer. | Clinical advances in hematology & oncology : H&O 20041001 |
| Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925 |
| Kinase inhibition with BAY 43-9006 in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040915 |
| B-RAF is a therapeutic target in melanoma. | Oncogene 20040819 |
| Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. | Bioorganic & medicinal chemistry letters 20040802 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040301 |
| Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent. | Bioorganic & medicinal chemistry letters 20040209 |
| Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. | BMC cancer 20040101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040101 |
| Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters? | International journal of clinical pharmacology and therapeutics 20031201 |
| Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. | International journal of clinical pharmacology and therapeutics 20031201 |
| Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. | International journal of clinical pharmacology and therapeutics 20031201 |
| A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. | International journal of clinical pharmacology and therapeutics 20031201 |
| Raf pathway inhibitors in oncology. | Current opinion in investigational drugs (London, England : 2000) 20031201 |
| Regulation of c-Raf-1: therapeutic implications. | Clinical advances in hematology & oncology : H&O 20030801 |
| BAY-43-9006 Bayer/Onyx. | Current opinion in investigational drugs (London, England : 2000) 20030601 |
| Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. | Clinical colorectal cancer 20030501 |
| ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. | International journal of clinical pharmacology and therapeutics 20021201 |
| Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. | International journal of clinical pharmacology and therapeutics 20021201 |
| Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics. | Hematology/oncology clinics of North America 20021001 |
| BAY 43-9006: early clinical data in patients with advanced solid malignancies. | Current pharmaceutical design 20020101 |
| BAY 43-9006: preclinical data. | Current pharmaceutical design 20020101 |
| [Thromboembolism and synthetic estroprogestational hormones. Apropos of 2 cases]. | Phlebologie 19750101 |